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1  Introduction  
 
Non-invasive medical imaging has played a pivotal role in the diagnosis of disease, as 
well as the development of new drugs and treatments for decades. Techniques such 
as magnetic resonance imaging (MRI), ultrasound, computed tomography (CT) and 
X-ray typically provide detailed structural informational, exceptionally useful for the 
rapid diagnosis of many conditions in the clinical environment.1,2,3 However, 
information regarding metabolic events and biological processes is much better 
achieved through the application of specific imaging probes. Imaging probes bearing 
positron (β+) emitting radiolabels are proving to have increasingly essential roles in 
medical imaging, both for clinical and research applications; and are utilised in the 
techniques known as Positron Emission Tomography (PET) and Single Photon 
Emission Computed Tomography (SPECT).4,5  
The uptake of PET into the medical world was initially relatively slow, largely due to 
the lack of cyclotrons to generate the required radioisotopes and the low number of 
facilities with the associated scanning capability, as well as the intrinsically high cost 
associated with the technology. However, growing clinical interest and developments 
in technology in PET have seen a substantial increase in the use of this imaging 
technique for clinical roles and a large number of pre-clinical studies.6 The array of 
commercially available PET imaging agents is rapidly increasing, delivering more 
disease specific imaging probes; and the nationwide demand multi-modality imaging 
platforms such as PET-computed tomography (PET-CT) is also on the rise. Both 
factors are fuelling an ever increasing requirement for further research in PET 
chemistry and PET-healthcare integration.7 
 
1.1  Positron Emission Tomography 
 
PET is a non-invasive imaging technique that utilises in vivo emission of positrons 
(anti-electrons) from neutron-deficient (or proton-rich) radionuclides that have been 
used to label tracers, drugs or metabolic probes. Thus biochemical changes and 
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interactions can be mapped in real-time to deliver information on the 
pharmacokinetic profile of a radiolabelled species across a full body scan, thanks to 
the essentially unlimited depth of penetration offered by PET. Such information can 
be used to scope the metabolic pathway of an experimental drug; the severity of 
tumour metastasis in a patient suffering from cancer or the neurodegenerative 
effects of Alzheimer’s disease to mention but a few. 
PET can be characterised as a molecular imaging technique in that it is capable of 
targeting specific tissue or cell types using target-specific molecular probes. Although 
other modalities such as MRI, CT and ultrasound can be used for molecular imaging, 
they are markedly less sensitive, with their relative contrast agents being in the 
chemical concentration range of µM to nM. Whereas PET and SPECT are able to 
detect radiolabelled materials at the pM to nM level, giving them a distinctive 
detection advantage.8 
The first use of positron-emitting isotope labelled imaging agents for medical 
applications was as early as 1951,9,10 whilst the first human studies were undertaken 
in 1974.11 However, it wasn’t until 2000 that the integration of PET with computed 
tomography (CT) allowed for mainstream use of the imaging techniques, thanks to 
the inclusion of the structural detail offered by CT. Continued advancements in the 
field are on-ongoing and continue to drive PET imaging into new applications of 
medical imaging and drug bio-distribution understanding.  
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Figure 1: A graphic depicting the positron emission and subsequent annihilation event that occurs 
inside of a patient during a PET scan having been injected with an imaging agent bearing a PET 
radionuclide.12 
 
The sequence of events that are responsible for the PET imaging process are 
summarised in the above representation (Figure 1). The patient is administered with 
the appropriate radiolabeled imaging agent (followed by a period of rest, typically 
30–60 min for [18F]FDG, allowing the imaging agent to localise at its target region) 
before the patient is moved into the scanner. As the radioisotope decays it emits 
positrons, which travel a short distance (1–2 mm) before encountering an electron, 
resulting in a matter–antimatter annihilation event.13 This collision event results in 
the release of energy in the form of two gamma rays (or photons) of 511 keV in 
energy, proportional to the total mass of the electron and positron, in agreement 
with the mass–energy equivalence equation, E = mc2. Crucially, these gamma rays 
are projected from the annihilation event simultaneously and at 180° to one another, 
allowing the PET scanner’s computer to back-calculate where that annihilation event 
occurred and hence where the PET imaging agent is situated (within a small area of 
uncertainty), which results in the production of a PET image like that shown below 
(Figure 2).  
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Figure 2: PET image showing colorectal cancer metastasis to the liver using [18F]fluorodeoxyglucose 
(FDG). The heart and kidneys display normal high uptake of FDG, whereas the two foci of increased 
FDG uptake situated in the liver indicate tumorous lesions.14  
 
PET imaging is reliant on the innate instability of proton-rich (or concurrently 
neutron-deficient) radioisotopes that decay by emitting positrons to regain nuclear 
stability. This process, termed as nuclear transmutation, involves the conversion of a 
proton into neutron whilst emitting a positron (β+) and an electron neutrino (ve); and 
is conventionally represented as: 
p   ‡  n  +  νe +  β
+ 
proton ‡ neutron + neutrino + positron 
Where the overall nuclear transformation can be signified by: 
𝑿.𝑵𝒁
𝑨
     →   𝑿.𝑵+𝟏𝒁−𝟏
𝑨
 
Thus for commonly used PET radioisotopes such as carbon-11, oxygen-15 and 
fluorine-18, the following decay products are observed: 
𝑪𝟔
𝟏𝟏
5     →   𝑩𝟓
𝟏𝟏
6                          𝑶𝟖
𝟏𝟓
7     →   𝑵𝟕
𝟏𝟓
8                          𝑭𝟗
𝟏𝟖
9    →   𝑶𝟖
𝟏𝟖
10 
Although the mechanism of positron emission goes beyond the scope of this work, 
the process essentially involves a ‘flavour’ change of elemental particles known as 
quarks, whereby an ‘up quark’ is converted into a ‘down quark’, changing the 
physical make-up of the proton to yield a neutron.15 However, there is an alternative 
route to stability available to proton-rich radionuclides, which is similarly isobaric in 
nature, known as electron–capture. Here, the proton-rich nuclide absorbs an inner 
shell electron, thus converting a proton into a neutron. This process occurs with 
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radioisotopes with insufficient energy to decay by positron emission and acts as a 
competing decay mode for heavier positron-emitting radioisotopes, as discussed 
further in Section 1.2. Unlike positron-emission, electron capture does not produce 
gamma rays and therefore cannot be detected by a PET scanner.16  
Ultimately, the performance of a PET scanner or gamma camera is ruled by the 
properties of the detector array, which are composed of scintillating materials. 
Despite substantial research in the area of scintillators, only a handful materials have 
found their way into widespread use amongst PET imaging platforms, namely 
thallium-doped sodium iodide (NaI(Tl)), bismuth germinate (BGO) and cerium-doped 
or yttrium-doped lutetium oxyorthosilicate (L(Ce)SO and L(Y)SO).17 Although 
scintillation materials have been developed as organic materials, liquids and even 
plastics; inorganic crystals such as the above are far more appropriate for PET, as 
their higher density allows for maximised photon capture and thereby improved 
detection efficiency. The key characteristic of a scintillating material is its ability to 
absorb ionising radiation and convert a small portion of that energy into a pulse of 
visible or UV light, within a very short amount of time (ns - µs) allowing a rapid 
return to the group state.18  
 
 
Figure 3: Simplified representation of a PET scanner detection ring and blocks comprised of 
scintillating crystals and photomultiplier tubes (PMTs)19  
 
With the development of scintillation materials being a key starting point in 
producing the PET scanners of tomorrow, much focus is aimed towards producing 
scintillation crystals with higher γ-ray detection efficiencies, which results in reduced 
scan times and lower necessary dose to the patient.20 Start-of-the-art PET scanners 
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usually employ LYSO based scintillators because of they offer increased γ-ray 
detection efficiency versus more traditional systems, as well as other related 
advantages including the possession of high scintillation light output, rapid decay 
time and practical considerations such as having a low hygroscopicity.21 The further 
development of these faster and brighter scintillators has paved the way for new PET 
technologies with improved correction methods and superior resolution, with time-of-
flight PET (TOF-PET) being a very successful example of such a technology.22 TOF-
PET utilises these high-speed detectors to capitalise on the minuscule time-of-flight 
difference of the generated gamma rays, allowing more accurate localisation of the 
positron-electron annihilation.23 
After scintillation technology, the next area of continuing development in the PET 
image acquisition chain is the development of photomultipliers tubes (PMTs), which 
allow for the conversion of the photonic energy (produced by the scintillation array) 
into electrical pulses; a digital format more suitable for computed processing.24 PMTs 
consist of an evacuated enclosure with a thin photo-cathode window, which release 
photo-electrons when exposed to a scintillation photon, which are in turn accelerated 
through the chamber towards a dynode in the presence of an applied electric field 
and the resulting collision emits secondary electrons. This acceleration-emission 
process is repeated multiple times, hence amplifying the effect of the original 
scintillation photon into a more easily detectable and more quantifiable electrical 
signal. 
Traditional PET imaging relies on the above described analogue-type photomultiplier 
approach, however, more developed PET scanners employ the use of silicon solid-
state photomultipliers such as avalanche photodiode detectors (APDs); the inclusion 
of which also has also aided the integration of PET into MR systems for PET/MRI 
scanners.25,26 These semiconductor detectors exploit the photoelectric effect to 
convert light into electricity and are not only insensitive to magnetic fields but are 
also highly sensitive, more compact, relatively cheap and provide better timing 
properties than traditional means.27 In essence, APDs operate by impact ionisation, 
whereby the release of electrons when the semiconductor material is struck with 
incoming photons results in the release of more electrons; they are then accelerated 
through the chamber with the application of an external reverse voltage, producing 
the so-called avalanche effect. Eventually the multiplied electrons will reach the 
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anode and result in an amplified electrical signal, however, this technology relies on 
a sequence of photons and electrons reaching target detectors the majority of the 
time to produce a true representation of the PET imaging result, although in practise 
such complete detection cannot be guaranteed. 
In a PET scanner most gamma rays will not be detected by the array of detectors, 
but some will remain in the plane of the detection ring and two scintillating detectors 
will be hit. On photon impact each detector produces a timed electrical pulse, which 
are then combined in coincidence circuitry. If pulses are detected within a very short 
timeframe they are considered to be coincident, as depicted in the below diagram 
(Figure 4).28  
 
 
 
Each coincidence event is assigned a line of response (LOR), which provides the 
positional detail of the annihilation event by electronic collimation (without the need 
for physical collimation). The basis of PET relies on these coincidence events, which 
indicate that an annihilation event occurred at some point between the two 
detectors; this is referred to as a line of response (LOR).29 The number of gamma 
rays that hit the PET scanner’s detection array that successfully produce “true” LORs 
γ 
γ 
Annihilation 
event 
Coincidence 
events 
Channel 1 
Channel 2 
Summed 
Channel 
Figure 4: Coincidence detection in a PET scanner, PET image adapted from 
http://www3.gehealthcare.com/en/products/categories/ 
magnetic_resonance_imaging/optima_mr360_advance 
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is proportional to the resolution and quality of the PET image, making this a 
particularly important feature of PET imaging.  
There are two key phenomena that can hinder or falsify the acquisition of the LOR, 
Compton scattering and photoelectric absorption; both of which are consequences of 
the interactions of PET photons and matter. Attenuation is a direct consequence of 
Compton scattering, whereby the flight path of a photon emitted by the annihilation 
event is altered when it collides with an electron in the outer shell of a nearby 
atom.30 This results in loss of energy and crucially can cause the photon to be 
redirected, away from the PET scanner’s detection array and is therefore not 
accounted for. It is seen that an increase in patient body mass will amplify this 
effect, meaning that for larger, more rotund subjects, attenuation increases as a 
result of increased Compton scattering, reducing the number of LORs and ultimately 
a poorer PET image.31  
Photoelectric absorption sees the uptake of an emitted gamma photon by an atom 
with resulting ejection of an electron, an effect that increases with the increase of 
materials with high atomic number and density.32 Again this loss of a photon’s 
detection not only reduces the number of LORs and thereby attenuation, but also 
means the non-absorbed opposing photon contributes to background activity, 
reducing the signal to noise ratio (SNR). Given the electron-discharging nature of this 
occurrence, photoelectric absorption also has a considerable detrimental effect on 
PET-CT but can be corrected.33 These effects can contribute to a number of 
commonly occurring coincidence events that can detract from true LORs, as shown in 
Figure 5.  
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In essence, scattered and random coincidence events are results of two unpaired γ 
photons reaching the detector array within the coincidence timing window, a problem 
that is reduced as technology develops and the coincidence timing window is 
reduced.  
 
1.2  Radioisotopes in PET Imaging 
 
There are a number of commonly and less commonly exploited positron-emitting 
radioisotopes available for use in PET imaging (Table 1).34 Also termed as 
radionuclides, each of these radioisotopes have their own associated biological 
activity and physical characteristics; and thereby advantages and disadvantages in 
their utility in PET. Although there are exceptions, typically the lighter radionuclides 
present reduced half-lives, are more frequently seen within biological molecules and 
decay by largely positron-emission; whereas the heavier PET radiolabels decay by a 
higher proportion of electron capture, have longer half-lives and can inconveniently 
yield radioactive decay products. 
 
Figure 5: Types of potential coincidence from PET annihilation events 
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Radionuclide t1/2 Positron 
EMAX 
(MeV) 
Decay product % Decay 
by β+ 
emission 
Production 
method 
Carbon-11 20.4 min 0.959 Boron-11 100 Cyclotron 
Nitrogen-13 9.97 min 1.190 Carbon-13 100 Cyclotron 
Oxygen-15 2.04 min 1.732 Nitrogen-15 100 Cyclotron 
Fluorine-18 109.7 min 0.634 Oxygen-18 97 Cyclotron 
Copper-62 9.76 min 2.91 Zinc-62 98 Generator 
Copper-64 12.8 h 0.656 Nickel-64 19 Cyclotron 
Gallium-68 67.6 min 1.899 Zinc-68 89 Generator 
Bromine-75 98 min 1.74 Selenium-75 76 Cyclotron 
Rubidium-81 4.57 h 0.335 Krypton-81 96 Generator 
Yttrium-86 17.7 h 3.15 Strontium-86 34 Cyclotron 
Technetium-94m 53 min 2.47 Molybdenum-94 72 Cyclotron 
Zirconium-89 78.41 h 0.897 yttrium-89 22 Cyclotron 
Iodine-124 4.18 days 0.603 Tellurium-124  23 Cyclotron 
 
Table 1: Some radionuclides utilised in PET with their corresponding production and decay 
characteristics31 
 
A number of factors greatly influence the choice of positron-emitting isotope when 
targeting a specific PET imaging role; as preparation, lifetime, resolution, positron-
energy, toxicity, safety and cost can vary hugely from one radionuclide to another 
and also have a monumental impact on the resulting PET image and the patient. 
Initially, the convenience of availability is integral to a radionuclides use and there 
are two major routes to radionuclides, cyclotron production and generator 
formulation. The former, used to prepare the more commonly used radionuclides 
15O, 13N, 11C and 18F, involves the bombardment of a parent nuclide with high energy 
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charged species within a particle accelerator, yielding the daughter positron-emitting 
radionuclide. Alternatively, positron-emitting radionuclides can be obtained from a 
long-lived parent radioisotope as it readily decays to its daughter PET isotope, which 
are typically separated from one another via chromatographic methods making use 
of a mobile phase that allows for rapid elution of the metal-radionuclide as a ready-
to-use reagent; the most commonly seen being copper-62 as [62Cu]pyruvaldehyde-
bis(N-4-methylthiosemicarbazone) (PTSM)35 and Gallium-68 as [68Ga]ethylene-
diaminetetraacetic-acid ([68Ga]EDTA) or [68Ga]GaCl3.
36 
The selection of generator-produced radionuclides is inherently based around their 
convenience, both in the application of such systems, but also in the labelling-
chemistry of the resultant metal-radionuclide. Versus the expense of cyclotron 
acquisition, installation and service, the adoption of a bench-top generator system is 
drastically lower in cost and far simpler. Generators offer a continuous supply of 
radio-metals with practical half-lives, which can often be conveniently incorporated 
into imaging agents via chelating groups, making for a high yielding and rapid 
radiolabelling process. However, the integration of such a large radiolabel and 
obligatory chelator in to a small molecule imaging agent target can alter the 
pharmacokinetics of the imaging agent versus the unlabelled species, potentially 
reducing its bioavailability in the necessary location. However, in the case of 
biomacromolecule labelling this is less of a concern.  
The alternative, cyclotron production of radionuclides, allows for the preparation of 
more biochemical compatible radionuclides, in particular 11C and 18F, which can be 
incorporated into small molecule imaging agents without a detrimental effect on the 
compound’s biophysical properties. Although traditionally the associated costs of 
cyclotron produced radiolabels were a significant barrier to their application, recent 
development has been driven towards more cost- and space-effective solutions, 
allowing for economical dose-on-demand production of imaging agents, typically on-
site or very near to a PET imaging centre.37,38 
The half-life of a radionuclide is also a tremendously important feature to be 
considered. The majority of biological processes would be extremely difficult to 
imagine with very short-lived radionuclides like oxygen-15 or nitrogen-13, given the 
time required to produce, purify, formulate, transport and finally administer an 
imaging agent; although there are some circumstances where these are useful, such 
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as the use of oxygen-15 in cerebral blood flow imaging.39 On the other hand, an 
imaging agent with an overly long half-life, for example iodine-124 (t½ = 4.18 days) 
could result in the patient receiving a needlessly high radiation dose, that could be 
avoided by using a radiolabel with an intermediary half-life, such as 18F or 68Ga. 
Some prior understanding of the radioligand/radiotracer’s biological route is required 
to forecast the PET scan timing and selection of radionuclide, i.e. sufficient time for 
the radionuclide to be produced, incorporated into a precursor molecule, 
administered and to bio accumulate in the desired location is necessary. Although all 
PET appropriate radionuclides decay by emitting positrons to produce gamma rays, 
there are distinct differences in the energy of that emitted positron which greatly 
influences the quality of the resulting PET image, as shown in Table 1. Ideally, the 
positron emitted should be of the lowest energy so that the resulting annihilation 
event is as close as possible to the imaging agent. Again, here 18F makes for a very 
practical choice since it possesses one of the lowest position energies.40  
In addition, fluorine-18 offers a decay mode that is largely positron-emission over 
alternative decay modes, whereas other radioisotopes such as 94mTe, may decay by 
mixed decay modes, presenting needless additional radiation dosage to the patient, 
as well as an inefficient decay process. Another key consideration is the nature of the 
daughter nuclide, which can be toxic or radioactive (e.g. 75Se) for some PET 
radionuclides, whilst 18F produces an idyllic decay product in 18O.  
These points make 18F an ideal candidate for the imaging of many biological 
processes and radiopharmaceuticals, providing a radioactive tag compatible with 
complex multi-step syntheses, whilst achieving high resolution with acceptably safe 
decay characteristics.  
 
1.3 Fluorine in Pharmaceuticals 
 
Although fluorine is the most abundant halogen found in the Earth’s crust, its natural 
incorporation into organic molecules is surprisingly rare, with only 13 naturally 
occurring organo-fluorine compounds known to date, versus over 3000 natural 
products containing chlorine, bromine and/or iodine.41 However, the occurrence of 
fluorine-containing compounds within the world of pharmaceuticals is far more 
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common.42,43 Developed as early 1950s, 9α-fluorohydrocortisone – a synthetic 
mineralocorticoid with anti-inflammatory activity; and 5-fluorouracil – a potent 
thymidylate synthase inhibitor used in cancer treatment (Figure 6) represent two 
historically successful fluorine-bearing compounds, recognised as having innate 
qualities provided by the inclusion of fluorine.  
 
 
Figure 6: Examples of fluorine containing pharmaceuticals 
 
The success of such fluorine-containing drugs has driven research on the 
incorporation of fluorine into medicinal chemistry targets ever since, making the 
synthesis of fluoro-derivatives standard practice. With the incorporation of fluorine 
considered such a substantial driver for success, it’s unsurprising that a considerable 
proportion (~20%) of new pharmaceuticals released, contain the element and can 
prove to be very profitable targets.44,45,46 Examples of particularly high earning 
fluorine-contain drugs include Ciprofloxacin (Bayer AG) – a second generation 
fluoroquinolone;47 Fluoxetine – the antidepressant more commonly known as 
Prozac48; Rosuvastatin (AstraZeneca/Shionogi) – for the treatment of high 
cholesterol;49 and Celecoxib (Pfizer) – a COX-2 selective NSAID used to treat 
arthritis-related conditions;50  as shown below in Figure 7. 
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Figure 7: Some top-selling fluorine-containing drugs 
 
Such drugs owe their much of their success to the native properties of fluorine and 
the distinctive interactions it creates in vivo. Firstly, the relatively strong bond it 
forms with carbon, particularly when installed on an aromatic ring, greatly reduces 
the risk of C-F cleavage during metabolism.51 This C-H to C-F substitution, can 
prevent hydroxylation of the would-be C-H group, a common pathway in metabolism. 
This is known as the ‘blocking effect’ and is used to strategically improve the 
bioactive longevity of a molecule, an effect accounted for by the distinct difference in 
bond dissociation energy of H3C-H (103.1 kcal/mol) versus H3C-F (108.1 kcal/mol).
52 
The incorporation of fluorine to reduce metabolic oxidation is a commonly used 
strategy, one such example includes work by Kath and co-workers,53  whereby the 
addition of fluorine greatly improves the potency and metabolic stability of the CCR1 
(CC-chemokine-1) antagonist drug candidate, (for the treatment of autoimmune 
diseases and organ transplant rejection), by hindering aliphatic metabolism at the 
positions shown in Scheme 1.  
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Scheme 1: The potency and stability benefits of fluorine when substituted for hydrogen in a 
metabolism critical position 
 
The metabolic oxidation of aromatics can also be hindered with the introduction of 
fluorine in a critical position. The scheme below demonstrates how aromatics can be 
readily oxidised during metabolism with cytochrome P450, whilst the appropriate 
fluorine substitution can reduce intermediate carbocation stability via a lack of 
resonance stabilisation and by inductive withdrawal of electron density.54 
 
 
Scheme 2: Reduced carbocation stability during metabolic oxidation as a result of fluorination of an 
aromatic. Mechanistic pathway for radical oxidation of an aromatic group (top) and the 
destabilisation effect of fluorine incorporation on an aromatic group as a result of less resonance 
stability (bottom) 
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Furthermore, the C-F functionality acts as a mimic or bioisostere for C-H and C-OH, 
often unrecognised by microorganisms or enzymes, thanks to similarities in Van der 
Waals radii (1.17 Å and 1.41 Å for H and F respectively) and bond lengths (1.41 Å 
and 1.43 Å for C-F and C-O respectively), hence making such substitutions well 
tolerated.55,56 The addition of even a single fluorine atom onto a drug candidate also 
substantially enhances the molecule’s lipophilicity, determined by the molecule’s logD 
value, although this is somewhat of a generalisation,57 this feature often gives 
fluorinated compounds a heightened ability to penetrate cell membranes. Aromatics 
bearing fluorine noticeably increase the lipophilicity of a molecule as a result of the 
effective orbital overlap between fluorine 2s / 2p orbitals and the equivalent orbitals 
on carbon, which makes said C-F bond non-polarisable and thus contributes to the 
lipophilicity of the molecule.58 In the event of C-F bond cleavage, the resulting 
fluoride released is considered relatively non-toxic, particularly at the exceptionally 
low concentrations administered for PET imaging.  
The electronegative nature of fluorine (Pauling scale = 3.98)59 and its resulting large 
inductive electron-withdrawing effect can have a considerable effect on the pKa of a 
drug and thereby effect its physio-chemical properties. This pKa reducing effect of 
fluorine is particularly noticeable on the addition of multiple fluorine atoms; for 
example acetic acid, monofluoroacetic acid, difluoroacetic acid and trifluoroacetic 
acid hold decreasing pKa values of 4.76, 2.59, 1.34 and 0.23 respectively. This 
increased acidity often produces a knock-on-effect on the bioavailability of a drug as 
well as its binding affinity for the target receptor, making the addition of fluorine(s) 
an integral consideration when predicting the desired structure-activity relationship of 
a drug candidate. The resulting change in pKa, alongside the steric effects of an 
additional CF3 group and/or electrostatic effects of an added C-F bond dipole can also 
substantially influence the bioactivity of a fluorinated drug by affecting its orientation 
when entering binding sites.60  
Although generally the inclusion of fluorine increases the lipophilicity of a molecule, 
the water solubility of a drug can sometimes be subtly tuned by the substitution of 
fluorine over other halogens, whilst maintaining the very good activity that is 
associated with halo-derivatives. One example of such a substitution includes Pfizer’s 
development of fluconazole (shown below in Scheme 3), which derived from early 
anti-fungal azoles including ketoconazole.61 Here the increased inductively 
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withdrawing nature of fluorine over chlorine improves the H-donor capability of the 
neighbouring hydroxyl functionality, hence improving the molecule’s water solubility. 
 
 
 
Scheme 3: UK-47,265 and Fluconazole, two halo-triazole derivatives of ketoconazole with potent 
activity against systemic fungal infections, but with significantly different water solubility 
 
1.4 PET Imaging with Fluorine-18 
 
 With the aforementioned physical and chemical properties that fluorine possess, and 
the radiochemical characteristics of fluorine-18 described in Section 1.3, the 
popularity of the radionuclides use in PET is easily conceivable. Whilst the 
development of novel 18F-labelled imaging agents continues to progress as the 
imaging modality gains appeal, the vast majority of PET scans today are still 
conducted with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG).62 First prepared by Ido 
and Wolf in 1978,63 the radiolabelled glucose analogue provides a gold standard 
method of PET imaging a wide array of cancers,64,65,66 as well as a host of 
neurological conditions,67,68,69 thanks to a common and effective uptake system.  
On administration, [18F]FDG is transported throughout the body, particularly to 
regions of high glucose uptake, before being phosphorylated by the enzyme 
hexokinase when taken up by cells, a typical pathway for unlabelled glucose. The 
unlabelled sugar would normally then undergo further metabolism via the glycolytic 
pathway for energy production. However, [18F]FDG cannot enter the glycolysis 
reaction cascade and effectively becomes trapped as [18F]FDG-6-phosphate within 
cells, providing a key benefit to the radiolabel’s imaging mode. Many tumours cells 
express increased numbers of glucose transporters, particularly GLUT-1 and GLUT-
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3,70 as well as higher levels of hexokinase,71 giving them increased metabolic activity. 
This correlates to the higher rates of mitosis that are seen with tumours, hence 
tending to result in higher glucose demand, particularly due to their preference for 
the less efficient anaerobic route of metabolism.72  
 
 
Scheme 4: Initial metabolic pathway of glucose versus [18F]FDG 
 
Although [18F]FDG provides a widespread solution to the imaging of many tumour 
types, offering particularly high sensitivity given the nature of PET imaging with 
fluorine-18, [18F]FDG is not tumour specific.73 The radiotracer will accumulate in area 
of high levels of metabolism and glycolysis, including the heart and brain, as well 
other areas of muscular and nervous hyperactivity; areas under inflammatory stress 
such as infections, arthritis and sarcoidosis; and tissue undergoing repair, thus 
making [18F]FDG unsuitable for imaging studies involving the heart, brain or inflamed 
tissue.74  
Prior to the administration [18F]FDG, patients are required to fast for a minimum of 
4-6 hours (preferably overnight), allowing blood glucose levels to drop to a desired 
sub-150 mg/dL level.75 The dose (usually 10-20 mCi for oncologic imaging) is 
administered intravenously 60 min before the PET scan, providing sufficient time for 
intracellular uptake and accumulation, as well as clearance from the blood, without 
losing excessive activity to decay. In this period the patient is instructed to restrict 
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movement and rest by lying on a lead-shielded bed until the scan, which can take 
between 30 and 90 min, where each bed scan can take 5-10 min.76 This usual 
procedure for [18F]FDG PET imaging represents the ease and non-invasive 
characteristics of imaging with 18F-labelled imaging agents. Figure 8 provides an 
example of how [18F]FDG PET imaging is used to track lymphoma regression 
(approximately 50% in this case) as a result of chemotherapy.77  
 
 
Figure 8: [18F]FDG PET imaging of a patient exhibiting large B cell lymphoma (a) prior to treatment 
and (b) after six cycles of chemotherapy. Also, transaxial PET/CT and CT pre-treatment images (c 
and d) and post-treatment PET/CT and CT images (e and f) 
 
1.5 Cyclotron Production of Fluorine-18  
As described in Section 1.2, fluorine-18 is routinely prepared via bombardment of a 
target parent nuclide within a particle accelerator known as a cyclotron to produce 
the daughter nuclide.78 In essence, cyclotrons utilise a high frequency alternating 
voltage to accelerate a charged particle beam, applied between two “D”-shaped 
electrodes within a vacuum chamber to approximately 1/10th of the speed of light. 
The charged particle beam, usually consisting of protons, deuterons or helium nuclei, 
is focussed towards the target through a spiral trajectory induced by two 
electromagnets sat above and below the vacuum chamber. With sufficient speed, the 
charged particle beams collide with the target nuclide with enough energy to induce 
change in the subatomic composition of the target nucleus, yielding the 
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radionuclide.79 The below schematic provides a simple representation of how a 
cyclotron functions (Figure 9).80 
 
 
Figure 9: Basic schematic of the workings of a typical cyclotron 
 
First developed by E. O. Lawrence and M. S. Livingston in 1934,81 winning Lawrence 
the 1939 Nobel Prize in physics,82 the cyclotron offered a number of notable 
advantages over traditional linear particle accelerators, in particular, the reduced cost 
and space requirements substantially increased their real world application. Unlike 
their linear counterparts, cyclotrons are capable of producing continuous streams of 
particles to bombard the target with, which results in a relatively high average beam 
energy; to achieve similar power a linear accelerator would need to be ludicrously 
long. The compactness of cyclotrons also reduces the costs associated with radiation 
shielding, supporting foundations and housing facility requirements.  
Since Lawrence’s early inventions, efforts in cyclotron advancement has continued to 
strive towards producing more powerful, higher beam energy accelerators, as well as 
the development of smaller and cheaper cyclotrons, allowing their incorporation into 
medical imaging centres more realistic. The development of lower energy, ultra-
compact cyclotrons has seen particular interest in the last 15 years, because of the 
ease of their integration into PET pharmacies. Manufacturing giants such as GE, IBA 
and Siemens have successfully exploited this demand for cyclotrons with greatly 
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reduced environmental footprints and running costs, with systems like the GE 
PETtrace (Figure 10, right).83  
 
 
Figure 10: Lawrence's '60 inch' cyclotron, the most powerful cyclotron at the time when pictured in 
1938 (left)82 and the GE PETtrace 800 series cyclotron (right) 
 
These compact cyclotrons are intended to produce isotope of sufficient quantity to 
provide for multiple patient doses, without occupying a large amount of space, 
allowing them to be installed as close to an imaging centre as possible. Not only are 
these systems designed to be easy to use, but their reduced power capability 
decreases the number of radioactive metal contaminants that are often seen in 
notable amounts with full-size, high power cyclotrons. A lower beam energy and low 
activity radioisotope products also reduces the safety concerns associated with 
particle accelerators; yet another features that has helped increase the accessibility 
of PET radioisotopes across the world as a result of low-power ultra-compact 
cyclotrons.84  
 
1.5.1 Radiochemical Terminology  
 
The products and processes of radiochemical reactions are characterised in a very 
different manner to the products of typical organic or inorganic chemical reactions. 
With only a handful of IUPAC definitions in place for radiochemical characterisation, 
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it’s important to understand which measurements give a true representation of the 
data under discussion.  
Achieving a very high reaction yield in a radiochemical reaction isn’t usually of 
significant importance to a radiochemist. Typically, radiochemists are concerned with 
the radiochemical yields (RCYs) of their reactions, which are defined as the yield of a 
radiochemical separation expressed as a fraction of the activity originally present,85 
i.e. the activity of the radioactive product versus the activity of the radioactive 
starting material. However, the RCY doesn’t take into account the activity lost as a 
function of time as the radionuclide decays, and without distinct indication of the 
start time and end time it becomes an inaccurate description of the true yield of a 
radiochemical reaction. More commonly, radiochemists take into account the decay 
constant of the radionuclide in question and report yields as decay-corrected 
radiochemical yields, which in practice is calculated as:  
 
Where ‘END’ is the activity of the product(s), ‘START’ is the activity of the starting 
material and n is the number of half-lives that have occurred in the time frame. 
However, theoretically the decay corrected RCY is more accurately described as:  
 
Whereby is the count at time 0 (the decay corrected counts), is the raw, 
uncorrected count at time t, ‘λ’ is the decay constant and ‘t’ is the elapsed time. The 
decay constant is derived from the half-life (t1/2) of the radionuclide under analysis 
and is represented as such: 
 
The decay constant, also known as the disintegration constant, describes the 
probability of a nuclear decay within a time interval divided by that time interval.  
Radioactivity itself has a number of conventionally used units, the becquerel (Bq), 
being the SI unit, is the modern format for activity; where 1 Bq is defined as one 
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disintegration per second.85 However, the curie (Ci) has long been the preferred 
format for activity for and despite its use being discouraged, it still sees regular use 
within the literature. Originally defined to correspond to one gram of radium-226,86 1 
Ci is now more accurately defined as being equivalent to 3.7 × 1010 Bq (37 GBq). 
Given the practical considerations of using radiation in medicine, as well as the safety 
concerns surrounding radioactive material, the dosage of radioactivity a subject 
experiences is usually a better indication of exposure rather than the actual activity. 
The gray (Gy) and the sievert (Sv) are both SI units used to quantify the intensity of 
radioactive exposure; whereas the roentgen equivalent man (rem) is an older, much 
less frequently used unit of dose (1 rem = 0.01 Sv). IUPAC defines the gray as the 
energy imparted to an element of matter by ionizing radiation, divided by the mass 
of that element equal to 1 joule per kilogram, (i.e. Gy = Jkg-1) hence the gray is 
often reserved for doses of radiation that can cause acute physical damage to a 
subject. The sievert itself is defined as the dose equivalent equal to one joule per 
kilogram i.e. the biological damage caused by the radiation, taking into account the 
total energy absorbed and also the rate of energy loss per unit distance as the 
radiation travels through the subject. To put sieverts as a measure of dosage into 
context, one can expect to receive 400–600 µSv per two-view mammogram,87 10–30 
mSv for a single full body CT scan,88 250 mSv for a 6-month trip to Mars,89 and an 
acute dose of 1 Sv provides a 5.5% chance to develop cancer.90 
Specific activity (SA), the activity of a material per unit mass of a material or per 
mole of compound, is another major consideration for synthetic radiochemists and is 
a key requirement for knowledge of the radiochemical purity of a sample. Often, 
specific activity is lost when unwanted inclusion of stable isotope counterparts of the 
radionuclide are incorporated into the product, i.e. 19F in place of 18F. This becomes 
of particular concern when the radiolabelled product is intended for use as a 
radioligand and the 19F-bearing variant acts as a competitor for the radioligand’s 
target active site.  
There are also a number of non-IUPAC terms of practical importance, including 
radiochemical incorporated yield (RCIY), which is the percentage of radioactive 
starting material that is successfully incorporated into the desired product 
(sometimes also referred to as the chromatographic radiochemical yield); and 
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effective specific activity, which takes into account any additional materials that bind 
to the same target(s) as the radioligand but do not contribute to PET imaging. 
 
1.5.2 Production of Electrophilic Fluorine-18 
 
Although fluorine-18 is largely prepared via cyclotron proton bombardment of 
oxygen-18 to yield nucleophilic [18F]fluoride, the production of electrophilic 
[18F]fluorine ([18F]F2) is useful in a number of applications,
91,92 and usually most 
organic chemists seek to introduce fluoro-groups into molecules by electrophilic 
means. Produced as a gas, [18F]F2 can be prepared from neon-20 by deuteron 
bombardment or by bombardment of oxygen-18 gas with protons in the presence of 
nickel, as signified by the nuclear conversions in Figure 11.93 
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Figure 11: Two nuclear conversions resulting in electrophilic fluorine-18 production, note the 
bombardment species (A) and the species lost as a result of bombardment (B) denoted as (A,B) 
 
[18F]Fluorine gas is fairly unattractive as a reagent itself; as well as being a very 
powerful oxidant and extremely reactive, it tends to react in a very exothermic 
manner. Further complicating the handling of [18F]F2, the gas reagent is incompatible 
with a vast number of solvents, hence, the overly reactive gas is usually rapidly 
converted into more amenable secondary or tertiary reagents, despite this inclusion 
of additional steps resulting in detrimental impact on the final RCY.94  
Hypofluorites ([18F]RCOOF) and N-F reagents ([18F]R1R2NF) can provide  electrophilic 
sources of fluorine-18 that are drastically easier to handle,95,96 have more selective 
reactivity and are compatible with an increased range of solvents, however, having 
stemmed from [18F]F2 means that they carry a very undesirable characteristic, low 
specific activity. This low specific activity is a consequence of the preparation 
process, as the [18F]F2 requires extraction from the target using carrier fluorine-19 
gas, resulting in isotopic contamination and a SA of 100–600 MBq/µmol).97 Being a 
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carrier added (c.a.) process leads to increased mass of the final radiotracer and 
hence reduced activity per gram or mole of material;98 and ultimately a reduction in 
PET signal from specific binding.99  
Cause of low specific activity can be attributed to more than use of the carrier added 
approach to fluorine-18 production alone, in fact, fluorine-19 contamination can 
present a significant challenge throughout the radiosynthetic pathway. Radiochemical 
impurities yielded by fluorine-19 incorporation can be acquired from precursors, 
solvents and tubing (particularly fluoro-polymers such as PTFE) and other reagents; 
and their presence even at nmol concentrations can result in much reduced SA.100 
With low SA being of particular concern for radiochemists working with electrophilic 
fluorine-18 there have been a number of efforts made to resolve this; including 
micro-scaling i.e. process miniaturisation which reduces contaminants available from 
starting materials and leeched from tubing and vessels. Alternative approaches 
include drastically upscaling the initial amount of radioactivity by increasing the 
bombardment time and maintaining the same target volume; or utilising process 
optimisation by eliminating all potential sources of contamination or by improving the 
target system.101,102 Another recent attempt to boost the specific activity of [18F]F2 
involves work by Bergman and Solin, where a specific activity of 55 GBq/µmol was 
achieved by preparation of [18F]methyl fluoride using nucleophilic [18F]fluoride, which 
was then mixed with carrier F2 in an inert neon matric and then atomized by 
employing an electric discharge to encourage isotopic exchange.103  
 
1.5.3 Production of Nucleophilic Fluorine-18 
 
Given the numerous drawbacks associated with the use and production of [18F]F2, 
the majority of fluorination strategies are developed with a nucleophilic 
radiofluorination strategy at their core. Regardless of cyclotron size or power, 
nucleophilic [18F]fluorine-18 is  prepared by proton bombardment of oxygen-18 
enriched heavy water ([18O]H2O) to yield an aqueous solution of [
18F]fluoride. Unlike 
[18F]F2, the resulting [
18F]F– is easily extracted from the target, hence the process is 
no-carrier added (n.c.a.) and therefore offers markedly higher in specific 
activity.103,104,105  
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The resulting [18F]fluoride requires extraction from the remaining target [18O]H2O, an 
unsuitable solvent for most radiofluorination chemistry, quickly and effectively to 
avoid loss of activity to time. The retained [18O]H2O can be recycled to avoid wasting 
the expensive stable isotope,106 which can cost $200 per gram107 or more depending 
on current worldwide availability. However, the poor solubility of the fluoride ion in 
the majority of organic solvents, coupled with its weakly nucleophilic nature makes 
the application of [18F]fluoride in organic solvents less than trivial.  
Typically, extraction from the aqueous media is achieved by trapping the anion on an 
ion exchange column or cartridge, followed by elution with a weak base, often 
potassium carbonate, as a solution in acetonitrile and water.99 Any remaining water 
can then be reduced by multiple cycles of azeotropic distillation and the application 
of a phase transfer reagent reduces solvation the fluoride anion and thereby 
substantially improves its nucleophilicity. Without this key step, the high charge 
density of fluoride would remain strongly hydrated (ΔHhydr = 506 kJ/mol) and hence 
nucleophilically inactive.  
The multidentate ligand, Kryptofix-222® (K222) 1 is commonly used as a phase 
transfer reagent for radiofluorinations; the cryptand complexes with the potassium 
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Figure 12: A scale chart comparing the theoretical and actual specific activities offered by 
[18F]F– and [18F]F2. *Highest SA for [
18F]F2 achieved by the Solin method via CH3F
102,103 
 27 
cation of [18F]KF strongly to afford a ‘naked’ and thereby more nucleophilic fluoride 
anion. 
 
 
Figure 13: Structure of [18F]KF.K222 (left) and x-ray crystal structure of [2.2.2]cryptand 
encapsulating a potassium cation (right)108     
 
Tetraalkylammonium compounds such as tetrabutylammonium bicarbonate and 
tetraethylammonium bicarbonate have also been shown to provide very suitable 
routes to organic-soluble, nucleophilic fluorination reagents; yielding [18F]tetra-
butylammonium fluoride ([18F]TBAF)109 and [18F]tetraethylammonium fluoride 
([18F]TEAF).110 The convenience of these reagents lies in their ability to both provide 
a means to solubilise the [18F]F– and to synchronously act as a source of weak base, 
allowing elution from the ion exchange resin and complexation to occur in tandem.111 
In addition, recent work by Reed et al, has highlight the use of [18F]TEAF as a 
reagent with comparable radiofluorination capabilities to  [18F]KF.K222, that also 
reduces the occurrence of blockages within microfluidic systems, a common problem 
for those operating such systems with [18F]KF.K222, and avoids the formation of 
clathrates when compared to [18F]TBAF, thereby providing a more anhydrous source 
of [18F]fluoride.110,112 
 
1.5.4 Radiopharmaceutical Production 
 
The production of radiopharmaceuticals places demand on fast, robust and 
automated systems that allow for the rapid conversion of cyclotron produced 
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[18F]fluoride into a patient-ready formulation, ensuring that there is sufficient activity 
on delivery, as well as high chemical and radiochemical purity.  
 
 
 
As the efficiency and output of cyclotrons has developed, and PET scanners have 
seen more frequent installation into imaging centres, the development of automated, 
micro-scaled radiolabelling platforms has also continued to grow to meet the need 
for safe and automated radiosynthesis.113,114 Efforts here focus on production speed, 
reduced contamination through use of closed, controlled systems, reduced manual 
handling through automation and thereby improved safety.115 
Whether the radiolabelled targets are intended for direct use in the clinical setting, 
drug discovery R&D, radiochemical methodology purposes or a combination there of, 
the installation of a PET pharmacy requires careful planning. Like many other 
emerging PET chemistry facilities across the globe, the assignment of Newcastle 
University’s radiopharmaceutical production facility, opened as ‘The Sir Bobby Robson 
Foundation PET Tracer Production Unit’ in 2012 by Lady Elsie Robson (Figure 15) 
was required to be multi-functional, ultra-compact and designed for streamlined 
radiosynthesis.  
Figure 14: Typical radiopharmaceutical production sequence. 
1) [18F]fluoride collection and transfer; 2) Trapping and drying of [18F]fluoride; 3) 
Radiofluorination (and additional chemical steps e.g. removal of protecting groups); 4) 
Isolation and purification of radiolabelled product e.g. radio-HPLC; 5) Formulation to clinical 
requirements and 6) QC and transport to PET imaging centre. 
CYCLOTRON  
[18F]F– 
Radiosynthesis 
Clinical  
Translation 
Isotope 
Adaptation 
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Figure 15: Facility layout schematic of The Sir Bobby Robson Foundation PET Tracer Production Unit 
at Newcastle University, School of Chemistry 
 
As discussed in Section 1.5 Cyclotron Production of Fluorine-18, the traditional 
approach to fluorine-18 PET chemistry involves the need for a large, concrete bunker 
shielded cyclotron, capable of producing [18F]F– in very high activity (>50 GBq), 
allowing for transportation of the radionuclide to remote scanning sites, dose splitting 
or even tolerating low RCYs. However, the convenience, reduced cost and improved 
safety offered by compact cyclotrons greatly outweighs the use of larger cyclotrons 
in condensed facilities like the Newcastle PET radiopharmacy, hence the acquisition 
of the ABT Biomarker Generator (Figure 16).116  
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The 7.5 MeV positive ion ‘dose-on-demand’ cyclotron, allows for the production of 2 
GBq of [18F]fluoride (maximum) per 1 h run, at a rate of 1.0 mCi/min. The miniature 
particle accelerator employs a 1.16 T magnet and provides a beam current of 2–5 
µA, making it highly suitable for the production of low-levels of [18F]fluoride for 
immediate, single dose production. Work within the group has also validated that the 
ABT system is capable of yielding [18F]fluoride with lower levels of radioactive metal 
contaminants versus other systems,117 and also extremely low tritium 
contamination,118 never exceeding 2.4 Bq per µL compared to the typical 140–180 Bq 
per µL.119 
The hazardous nature of working with sources of ionising radiation presents a 
number of risks, procedures and requirements that highlight the major differences 
between practical radiochemistry and standard laboratory bench chemistry. Most 
distinctly, the use of shielding throughout preparation is needed and the systems 
employed for radiolabelling and radiochemical analysis are ideally placed in shielded 
fume hoods, known as ‘hot cells’ (Figure 17).  
 
Figure 16: The Advanced Biomarker Technology (ABT) biomarker generator ‘mini-cyclotron’, 
with concrete shielding in the raised position (left) and the cyclotron without shielding 
(right) 
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Figure 17: Gravatom 'hot cells’ housing radiolabelling equipment, at The Sir Bobby Robson PET 
Tracer Production Unit, Newcastle University. 
 
When handling radioisotopes or radiolabeled compounds outside of ‘hot cells’, the 
use of lead bricks, leaded glass windows and lead transport containers provide ample 
protection against the gamma radiation produced by positron-emitters, similarly lead 
safes allow for safe storage of radioactive standards used for equipment calibration. 
Stringent radiation safety training is also undertaken by radiochemists, which teaches 
users to maintain a minimum safe working distance between the operative and the 
open source by using tongs and other forms of remote manipulation where possible. 
The effective dose to the radiation worker (in sieverts) is strictly monitored by the 
use of electronic personal dosimeters (EPDs) for live readings, as well as other 
cumulative dosimeters for long-term monitoring; and area activity counters to 
safeguard other workers in the laboratory throughout radiation work.   
 
1.6 Approaches to [18F]Fluorine Radiolabelling 
 
Formerly, methods of incorporating fluorine-18 into organic molecules were rather 
limited, however, ever expanding research into the area has afforded new, more 
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diverse applications for radiofluorination chemistry. For a full spectrum of fluorine-18 
radiolabelling strategies, the reader is directed to a number of a detailed 
reviews,97,120,121,122 however, the remainder of this chapter will highlight a number of 
key approaches. The numerous labelling strategies can be divided into direct 
labelling i.e. incorporation of fluorine-18 onto a target drug; or alternatively indirect 
labelling, whereby a smaller prosthetic group is tagged with fluorine-18, which can 
then be used to label biomolecules such as peptides. This two-step tagging approach 
allows radiolabelling of molecules with sensitive functionalities and/or larger 
biomolecules that would usually be intolerant of standard radiofluorination 
conditions. Similarly, the use of either electrophilic [18F]fluorine or nucleophilic 
[18F]fluoride present two contrasting strategies for fluorine-18 integration.   
 
1.6.1 Electrophilic [18F]Fluorinations 
 
As described in Section 1.5.2, the use of overly reactive [18F]F2 is generally avoided 
by converting the radiolabelled gas into a easier to handle, more selective reagents, 
such as those depicted below (Figure 18). Although these reagents offer definite 
practical improvements over the direct use of [18F]F2, complete regioselective control 
when radiolabelling electron-rich arenes and alkenes remains a challenge.123 
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Figure 18: Several reported electrophilic [18F]fluorinating agents.124,125  
 
However, some strategies involve in situ formation of these intermediate fluorination 
reagents, hence omitting the need for an additional isolation step which would likely 
result in a lower RCY; an example of which is preparation of 5-[18F]fluorouracil 11, 
first reported by Visser et al (Scheme 5).126 Direct administration of [18F]F2 to a 
solution of 10 in acetic anhydride and a trace amount of acetic acid at room 
temperature afforded [18F]11, with selectivity ensured by the simultaneous formation 
of [18F]acetyl hypofluorite 8. 
 
 
Scheme 5: Preparation of 5-[18F]fluorouracil via in situ formation of [18F]acetyl hypofluorite. 
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Another historically important example of [18F]acetyl hypofluorite 8 application is in 
the early preparations of [18F]FDG 13 from precursor 12 (Scheme 6). Although 
modern preparations of [18F]FDG utilise higher SA nucleophilic [18F]fluoride, early 
radiosyntheses with [18F]acetyl hypofluorite allowed for rapid preparation of 
radiolabelled sugar in relatively good RCYs, suitable for successful PET imaging.127 
 
 
Scheme 6: Preparation of [18F]FDG via electrophilic [18F]acetyl hypofluorite 
 
This method provided a large improvement over previous methods, where direct 
electrophilic fluorination with [18F]F2 yielded a 3:1 ratio of the [
18F]fluoro-glucose and 
[18F]fluoro-mannose isomers, which required subsequent separation by preparative 
gas chromatography before hydrolysis, affording [18F]FDG with a poor RCY of 8%.128  
Other major approaches for improving electrophilic radiofluorinations by enhancing 
regioselectivity largely involve demetallation of organometallic precursors; for 
example, early work by Coenen et al allowed for improved radiofluorination 
regioselectivity of aromatics bearing both electron-rich substituents and some 
electron-deficient substituents via fluorodestannylation with [18F]F2 or [
18F]acetyl 
hypofluorite (Scheme 7).129  This work highlighted the scope for highly regiospecific 
radiofluorinations provided by arylstannane precursors, however specific RCYs were 
not provided.  
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Scheme 7: Electrophilic [18F]fluoro-destannylation of electron-rich and electron-deficient aromatics 
(RCYs not given) 
 
Although precursors based on alternative metals for fluoro-demetallation 
radiochemistry have been explored, namely silicon,130 germanium,129 and  
mercury,131 organotin precursors remain the prevalent reagent for this approach, 
despite the obvious toxicity concerns. 
N-F fluorinating reagents have also demonstrated utility in selective electrophilic 
fluorination strategies, one of definite worth is N-[18F]fluorobenzenesulfonamide 5 
([18F]NFSi), which displays highly stable yet reactive character and allows for 
selective 18F-labelling of silyl enol esters and allylsilanes to yield α-fluorinated ketones 
and [18F]allylic fluorides, respectively. The preparation for which was first realised by 
Teare et al who bubbled [18F]F2 through a solution of sulfonamide 18 in 
acetonitrile:water to yield a stock solution of [18F]NFSi (Scheme 8) as well as 
[18F]NaF as a by-product.132 
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Scheme 8: Preparation of [18F]NFSi 
 
Teare et al demonstrated the highly selective nature of [18F]NFSi in the radiolabelling 
of allylsilane 19 to afford drug-like structure 20 (the 1α–fluoro-substituted fragment 
of an important fluorinated analogue of vitamin D3) and the syn-diastereomer 21 as 
a minor product (Scheme 9), with a total chemical conversion of 87% (for 20 and 
21), however, RCYs were not provided.132 
 
 
Scheme 9: Electrophilic fluorination of an allylsilane with [18F]NFSi 
 
More recently, the preparation of a N-F reagent based on SelectfluorTM, 
[18F]Selectfluor bis(triflate) affords another highly selective, non-toxic, electrophilic 
fluorination reagent suitable for [18F]fluorination of organotin reagents, mediated by 
silver triflate, under very mild conditions.124 The reagent bares favour over [18F]NFSi 
due to increased reactivity with a wide array of substrates and the already much 
accepted use of the 19F counterpart. 
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Scheme 10: Preparation and reactivity of [18F]SelectfluorTM for fluoro-destannylation of aromatics 
under mild conditions 
 
1.6.2 Nucleophilic [18F]Fluorinations 
 
The attractiveness of nucleophilic [18F]fluorination strategies largely owe themselves 
to the higher SA offered by the carrier-free method of preparing [18F]fluoride, despite 
the relatively poor nucleophilicity of the reagent. As a result, there are host of very 
varied chemistries already available, with newer strategies focussed on the benefits 
acquired by a late-stage radiofluorination to attain high RCYs which will be 
summarised in a latter sub-section, for further information the reader is directed to a 
number of excellent reviews. 98,120,133 
As with electrophilic 18F-labelling strategies, nucleophilic approaches to fluorine-18 
incorporation can also be divided into a number of sub-genres, most simply they can 
be split into aliphatic radiolabelling and aromatic radiolabelling, both of which can be 
direct labelling to yield a complete imaging agent or can involve indirect ‘tagging’ of 
biomolecules using prosthetic groups (Section 1.7).  
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Figure 19: Summary of nucleophilic [18F]fluoride radiolabelling strategies 
 
1.6.2.1 Nucleophilic Aliphatic Substitutions with [18F]Fluoride 
 
Due to the simplicity of precursor design, radiofluorination strategies that operate via 
nucleophilic aliphatic substitution remain the most prominent of routes to a number 
of clinically important 18F-labelled radiopharmaceuticals, including [18F]FDG, 
[18F]fluoroethylcholine (FEC) 23, 3’-deoxy-3’-[18F] fluoro-L-thymidine (FLT) 24 and 
O-2-[18F]fluoroethyl-L-tyrosine (FET) 25 (Figure 20).134,135  
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Figure 20: Important 18F-labelled radiotracers routinely prepared by nucleophilic aliphatic 
substitution for clinical use 
 
As with most SN2 type reactions, the successful radiosynthetic design of a precursor 
relies heavily on the choice of leaving group, where expected reactivity follows the 
order of leaving group ability; Cl < Br < I < tosylate < mesylate < nosylate < 
triflate.102 Similarly, precursors bearing a primary benzylic or a primary alkyl 
substituted carbon adjacent to the leaving group fare better, as do precursors that 
allow solubility in polar aprotic solvents.  Leaving group selection requires further 
consideration, given the usual requirement for a basic radiofluorination environment 
to promote successful labelling and the competing elimination reaction that occurs 
under basic conditions, which is enhanced for better leaving groups.98  
It may worth noting at this stage, that the use of acids as catalysts or reagents in 
tandem with [18F]fluoride presents a major concern in the potential formation of 
[18F]HF, which even at low concentrations holds significant destructive capabilities 
and is hence avoided.136 This highly favourable protonation (EB = 565 kJ/mol) also 
renders the [18F]fluoride unavailable for further chemistry. 
Although imaging agents 23 and 25 can be prepared by direct tosylate displacement 
with [18F]fluoride, they are more commonly prepared by [18F]fluoroalkylation with 
[18F]fluoroethyltosylate 26. Similarly, both strategies of direct and indirect 
[18F]fluoride radiolabelling have been successfully implemented to yield human 
benzodiazepine receptor imaging agents 28 ([18F]fluoroethylflumazenil) and closely 
related flumazenil derivative 30; from either precursor 27 to afford 28 (Scheme 
11)98 or from desmethyl-flumazenil precursor 29 (Scheme 12) via N-
[18F]fluoroalkylation  in a one-pot protocol utilising tosylate 26 to yield 30.137,138  
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Scheme 11: One step preparation of [18F]fluoroethylflumazenil via direct nucleophilic aliphatic 
substitution 
 
 
 
 
Scheme 12: One-pot preparation of [18F]30 via N-[18F]alkylation of precursor 29 (RCY not provided) 
 
Other interesting approaches to nucleophilic aliphatic substitution include 
[18F]fluoride ring-opening reactions, such as that in the preparation of cancer 
proliferation marker 24 from cyclic pyrimidine analogue 31 (Scheme 13).139 
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Scheme 13: Preparation of [18F]FLT via ring opening of cyclic precursor 31 with [18F]F– 
 
Once a nucleophilic aliphatic substitution fluorine-18 labelling approach is fully 
optimised, (in terms of leaving group choice, counter-ion selection, etc.), high RCYs 
under moderate temperatures (< 100 °C) can often be achieved, usually with 
beneficially short reaction times (< 15 min),140 and can be easily automated. 
However, the use of aliphatic substitution as a radiolabelling strategy in this manner 
is accompanied by a number of drawbacks; firstly the metabolic stability of 
[18F]fluoroalkyl groups is relatively poor, particularly versus [18F]fluoroaryl 
radiolabelling strategies; and secondly the range of tolerated functionalities and 
substitution positions can be limited target receptor morphology.74,99  
 
1.6.2.3 Nucleophilic Aromatic Substitutions with [18F]Fluoride 
 
As previously mentioned, the possession of an aryl-18F label within an fluorine-18 
imaging agent provides a very attractive means to drive towards successful PET 
imaging, hence strategies towards robust aromatic [18F]fluorinations are well 
developed.98 Considered as the simplest approach to this challenge, nucleophilic 
aromatic substitution (SNAr) chemistry allows for direct [
18F]fluoride radiolabelling of 
aromatics bearing strongly electron-withdrawing groups in ortho- or para- positions, 
with an appropriate leaving group (Scheme 14).141,142,143  
 42 
 
Scheme 14: Preparation of [18F]fluoroarenes from arenes bearing electron-withdrawing 
substituents 
 
However, there are a number of prerequisites that dictate the success of these 
reactions; firstly the use of a phase transfer reagent, such as K2CO3/Kryptofix-222
® 
or tetraethylammonium bicarbonate to activate the fluoride towards nucleophilicity, is 
crucial, secondly the reaction only proceeds through relatively harsh conditions, 
requiring temperatures exceeding 100 °C with DMSO typically as the solvent.98 The 
use of a base is also often necessary, however, with precursors possessing base 
labile hydrogen atoms, the use of a Kryptofix-222® bicarbonate / oxalate buffer 
system can be employed.144 The reactivity of arenes with different leaving groups 
and electron-withdrawing groups in ortho- and para- positions has been studied by 
multiple groups in depth.141,142,144,145 Provided below is a summary of the effect of 
leaving groups on the RCY for para- substituted nitro-arenes and cyano-arenes 
subjected to nucleophilic aromatic substitution with [18F]F– (Table 2).144 
 
EWG LG 
 I Br Cl F NO2 NR3
+ 
NO2 10% 35% 70% 47% 87% - 
CN - 33% 24% 70% 73% 68% 
 
 
Table 2: The effect of leaving group on RCY with para-nitro and para-cyano substituted arenes 
when reacted with [18F]KF.K222 at 150 °C in DMSO. NR3
+ as the triflate salt 
 
Note that the above table also describes a commonly utilised route for direct 
displacement of a [19F]fluoro- leaving group by [18F]fluoride, known as isotopic 
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exchange, which is somewhat effective for strongly activated arenes, as seen above. 
However, as with other strategies where fluorine-19 contamination is unavoidable, 
the detrimental effect on the final specific activity of the product may nullify the use 
of this approach for radiotracers in imaging applications that are limited by low 
binding capacities.146 The trialkylammonium leaving group provides excellent 
nucleofugic properties, particularly when employed with weakly electron-withdrawing 
para-substituents such as halides. (Table 3).147,148 Although a range of counter-ions 
are available, trialkylammonium triflates typically provide superior results, particularly 
when used in conjunction with dimethylacetamide as the solvent, as illustrated in 
Table 3.98  
 
LG EWG 
 Cl Br I COCH3 CHO CN CF3 NO2 
NO2 <0.1% <0.1% - 67% 77% 81% 67% 88% 
NMe3
+ - 12.5% 15% 79% 71% 87% - 88% 
 
 
Table 3: The effect of various para-substituted electron-withdrawing groups on the SNAr 
[18F]radiofluorination of nitro-arenes and trimethylammonium-arenes as RCYs where p-nitro-arene 
fluorinations are conducted at 150 °C in DMSO and p-trimethylammonium-arene fluorinations are 
conducted at 140 °C in dimethylacetamide 
 
The radiosynthesis of [18F]labelled cyclooxygenase inhibitor 33 ([18F]SC58125) by 
McCarthy et al provides an excellent example of nucleophilic aromatic substitution 
achieved through use of a trialkylammonium triflate leaving group, permitting late-
stage radiofluorination of a weakly activated aromatic (Scheme 15).149  
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Scheme 15: Preparation of [18F]SC58125 (33) via direct SNAr utilising a trimethylammonium triflate 
leaving group 
 
However, the use of trialkylammonium leaving groups does present a notable 
disadvantage versus some methods; the functional group is susceptible to direct 
nucleophilic aliphatic substitution and hence [18F]SNAr is contested by formation of 
[18F]fluoromethane. This competing reaction is amplified with haloarenes, an 
observation which correlates to the low σ Hammett constants observed for 
haloarenes subject to para- substitution (Figure 21),150 which mirrors the limited 
RCYs of 1-[18F]fluoro-4-haloarenes described in Table 3. Whereas para-substituted 
arenes with higher σ Hammett constants correlate to a preference for 
[18F]fluoroarene formation over the competing [18F]fluoromethane side product 
(Figure 21).  
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Figure 21: Competing nucleophilic aromatic substitution and nucleophilic aliphatic substitution of 
trimethylammonium triflates with [18F]fluoride (top) and corresponding Hammett plot (bottom)98 
 
The benefits of using phase transfer reagents to enhance the nucleophilicity of 
[18F]fluoride in direct nucleophilic radiolabelling are clear, however, in doing so the 
potential for nucleophilic attack on other labile functionalities (as seen above) 
increases and results in the necessity for the application protecting groups for 
precursors bearing alcohols, primary amines and/or carboxylic acids. However, the 
subsequent deprotection, being an additional post-radiofluorination step, can only 
result in a reduction in product RCY. 
An alternative strategy to [18F]fluorination of aromatics is the preparation of 
[18F]heteroaromatics, which when they are of sufficient electron deficiency can 
facilitate [18F]fluorination of simple precursors via direct nucleophilic 
[18F]fluorination.151 Nucleophilic attack on mono-substituted pyridine, for example, 
benefits from a markedly lower LUMO energy versus the benzene analogue; a 
common feature of heteroarenes that together with the recently improved availability 
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of heteroaromatic pharmaceuticals, has aided popularisation of this approach to 
[18F]fluoroheteroarenes.  
Unlike standard aromatics, 2- and 4- [18F]fluoropyridines are afforded without the 
need for a para- electron-withdrawing group, utilising similar leaving groups and 
reaction conditions (>100 °C, inclusion of a base and DMSO/DMF as solvents) as the 
hetero-atom-free counterparts to achieve rapid [18F]SNAr (Scheme 16). However, 
[18F]fluorination of pyridine derivatives in the 3- position demands the use of a 
strongly electron-withdrawing group para- to the leaving group in order to progress 
the reaction.152  
 
 
Scheme 16: [18F]fluorination of pyridine without the need for an electron-withdrawing substituent 
  
The radiosynthesis of high-affinity metabolic glutamate receptor subtype 5 (mGluR5) 
ligand 35 from 2-chloro-thiazole 34 (Scheme 17)153 provides an example of where 
direct nucleophilic aromatic substitution of heteroarenes can be useful tool. 154 Here, 
the installation of fluorine-18 directly onto the 1,3-thiazole moiety reduces the risk of 
radiodefluorination that is seen with human PET studies of related compound 36;155 
and is a considerably easier approach than preparing analogue 37 ([18F]MTEB) 
(Figure 22),156 both of which have also been used for preclinical imaging mGluR5 
receptor expression.153  
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Scheme 17: Preparation of 2-[18F]fluorothiazole 35 via nucleophilic aromatic substitution for use as 
a mGluR5 ligand 
 
 
 
 
Figure 22: Structures of 36 ([18F]SP203) and 37 ([18F]MTEB), both PET ligands for mGluR5 receptors 
with distinct limitations 
 
This nucleophilic heteroaromatic substitution approach to 35 triumphs over the two 
pre-existing radioligands presented above (Figure 22) by providing a robust route to 
a mGluR5 ligand with sub-nanomolar target affinity, over 10,000 fold selectivity for 
mGluR5 over other metabotropic receptor subtypes and doesn’t suffer from in vivo 
radiodefluorination.153 
 
1.6.2.3 The Balz-Schiemann and Wallach Reactions 
 
The preceding section describes how the use of SNAr chemistry to install fluorine-18 onto 
aromatic rings provides a sound strategy for the preparation of some [18F]fluoroarenes, 
however, this approach is limited to arenes and heteroarenes with regiospecific electron-
withdrawing functionality, thus negating the preparation of a huge number 
[18F]fluoroaromatics. Two classical transformations that provide access to other 
regioisomers of [18F]fluoroaromatics via dediazoniation with [18F]fluoride and without the 
 48 
need for SNAr activating groups are the Wallach and Balz-Schiemann reactions.
157,158 
Initial work by Wallach in 1886 highlighted an opportunity for radiochemists to achieve 
regiospecific incorporation of a [18F]fluoride onto electron-rich arenes by exploiting the 
thermal decomposition of aryltriazenes in the presence of an acid catalyst (Scheme 
18).157  
 
 
 
Scheme 18: The Wallach labelling reaction, most effective where R is an electron donating 
substituent 
 
The RCYs of Wallach transformations are, however, often quite poor as a result of 
mechanistic limitation; the reaction proceeds via a SN1 type route, resulting in the 
formation of a reactive aryl cation species which is susceptible to attack from any 
nucleophile in the system. This ultimately results in the production of multiple side 
product and as a result a reduced RCY. The radiosynthesis of [18F]haloperidol 39, a 
dopamine receptor ligand that allows regional mapping of brain metabolism 
hemodynamics, does demonstrate how this labelling method can be advantageous 
when a controlled reaction system is employed (Scheme 19).159 
 
 
Scheme 19: Preparation of [18F]haloperidol 39 via the Wallach reaction (RCY not provided) 
 
Similarly, the application of the Balz-Shiemann reaction is accompanied by a 
considerable drawback in the formation of a cationic arene intermediate, which is 
again highly vulnerable to nucleophilic attack.158 The reaction utilises pyrolysis of aryl 
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diazonium tetrafluoroborate salts in the presence of [18F]fluoride to yield the product 
[18F]fluoroarene, however, use of the BF4
– counter-ion, in theory, limits the RCY to 
25% at best, as a result of 19F/18F isotopic exchange, which will also greatly reduce 
the SA of the radiolabelled product.98 
  
 
Scheme 20: Formation of [18F]fluoroarenes via the Balz-Shiemann reaction 
 
1.6.2.4 Newer Strategies for Fluorine-18 Incorporation 
 
The expansion of PET into common clinical imaging practise has largely been limited 
by the development of robust and high-performance [18F]radiolabelled 
pharmaceuticals beyond [18F]FDG, rather than PET scanner quality or lack on 
demand.160  Amongst the many challenges radiochemists face, developing new 
radiolabelling chemistry that coincides with the demands of radiosynthetic practise 
and yields highly selective target labelling, whilst maintaining high RCYs and high SA 
is the most demanding. However, in the last 10–15 years, the integration of other 
more specialised areas of chemistry into PET chemistry has allowed for the growth of 
new routes to radiolabelled compounds, and with better understanding of target 
receptors and proteins, new and improved target molecules have been elucidated. 
Although there has been a host of new and unconventional strategies produced, 
such as supramolecular PET nanoparticles,161 multimodal PET/MRI/fluorescence 
imaging agents,162 and miniaturised digital microfluidic PET chips,163 to mention just 
a few, this sub-section will focus on new routes to [18F]fluoroarenes relevant to the 
project.  
Activated sulfur systems, such as triarylsulfonium salts have recently been employed 
to provide a strategy for SNAr [
18F]fluorinations that encompasses a broad range of 
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substrates, without the need for activating groups.164 This approach has been proven 
to provide high RCYs of substrates with numerous sensitive functionalities, such as 
the preparation of tetra-peptide 41 from triarylsulfonium salt 40 (Scheme 21), 
without the formation of the expected by-product [18F]fluorobenzene, and achieved 
under standard [18F]SNAr conditions (i.e. with a base at 110 °C).
164  
 
 
Scheme 21: Preparation of [18F]labelled tetra-peptide 41 from triarylsulfonium salt 40 
 
Through a similar approach, Chun et al have explored the use of diaryl sulfoxides as 
precursors to [18F]fluoroaromatics bearing para-substituted electron-withdrawing 
groups, [18F]fluorinated under relatively mild conditions.165 Although the route is 
limited to substrates with electron-withdrawing functionality, the reaction proceeds 
within minutes and affords excellent RCYs, demonstrated by the [18F]fluorination of 
sulfoxide 42 to selectively yield [18F]fluoroarene 43 (Scheme 22).165 
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Scheme 22: High yielding [18F]fluorination of a diaryl sulfoxide 
 
Electrochemical approaches to [18F]fluoroaromatics via potentiostatic anodic oxidation have 
also been exposed as potentially very useful transformations,120 however, further work in the 
area is required to raise RCYs to a standard that is radiosynthetically useful.166 This approach 
entails the use of an electrolytic solution of [19F]Et3N.3HF/Et3N.HCl in acetonitrile (therefore 
making it a carrier added process) and platinum electrodes which produces an aryl cation 
species, regaining aromaticity as it fluorinated with [18F]fluoride.167  [18F]fluorophenylalanine 
derivative 45, an imaging agent suitable for imaging central motor disorders in the brain that 
correlate to Parkinsonian symptoms,168 has been successfully prepared by Kienzle et al from 
protected precursor 44 via this electrochemical method as a mixture of regioisomers (ortho- 
50%, meta- 11%, para- 39%) (Scheme 23).166 
 
 
 
Scheme 23: Preparation of [18F]fluorophenylalanine derivatives via electrochemical 
radiofluorination 
 
More recently and so far more successfully, an umpolung approach to 
[18F]fluorinations has accomplished some excellent progress in the field of high SA, 
high RCY [18F]fluoroarene preparation.120 Much of this work has been centred around 
the uptake of [18F]fluoride into palladium based aryl complexes, which essentially 
affords a reactive, no carrier added source of electrophilic fluorine-18.169 Typically, 
direct oxidation of fluoride into electrophilic ‘F+’ is infamously challenging (for 2 F– –> 
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F2 + 2e
– E0 = -2.87 volts), 170 however, Brandt et al conceptionalised a radiosynthetic 
strategy that allows for integration of the oxidant and the [18F]fluoride within a high 
oxidation state Pd complex, where direct oxidation of the [18F]fluoride is avoided.171 
Although there are a number of plausible mechanisms discussed regarding this 
approach (SN2 at fluoride, SET/fluorine atom transfer and SET/fluoride 
transfer/SET),176 generally pre-synthesis of an aryl precursor-Pd complex 48 from 
boronic acid 47 and complex 46 under mild conditions is required, before rapid 
[18F]fluoride capture by the palladium complex 49 yielding the electrophilic [18F]F-Pd 
complex 50 (Scheme 24). The subsequent oxidation reaction facilities rapid 
fluorination of the aromatic precursor, reductively eliminating the [18F]fluoroarene 
product, often with good RCYs, as outlined in the below scheme.170 
 
 
Scheme 24: Preparation of [18F]fluoroarenes via umpolung fluoride trapping with paladium (IV) 
complexes and subsequent oxidative fluorination 
 
Further work by the Ritter group utilised this innovative palladium-mediated 
approach to aromatic radiofluorination, which allows for highly desirable late-stage 
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fluorination, to afford [18F]labelled deoxyestrone 52 from precursor 51 (Scheme 
25),172 a potentially useful imaging agent for estrogen receptor breast carcinomas.173 
 
 
Scheme 25: Preparation of [18F]deoxyestrone 52 via palladium mediated [18F]fluorination 
 
An alternative radiosynthetic umpolung strategy has also been developed, a route 
that promotes oxidative radiofluorination of electron-rich arenes,174 a highly sought 
after target class given the lack of available routes to n.c.a. [18F]fluoroaromatics with 
electron-rich character.  Here, Gouverneur et al have provided a method of 
producing arene umpolungs (contrary to the [18F]fluoride strategy described above) 
via oxidation, followed by direct nucleophilic [18F]fluorination to afford a series of 
[18F]fluorophenols in a one-pot protocol (Scheme 26), without the need for prior 
phenol protection, which thereby removes the necessity for an additional post-
radiofluorination deprotection step.174 
 
 
Scheme 26: Preparation of [18F]fluorophenols via a one-pot oxidative [18F]fluorination 
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This new route makes use of iodine (III) compound phenyliodonium diacetate 
(PIDA), also known as bis(acetoxy)iodobenzene, as an effective, metal-free oxidant 
that allows the transformation to occur rapidly under mild conditions described above 
(Scheme 26). The group expanded the scope of this work by including a range of 
functionalities in the ortho- and meta- positions, demonstrating the reactions 
tolerance for other reactive moieties as well as the potential for further chemical 
coupling and prosthetic group chemistry.175  
Another recently developed approach to the challenge of late-stage aromatic 
[18F]fluorination that employs the use of an oxidative transition metal process as well 
as another hypervalent iodine oxidant is that work by Lee et al.176 This preparation 
involves the use of aryl-nickel complex precursors, such as 53, that allow for 
nucleophilic [18F]fluorination with tetrabutyl ammonium difluorotriphenylsilicate 
([18F]TBAT) 54 with iodine(III) reagent 55 to afford ultra-fast radiolabelling (Scheme 
27). This method benefits from a reduced number of radiosynthetic steps versus the 
aforementioned two-step approach with palladium complexes,172 as well as omitting 
the need for time-consuming azeotropic [18F]fluoride drying, as here aqueous 
[18F]fluoride can be used.176  
 
 
Scheme 27: Direct oxidative [18F]fluorination of Ni(II)-aryl complex precursors under mild, aqueous 
conditions 
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The very fast reaction times and reduced number of post fluorine-18 incorporative 
steps provide a real benefit towards the radiosynthesis of [18F]fluoroarenes, those 
features coupled with reproducibly good RCYs, such as the radiofluorination of 57 to 
yield [18F]estrone derivative 52 (Scheme 28), make this route an excellent strategy 
towards [18F]fluoroarene production.176  
 
 
Scheme 28: Preparation of [18F]deoxyestrone 52 via nickel mediated [18F]fluorination 
 
Many of the approaches described above are limited to aromatics with activating 
moieties and specific electronic character; require extensive and complex precursor 
synthesis; are restrained by substrate functionality; or result in poor RCYs and/or low 
SA. Although methods utilising transition metals present an attractive means to 
achieve late stage radiofluorination of complex precursors, in the practice the metal-
carbon bond is highly prone to protolysis and application of these organometallic 
precursors in radiofluorination can result in the production protio- by-products. And 
given that the protio- and [18F]fluoro- products will be bioisosteres of one another 
and thereby difficult to separate, they will competitively target the same receptor and 
ultimately result in a lower virtual specific activity (as opposed to typical specific 
activity as an artefact of [18F]/[19F] competition).  
The application of diaryliodonium salts presents an opportunity to achieve n.c.a. 
[18F]fluoride incorporation on aromatic systems, without the need for prior activation 
and without regiospecific constraints via a one-step radiofluorination that typically 
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affords high RCYs and high SA.98 The first published use of diaryliodonium salts for 
this purpose was provided by Pike et al in 1995,177 where the group prepared a 
range of simple symmetric and asymmetric diaryliodonium salts (Scheme 29), with a 
range of counter-ions and investigated the outcome of radiofluorination with 
[18F]fluoride.  
 
 
Scheme 29: Nucleophilic [18F]fluorination of diaryliodonium salts 
 
The study highlighted the value of diaryliodonium salts as a versatile, late-stage n.c.a. 
radiofluorination strategy and provided preliminary information on the effect of counter-ions 
and substituents on the resulting [18F]fluoroarenes, which some of the key outcomes 
summarised below (Table 4).177 
 
Precursor  
Diaryliodonium 
  Distribution of  
Product [18F]Fluoroarenes  
R R’ X– Conditions RCY % A % B 
H H Cl– 110 °C, 35 min 78% 100 
H H CF3SO3
– 110 °C, 35 min 15% 100 
H Me CF3SO3
– 85 °C, 40 min 68% 60 40 
H Cl– CF3SO3
– 110 °C, 35 min 14% 40 60 
H OMe Br– 110 °C, 35 min 35% 100 0 
H OMe Br– 85 °C, 40 min 88% 100 0 
 
Table 4: Summary of n.c.a. [18F]fluorinations of diaryliodonium salts by Pike et al, demonstrating 
RCY and product distribution dependence on reaction conditions, the choice of counter-ion and the 
electronic nature of aromatic substituents177 
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This initial investigation into diaryliodonium precursors paved the way for much more 
work in the area, including numerous mechanistic studies into the reaction of 
diaryliodonium salts with nucleophiles; development of many diaryliodonium salt 
precursors to existing and new [18F]fluoroaromatics bearing imaging agents; and 
augmentations of the fluorination reaction such as those using iodonium ylide 
precursors and transition-metal catalysed fluorinations.178,179,180  
The preparation of benzodiazepine receptor marker [18F]DAA1106 59 from 
diaryliodonium salt 58 provides an excellent example as to how the iodonium 
approach to nucleophilic [18F]fluorination can allow for direct regiospecific n.c.a. 
radiofluorination, with a precursor bearing sensitive functionality and afford both 
selectivity for the target ring systems and a high RCY (Scheme 30).181 Here the 
resulting ratio of the two possible [18F]fluoroarenes exhibits a major preference for 
the target ring; 71:29 [18F]59: 4-[18F]fluoroanisole. Substitution of the 4-
methoxybenzene moiety in precursor 58 for unsubstituted benzene resulted in a 
substantial reduction in the RCY of 59 (RCY = 3%), highlighting the necessity for an 
electron-rich aromatic in this site, given the electron-rich nature of the target.181  
 
 
Scheme 30: Preparation of [18F]DAA1106 59 via nucleophilic [18F]fluorination of diaryliodonium salt 
precursor 58 
 
Given the relevance of diaryliodonium salt precursors to the main study of this thesis, 
further discussion on the synthesis of hypervalent iodine reagents; the chemistry 
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surrounding these compounds and their application in the preparation of electron-
rich [18F]fluoroarenes can be found in Chapter 2. 
Recent developments in the area of diaryliodonium salts towards the production of 
electron-rich [18F]fluoroarenes includes work on the aforementioned iodonium 
ylides,180 which when prepared as dicarbonyl or (PhIC(COR)2)
182 or sulfonyl 
(PhIC(SO2R)2)
183 derivatives are sufficiently stable to permit applications in various 
applications, including carbine synthesis.184 Although unsubstituted 
dicarbonyl(phenyl)iodonium ylids are inherently unstable and poorly soluble in most 
solvents, introduction of electron-donating substituents on the systems aryl ring, 
particularly in the ortho position, improves stability of the precursor and allows for 
practical application in common solvents.180 Iodonium ylides exhibit very similar 
hypernucleofugic reactivity to diaryliodonium salts when presented with an 
appropriate nucleophile and x-ray crystal structures have shown that they also afford 
a close to 90° C-I-C bond angle between the aryl and stabilised carbanion 
components, confirming their equivalence to diaryliodonium salts and agreement 
with the hypervalent iodine(III) model.185   
Here the use of Meldrum’s acid as the preferred malonate ester has seen regular use 
a substrate for iodonium ylid preparation, which are can be coupled with 
(diacetoxy)iodoarenes or utilised in one-pot procedures with an appropriate oxidant 
and the substrate iodoarene to afford the target ylid. The latter method has been 
applied to the preparation of iodonium ylid 61 from protected iodoarene 60 (Scheme 
31), which was subsequently fluorinated to afford neuroendocrine tumour (NET) and 
serotonin transporter (SERT) imaging agent 3-[18F]FPPMP 62.186 
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Scheme 31: Preparation of [18F]FPPMF 62 via nucleophilic [18F]fluorination of iodonium ylid 61, 
which was prepared by a one-pot procedure from 60 
 
The widespread adoption of iodonium ylides as precursors to electron-rich 
[18F]fluoroarenes has been relatively slow however, potentially as a feature of the 
poorly reproducible one-pot preparation utilised or the challenge of preparing the 
(diacetoxy)arenes involving sensitive or complex functionality when preparing 
iodonium ylides via the step–wise approach.180 Some groups have also reported 
difficulty in the numerous by-products produced in the iodonium ylid reaction from 
the [18F]fluorinated product, hence posing a threat to the SA of the resulting imaging 
agent.186 
 
1.7 Fluorine-18 Labelling with Prosthetic Groups 
 
For the fluorine-18 radiolabelling of small molecules direct incorporation of 
nucleophilic [18F]fluoride is generally preferred, however, larger molecules and/or 
those bearing multiple sensitive functionalities are often unsuitable for direct 
fluorination. Here, the application of radio-labelled ‘tagging’ molecules, termed 
prosthetic groups, is more appropriate for [18F]fluorination of macromolecules such 
as aptamers and oligonucleotides, as well as for labelling small molecules 
incompatible with direct fluorination conditions.133 A prosthetic group is defined as a 
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pre-[18F]radiolabelled small molecule bearing a reactive functionality that allows the 
molecule to be rapidly incorporated into another structure, usually under mild 
conditions. 
The use of [18F]radiolabelled bioactive macromolecules are rapidly gaining popularity 
over small molecule imaging agents for a number of reasons, firstly the application of 
non-labelled oligomers within therapeutics is already well known and very effective, 
often providing very high target specificity and nanomolar potency.187  This highly 
specific nature of therapeutic macromolecules also reduces the likelihood of 
interacting with other biological processes and therefore diminishes the risk of side 
effects; and their functionality is a direct feature of their complex structure, 
something that small molecules struggle to convincingly mimic. The body is also 
drastically more familiar with biomolecules, than it is to alien small molecules with 
unnatural pharmacophores and hence is less likely to produce an aggressive immune 
system response to a bioactive macromolecular drug.187 Thereby PET imaging with 
[18F]fluorinated biomolecules presents an attractive alternative to traditional small 
molecule approaches. 
In terms of commercialisation, macromolecular therapeutics generally benefit from 
faster FDA/EMA approval than small molecules; possessing unique structural qualities 
and exclusive functionality makes the patenting of specific proteins for a specific 
applications a very attractive prospect.188 As is commonly seen with the development 
of therapeutic trends, the continued development of peptide-based treatments is 
catalysed by the continued growth of the market, which coupled with their ever 
increasing success rate (now over 35%, which is better than that of small 
molecules),189 makes the sustained growth of peptide based drugs; and by extension 
[18F]fluorinated biomolecules, a very likely scene.190  
Although there are a handful of examples that describe successful direct 
[18F]radiolabelling of biomolecules,191,192,193 biomolecules largely undergo 
hydrolysis/decomposition when subject to direct radiofluorination conditions; hence 
[18F]fluorination via modular synthesis provides a more feasible route to [18F]labelled 
biomolecules. With much of the focus of prosthetic group development directed 
towards the radiolabelling of biomolecules, a wide number of strategies have been 
developed that allow for tagging macromolecules bearing commonly occurring 
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moieties, such as amines, thiols, and suitably reactive carbonyl groups, making each 
prosthetic group strategy instantly widely applicable.97  
Figure 23 provides a handful of commonly utilised prosthetic group strategies used to 
radiolabel biomolecules, however, the literature can offer a vast number of 
alternative approaches,97,122,133 many of which are beyond the scope of this work, 
but some key examples will be highlighted in coming sub-sections.  
 
 
 
Figure 23: An overview of various prosthetic groups for [18F]labelling of bioactive macromolecules, 
many of which are also applicable to modular build up small molecule targets. (R = alkyl or aryl 
linker)133 
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One commonly employed prosthetic group based radiolabelling strategy not 
illustrated above (Figure 23) is [18F]fluoroalkylation, which has been described in an 
earlier section (Section 1.6.2.1) in the application of 2-[18F]fluoroethyltosylate 26 for 
indirect small molecule labelling, in which it has a wide number of applications.194 
Similarly, 2-[18F]fluoroethyltosylate has been utilised in simple peptide labelling, such 
as prostate specific membrane antigen (PSMA) ligand 72 ([18F]FEt-Tyr-urea-Glu) 
from precursor 71 (Scheme 32).195 The simplicity of this modular labelling strategy 
allows for rapid incorporation and a high RCY, demonstrating the capability of 
biomolecule [18F]fluoroethylation, which is often less controlled with larger peptides 
bearing multiple reactive functionalities.196  
 
Scheme 32: Preparation of [18F]FEt-Tyr-urea-Glu ([18F]FEtTUG) via [18F]fluoroethylation of 
precursor 71 
 
[18F]Fluoroalkylation chemistry can also be extended to the use of [18F]trifluoroalkyl 
prosthetic groups, which have recently come into precedence for providing effective 
N-, S- and O-[18F]fluoroethylations (as well as [18F]fluoromethylations and 
[18F]fluoropropylations). This resourceful approach allows for the direct 
[18F]fluorination of  difluorovinylsulfonate to yield [18F]fluoro-2,2-
difluoroethyltosylate, which was then subsequently used to radiolabel a number of 
nucelophile bearing precursors.197 
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1.7.1 Amine Reactive Prosthetic Groups 
 
Numerous research groups have exploited the work of peptide chemists in utilising 
amide bond formation to couple free amine groups within peptides and amine-
terminated oligonucleotides with various [18F]labelled prosthetic groups, often 
manipulating coupling agents and global protection strategies to achieve rapid 
[18F]radiolabelling under very mild conditions.198,122 
N-Succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) 67 is one amine reactive prosthetic 
group that has proven to be a very popular approach to peptide,199,200 however, 
preparation of the prosthetic group is far from trivial and most preparations require a 
multi-step synthesis including post-[18F]fluorination conversions (Scheme 33).201 
 
 
Scheme 33: Modular preparation of [18F]SFB via nucleophilic aromatic substitution of a 
trimethylammonium aryl precursor followed by additional steps.  
 
Many other amine reactive prosthetic groups utilise the [18F]fluorobenzoyl moiety in a 
similar fashion, including 4-[18F]fluorobenzoic acid 63, 4-[18F]fluorobenzaldehyde and 
N-succinimidyl-4-([18F]fluoromethyl)benzoate,202,203 to produce a highly stable 
[18F]radiolabelled amide-macromolecule link, further benefitting from the increased 
metabolic stability of the [18F]fluoroarene label. The dimeric cyclic RGD 
(arginylglycylaspartic acid) peptide E[c(RGDyK)]2 73 (Figure 24) has been effectively 
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radiolabelled in this manner in a RCY of 20–30% (from [18F]SFB, n=3) and allows for 
glioblastoma imaging thanks to high tumour uptake and prolonged cellular 
retention.204  
 
 
Figure 24: [18F]FB-E[c(RGDyK)]2; a demonstration of macromolecule radiolabelling via acylation of 
the peptide amino group with [18F]SFB 
 
In a very similar approach, the use of 4-[18F]fluorobenzaldehyde ([18F]FBA) 64 as a 
prosthetic group for biomolecules terminated with aminooxy functionality, to form 
oxime linkers has been well explored,205,206 as has the application of [18F]FBA for 
producing hydrazone linkers when reacted with hydrazinyl-terminated 
macromolecules.207 The preparation of oncology target [18F]FBOA-minigastrin 74 
(Scheme 34, left) via the former method yields the radiolabelled peptide in an 
excellent RCY of 90% within 15 min (from [18F]FBA);205 whereas the later hydrazone 
linker strategy has been applied to the formation of  blood-pool imaging agent 
[18F]fluoro hydrazinonicotinicacid-human serum albumin conjugate ([18F]HYNIC-HSA) 
75 (Scheme 34, right), with RCYs reported to be in a very similar range.207  
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Scheme 34: Two examples of rapid and effective peptide radiolabelling with the prosthetic group 
[18F]FBA via oxime formation (74) and hydrazone formation (75) 
 
1.7.2 Thiol Reactive Prosthetic Groups 
 
Thiol-bearing cysteine residues are commonly seen within peptides and proteins, 
their presence provides a distinct handle for prosthetic group radiochemistry. The 
inclusion of multiple cysteine units within a macromolecule also often sees the 
formation of disulfide bridges, another functionality that radiochemists can exploit to 
incorporate [18F]fluoroaromatic tagging groups.122 A wide number of thiol reactive 
prosthetic groups have been developed, including [18F]fluorophenacyl bromide 
([18F]FPB), N-(4-[18F]fluorobenzyl)-2-bromoacetimide ([18F]FBnBrA 68, 4-
([18F]fluorophenyl)maleimide ([18F]FPM) and ([18F]fluorobenzamido)ethyl maleimide 
([18F]FBEM) 69, many of which make use of the maleimide moiety to achieve thiol 
specificity.208,209,210 
One of the more popular examples, [18F]FBEM 69, is prepared via coupling of N-(2-
aminoethyl)maleimide with [18F]SFB 70 (Scheme 35), despite the inclusion of this 
additional post-18F-incorporation step the prosthetic group has been used to label 
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sulfhydryl-RGD peptides to yield analogues of [18F]FB-E[c(RGDyK)]2 73 in similarly 
high RCYs (RCY = 85%) in just 20 min.209 
 
 
Scheme 35: Preparation of [18F]FBEM 66 from [18F]SFB 67 and subsequent coupling with sulfhydryl-
RGD peptides 
 
Phosphorothioate monoester functional groups which are often commercially 
available end groups of oligonucleotides can be selectively alkylated with the 
haloacetimide prosthetic group [18F]FBnBrA 68, thus omitting the need for 
biomolecule functionalisation prior to radiolabelling and reducing the need for 
additional purification steps, which is often a challenge with macromolecules. This 
approach has seen successful application in the mild and rapid radiolabelling of 
18mer oligonucleotide 76 to afford 18F-tagged oligonucleotide 77 by Kühnast et al 
(Scheme 36).211   
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Scheme 36: Prosthetic group tagging of an oligonucleotide phosphorothioate monoester group 
using [18F]FBnBr 68 
 
[18F]Fluorinated glycosyl phenylthiosulfonates, such as prosthetic group 67 have 
been introduced as appropriate glycosyl donors for the glycoconjugation of thiol 
containing peptides and proteins.212 Prante et al have demonstrated the efficiency of 
this peptide labelling strategy in the radiosynthesis of [18F]CAKAY ([18F]C(S,S’-Ac3-
FGlc)AKAY) 79 (Scheme 37), a model pentapeptide to demonstrate substrate 
potential, achieving a RCY of 95% in a mere 15 min.213 
 
 
Scheme 37: Preparation of pentapeptide [18F]CAKAY 77 via [18F]glycosylation using fluorine-18 
labelled glycosyl phenylthiosulfonate 67 
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1.7.3 Click-Chemistry Approaches to Fluorine-18 Labelling  
 
Bioorthogonal approaches to modular build up, such as some click chemistry 
strategies have also proven to be highly successful methods of prosthetic labelling, 
particularly because such systems are intended to be rapid, highly selective and are 
typically conducted in mild, biological environments.97 These efficient copper-
catalysed click reactions allow for the formation of very stable 1,4-disubstitued 1,2,3-
triazoles at ambient temperatures and provide a highly robust means for the 
incorporation of [18F]fluoroalkyl/aryl azides and alkynes into appropriate 
biomolecules.214 Despite the inherently reactive nature of azides and alkynes, they 
are usually inert to biological species and hence this orthogonality removes the need 
for protecting groups, making their application very convenient.215  
An excellent example of this copper-catalysed azide alkyne cycloaddition (CuAAC) 
method of radiofluorination is provided in the preparation of [18F]labelled folic acid 
derivative 82, utilising 6-[18F]fluorohexyne 81 (Scheme 38) by Ross et al.216 
Achieving RCYs as high as 35% and radiochemical purity of >99% for the complete 
radiosynthesis of 82 allowed the group to apply the radiolabelled biomolecule to 
mice bearing folate receptor(FR)-expressing KB tumours.216 
 
 
Scheme 38: Preparation of [18F]-labelled folic acid derivative via copper-catalysed click chemistry 
using a 6-[18F]fluorohexyne prosthetic group 
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The inverse approach, the employment of an azide bearing prosthetic group for 
coupling with a propargyl-terminated biomolecule has also been explored 
extensively, such as in common use of [18F]FDG azide derivative 84 for targets such 
as [18F]FRGD type peptides or [18F]labelled neurotensin derivatives (Scheme 39). The 
application of this [18F]fluorodeoxyglcosylation prosthetic group strategy has shown 
to benefit from good blood clearance and stability in αvβ3-integrin expressing 
tumours, thus prolonging the PET imaging window.217  
 
 
Scheme 39: [18F]glycosylation via a click chemistry approach using [18F]fluoro-mannopyranosyl 
azide 84  
 
Although a large number of innovative click-based routes to fluorine-18 prosthetic 
group radiolabelling have been developed, only one target, [18F]FRGD-K5 has made 
it as far as clinical trials.214 This likely to be an artefact of the potentially cytotoxic 
nature of copper catalysts utilised in the 1,3-dipolar Huisgen cycloadditions described 
above and hence a demand for metal-free click reactions for use in PET chemistry is 
desired.  Other related approaches to click-based incorporations of prosthetic groups 
include strain-promoted alkyne-azide cycloaddition, where this need for a metal 
catalyst is removed by introducing strain on the alkynyl systems increasing their 
reactivity towards terminal azides;218 and Staudinger Ligation, a method of utilising in 
situ formation of an aza-ylide via hydrolysis of an iminophosphorane species 
produced by the reaction of an azide and a phosphine group. The nucleophilic aza-
ylide can then be captured by an ester moiety (or other electrophilic trap) to form a 
covalent adduct, capable of forming a stable amide bond upon rearrangement.219,220  
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1.7.4 Transition-metal Catalysed Cross-coupling Prosthetic Groups 
 
Another important class of indirect [18F]fluorination reactions includes the use of 
transition-metal mediated coupling reactions, many approaches of which are likely to 
be a consequence of the palladium-catalysed cross-coupling reactions bloom initiated 
by the 2010 Nobel Prize in Chemistry awarded to Heck, Negishi and Suzuki.122 
Although the use of cytotoxic metals in pharmaceutical production is generally 
avoided, the scope for rapid formation of C-C bonds is too attractive a concept to be 
ignored and many groups have developed strategies that utilise this strategy very 
effectively. 
Here, the application of diaryliodonium salt chemistry has proven to be useful direct 
method of preparing 4-[18F]fluoro-1-iodobenzene,221 an exceptionally useful 
prosthetic group for palladium-catalysed Sonogashira,222 Suzukhi223 and Stille 
coupling reactions (Scheme 40).224 
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Scheme 40: Various palladium-mediated cross-coupling reactions using 4-[18F]fluoro-1-
iodobenzene 
 
A vast number of variations on this chemistry exist, such as the preparations 
involving inversely reactive [18F]fluoroboronic acids and [18F]fluorophenyltrialkyltin 
reagents; as well as Grignard intermediates such as [18F]fluorophenyl lithium, 
however, their discussion is beyond the scope of this chapter, for further information 
the reader is directed to a number of review articles.98,122 
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1.7.5 Carbonyl Reactive Prosthetic groups 
 
The literature presents just a handful of prosthetic groups bearing amine- and 
alcohol- moieties intended on targeting carboxylic acid and activated ester 
functionalities, despite these approaches leading to relatively stable [18F]labelled 
products. The reason behind this is likely to be selectivity concern, as substrates with 
amine or alcohol functionalities are likely to form inter- or intramolecular crosslinks. 
However, for simpler substrates that don’t possess such nucleophilic character, a -OH 
or NH2-bearing prosthetic group provides an excellent means to achieve rapid 
coupling under mild conditions; or alternatively, protecting group chemistry can be 
applied to safeguard these sensitive functionalities.  
Successful [18F]radiolabelling of the hormone peptide insulin 92, as model for 
general peptide radiolabelling has been achieved via these means as early as 1989, 
utilising carboxyl-reactive prosthetic group 1-(4-[18F]Fluoromethylbenzoyl)-
aminobutane-4-amine ([18F]FMBAA) 65 (Scheme 41).225 This approach, whilst fairly 
lengthy, demonstrates the ability to selectively radiolabel a strategic portion of the 
peptide, by utilising simple protecting group chemistry to defend reactive 
functionalities within the macromolecule and activation of the desired amine through 
an alkyl-linked N-succinimidyl ester using disuccinimidyl suberate (DSS).  
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Scheme 41: Preparation of [18F]labelled porcine insulin (closely related analogue of human insulin) 
using carboxyl-reactive prosthetic group ([18F]FMBAA 65 
 
1.8  [18F]Fluorophenols as Prosthetic Groups 
 
Section 1.7 provides an overview of the various approaches radiochemists have 
taken to achieve modular synthesis of fluorine-18 labelled bioactive macromolecules, 
as well as small molecule targets that benefit from a convergent radiosynthesis 
strategy. As was indicated in the closing sub-section of the literature review, 
strategies involving [18F]fluorophenols and [18F]fluoroarylamine prosthetic groups are 
relatively underdeveloped, and present an opportunity for further study. The 4-
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[18F]fluorophenoxy- moiety is a radio-synthon of particular interest for segmental 
radiosynthesis given its frequency in a wide number of pharmaceuticals and bioactive 
molecules.120 Traditional preparations of [18F]fluorophenols typically utilised Wallach 
or Balz-Shiemann chemistry (Section 1.6.2.3), which are restricted to low RCYs and 
long reaction times (maximum achieved = 33% in 60 min) and require multiple steps 
post fluorine-18 incorporation or preparation of anhydrous tetrachloroborate, 226 
making them far from ideal.  
Baeyer-Villiger oxidations on [18F]fluorobenzaldehydes and [18F]fluorobenzo 
/acetophenones provided an advancement on the preparation of [18F]fluorophenols, 
where RCYs as high as 60% have been achieved, but require strongly electron-
withdrawing substituents on the [18F]fluorobenzophenone system to reach these 
RCYs.227 Again, this approach suffers from the necessity for multiple post-
radiofluorination steps and a lengthy reaction time, which ultimately limits the 
maximum RCY complicates radiosynthesis, as seen in the synthesis of 4-
[18F]fluorophenol 97 by oxidation of [18F]fluorobenzophenone 90 using hydrogen 
peroxide (Scheme 42). 
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Scheme 42: Preparation of 4-[18F]fluorophenol 97 via Baeyer-Villiger oxidation of 4-[18F]fluoro-4’-
trifluoromethylbenzophenone 93 
 
More recently, oxidative [18F]fluorinations of tert-butylphenols via the aryl umpolung 
as discussed in Section 1.6.2.4 (Scheme 26), present an innovative route to 
[18F]fluorophenols, which benefit from not requiring a phenol protection strategy, but 
are again limited by the substituents required on the aromatic to allow for successful 
radiofluorination, thus limiting their application.174  
Diaryliodonium salts as precursors provide a drastically more versatile route to 
[18F]fluorophenols, being relatively unrestricted by substituents on the ring system 
enhancing the range of potential applications greatly. Work on aryl(thienyl)iodonium 
salt precursors to yield 4-[18F]fluorophenol via batch-type radiosyntheses by Ross et 
al highlights the greatly improved reaction times (as fast as 20 min) offered by these 
hypervalent iodine precursors;228 which outweighs the need for protecting group 
chemistry providing a strategy that allows for rapid deprotection is selected. This 
approach to the highly versatile 4-[18F]fluorophenol prosthetic group, and commonly 
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occurring [18F]fluorophenoxy- moiety has formed the basis of work in later chapters, 
with a focus on optimising the conditions towards high RCYs and increasing the 
speed of radiosynthesis.    
One previously developed method of incorporating 4-[18F]fluorophenol into small 
molecule imaging agents includes more work from the Coenen group, whereby 
Ullman ether coupling was used to produce 2-(4-[18F]fluorophenoxy)-N,N-
dimethylbenzylamine 99 and 2-(4-[18F]fluorophenoxy)-N,N-methylbenzylamine 98, 
(Scheme 43) developed as analogues of serotonin reuptake transporter site (SERT) 
imaging agent [123I]ODAM 100.229  
 
 
Scheme 43: Application of Ullman ether coupling for 4-[18F]fluorophenol incorporation 
 
Here the catalytic application of tetrakis(acetonitrile)copper(I) hexafluorophosphate 
permitted short reaction times for the coupling stage (20 min) and ultimately 
resulted in RCYs as high as 65% (from 4-[18F]fluorophenol) despite multiple post-
radiofluorination synthetic steps.  
Another successful introduction of the [18F]fluorophenoxy- moiety into a small 
molecule target includes work by Mühlhausen et al, here the group utilised 1-(3-
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bromopropoxy)-4-[18F]fluorobenzene 101 prepared from 4-[18F]fluorophenol 97 as a 
amine-reactive prosthetic group in the radiosynthesis of [18F]R91150 102 (Scheme 
44), a selective and high-affinity ligand for serotonin 5-HT2A receptors.
230 This 
strategy allowed for relatively late-stage incorporation of the [18F]radiolabel, 
affording a RCY of 4% over six steps and a SA of 335 GBq/µmol.  
 
 
Scheme 44: Preparation of [18F]R91150 102 demonstrating the application of 4-[18F]fluorophenol 
via  amine-reactive prosthetic group 101 
 
This prosthetic group, 1-(3-bromopropoxy)-4-[18F]fluorobenzene 101 was used in 
the same context to prepare the highly selective dopamine D4 receptor ligand (3-4-
[18F]fluorophenoxy)propyl)-2-(4-tolylphenoxy)ethyl)amine ([18F]TEFPA) with a 
respectable RCY of 50% from 4-[18F]fluorophenol 97, where again the approach 
benefits from a convergent strategy.231 
Despite these successful applications of [18F]fluorophenol towards modular 
radiosynthesis of small targets, very few strategies have extended this application 
towards the radiolabelling of bioactive macromolecules, most likely because the poor 
compatibility of [18F]fluoride with these substrates and the relatively poor 
nucleophilicity of alcohols,  particularly aryl alcohols, however, the chemistry 
described in Section 1.7.5 demonstrates that there is scope for this work. 
Nonetheless, the frequency of the fluorophenoxy- moiety in drug-like molecules and 
bioactive compounds makes the availability of [18F]fluorophenols a very attractive 
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concept, demonstrating the demand for a robust route to n.c.a. [18F]fluorophenol, in 
particular the para- substituted regioisomer.  
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2 Diaryliodonium Salts for Radiolabelling Electron-rich 
Aromatics 
 
Chapter 1 discusses a broad range of methods for incorporating [18F]fluorine into 
organic compounds, focussing on approaches yielding [18F]fluoroaromatics within 
PET imaging agents using nucleophilic n.c.a. [18F]fluoride. This chapter goes on to 
describe the use of diaryliodonium salts as precursors that allow for late-stage 
radiofluorination of electron-rich aromatics, centering on the first radiosynthetic 
target, 4-[18F]fluorophenol, a valuable prosthetic group for convergent radiosynthesis 
and a model for other electron-rich systems. Here the aim of this work was to 
develop an easy to follow route to electron-rich diaryliodonium salt preparation, 
allowing for the preparation of multiple, stable diaryliodonium salt precursors bearing 
a series of phenolic protection strategies; followed by validation of their potential as 
precursors to [18F]fluorophenol by conducting model [19F]fluorinations. 
 
2.1  Introduction to Hypervalent Iodine Chemistry 
 
First reported in 1886 by Willgerodt,232 hypervalent iodine reagents have received 
notable attention for their use as clean, metal-free oxidants and versatile cross-
coupling reagents for C-C and C-N bond formation. Willgerodt’s first hypervalent 
iodane, (dichloroiodo)benzene, prepared by passing chlorine gas through a solution 
of iodobenzene in cold chloroform,233 demonstrated the potential for iodine oxidation 
states beyond (I); with iodine (III), (VI) and (VII) compounds now well understood 
and with characterised hypervalency.234  
IUPAC nomenclature gives these (and other) hypervalent iodine species the λ-
notation to signify their atypical bonding arrangement, since any element within 
groups 15-18 can have the potential to exhibit hypervalency, when it possesses more 
than 8 electrons than the octet in their valence shell.235 Iodine (III) reagents with 3 
ligands possess 10 electrons in their valence shell, giving them the classification [10-
I-3] versus mono-valent iodine compounds which would typically be classified as [8-
 80 
I-1], a system that can be extended to all hypervalent iodine compounds (Figure 
25).234  
 
 
Figure 25: Oxidation of iodides and resulting classifications of hypervalent iodine compounds 
 
Although the term “iodonium salt” is commonly used and accepted as a descriptor for 
a hypervalent iodine compound bearing three ligands, the compounds in this class 
are more accurately defined as λ3-iodanes. In actual fact, the term “salt” in iodonium 
salts is a poor descriptor for these compounds, as x-ray crystallography has revealed 
they commonly adopt a pseudotrigonal bipyramidal structure (Figure 26). 
 
 
 
Figure 26: General structure of aryl-λ3-iodanes (left) and a 3-centre–4-electron bond molecular 
orbital diagram (right). One heteroatom ligand X is exchanged for an aryl group in the case of 
diaryliodonium salts 
 
Occupancy of the apical positions of the λ3-iodane by electronegative ligands is 
preferred, as this contributes to stabilisation of the electron density provided by the 
surplus pair of electrons on iodine, giving those ligands a partial negative charge.236 
This affords a three centre–four electron bond (3c–4e) including the two apical 
ligands and iodine (Figure 26), an iconic feature of λ3-iodanes that gives the 
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compound class its distinct reactivity properties.  The resulting filled non-bonding 
orbital, which features a node on the iodine atom promotes a positive charge build 
up on iodine giving the iodane its characteristic electrophilic behaviour. The build-up 
of positive charge on iodine is partially alleviated by electron-deficient ligands, 
typically aryl, alkynyl or alkenyl groups, inhabiting the equatorial position, hence 
supporting stabilisation of the hypervalent species. It is worth noting here, that in the 
case diaryliodonium salts bearing electron-rich aromatics, only one electronegative 
ligand is able to provide reasonable stabilisation of the hypervalent 3c-4e bond, 
making these compounds less stable than the ArIX2 counterparts.
235   
The discovery and application of λ5-iodanes Dess-Martin Periodinane (DMP) 103237 
and iodoxybenzoic acid (IBX) 104238 (Figure 27) as highly effective and selective 
oxidising agents,239 drastically improved the reception of hypervalent compounds, 
opening up their development to more applications. Many of the advantages these 
reagents provide over chromium and Swern based approaches, such as milder 
reaction conditions, shorter reaction times, reduced toxicity, higher yields, etc.), can 
be accredited to their hypervalent nature and the two orthoganol 3c-4e bonds that 
they each possess.  
 
 
Figure 27: Examples of λ5-iodanes used as oxidants, Dess-Martin Periodinane (DMP) 103 and 
iodoxybenzoic acid (IBX) 104 
 
Oxidations with λ3-iodanes are also often applied in organic chemistry, with 
phenyliodo bis(acetate) 105, (also commonly referred to as diacetoxyiodobenzene, 
or phenyliodo diacetate) and iodosobenzene (also known as iodosylbenzene) 106 
providing two commonly utilised examples (Figure 28).240  
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Figure 28: Examples of λ3-iodanes used as oxidants, phenyliodobisacetate 103 and iodosobenzene 
(iodosylbenzene) 106 
 
Other RIL2-type λ
3-iodanes have similar oxidative properties, but are also commonly 
employed as precursors to R2IL reagents like diaryliodonium salts, classical examples 
include Koser’s reagent 107,241 Stang’s reagent 108242 and Zefirov’s reagent 109243 
(Figure 29); all of which have seen further development into augmented derivatives 
with improved reactivity or selectivity.178 R3I-type λ
3-iodanes, i.e. iodonium species 
bearing three carbon-based ligands, are thermally unstable and usually not 
synthetically useful, although the literature does describe a handful of examples that 
presented sufficient stability to allow characterisation.244,245 
 
 
Figure 29: Structures of Koser's reagent 107, Stang's reagent 108 and Zefirov's reagent 109 
 
However, the focus of this work on diaryliodonium salts explores the use of Ar2IL 
type λ3-iodanes, which exhibit somewhat different chemical properties and 
reactivities. Although the solid state structure of diaryliodonium salts is known to be 
pseudotrigonal bipyramidal, little is known about the structural conformation of these 
compounds in solution, as it is likely the counter-ion, solvent use and temperature 
will affect the structural characteristics of these λ3-iodanes. Similarly, asymmetric 
diaryliodonium salts can adopt either of two structures, depending on which aromatic 
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ring has higher preference for the equatorial position. The T-shaped structural format 
is widely accepted as the most accurate representation of these compounds, 
however, diaryliodonium salts are conventionally drawn in their “salt form” (Figure 
30). Note that radiochemists that utilise these compounds as precursors to 
[18F]fluoroaromatics often refer to the aromatic to be fluorinated as the target ring 
and the other aryl group as the non-participating ring (n.p.r.), although use of this 
terminology is mainly used in context with the electronic and steric characteristics 
that dictate the outcome of radiofluorination.253  
 
 
Figure 30: Equatorial/apical exchanging of aryl groups of diaryliodonium salts in solution (left) and 
the conventional representation of diaryliodonium salts in the “salt form” (right).   X = Cl, Br, I, OTf, 
OTs, TFA, BF4, PF6, etc. 
 
The choice of counter-ion plays an important role in diaryliodonium salt design 
because of the resulting effects it can have on the salt’s stability and reactivity. The 
nucleophilic nature of halides make them poor counter-ions, as do anions that 
strongly coordinate to the I+ centre, hence poorly nucleophilic, weakly coordinating 
counter-ions such as trifluoroacetate, triflate, tosylate and tetrafluoroborates (and 
other non-exchangeable fluoride bearing counter-ions) are usually preferred.  
 
2.2 Reactivity of Diaryliodonium Salts 
 
Generally, initial nucleophilic attack on the electrophilic iodonium salts species 
initiates with a ligand exchange, with displacement of a heteroatomic ligand by the 
nucleophile. There is much debate surrounding the mechanism of this reaction and a 
number of mechanisms have been suggested,246 mechanistically, it is plausible for 
both the ligand to dissociate from the iodonium salt prior to nucleophilic attack or for 
ligand loss to occur after coordination of the nucleophile; providing two conceivable 
reaction pathways (Scheme 45).246  
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Scheme 45: Dissociative and associative pathways for formation of "T-shaped" PhLINu complexes 
as a result of nucleophilic attack on λ3-iodanes 
 
The existence of the cationic [8-I-2] species above (Scheme 45) has been validated 
for many λ3-iodanes by mass spectrometry thus enforcing the dissociative 
mechanism, however, studies have also shown that on dissociation of the counter-
ion/ligand, the vacant position is rapidly reoccupied by a solvent molecule.247 X-ray 
diffraction studies on iodosylbenzene whilst subjected to aqueous conditions 
indicated that the species was ligated by a water molecule as [PhI(H2O)OH]
+, where 
the water molecule occupied one of the apical sites as part of the hypervalent 3c-4e 
bond, displaying a bond angle of nearly 180° which satisfies λ3-iodane “T-shape” 
geometrical requirements.248 There is also research to suggest that the associative 
pathway, which involves the formation of the intermediary square planar [12-I-4] cis 
and trans complexes (Scheme 45), is also valid; as x-ray analyses of similar, stable 
square planar tetra-ligand iodanes, i.e. [IL2L’2]
–[SCl3]
+ have been observed.249 
In the case of nucleophilic attack of diaryliodonium salts it is widely accepted that the 
nucleophile displaces the ligand to yield a “T-shaped” intermediate by one of the 
above two mechanisms, before undergoing simultaneous reductive elimination of the 
iodoarene leaving group and ligand coupling between the nucleophile and the 
equatorial aryl group. With this process being critical to radiochemists that conduct 
radiofluorinations of diaryliodonium salts, the mechanism and resulting 
regioselectivity between [18F]fluorination of the two aromatic ligands has been 
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studied in detail and the below “turnstile” mechanism has been proposed (Scheme 
46).152 
 
 
Scheme 46: [18F]Fluorination of a diaryliodonium salt via the proposed "turnstile" mechanism152 
 
The final irreversible step sees the collapse of the tricovalent intermediate to yield 
the [18F]fluoroaromatic and iodoarene products, potentially as a mixture of both 
regiochemical outcomes. The stable iodoarene leaving group, bearing no formal 
charge on elimination, is an outstanding leaving group, which is 106 times better 
leaving group than the “super leaving group” triflate anion.250 This extraordinary 
leaving group ability of the iodoarene earns it the term hypernucleofuge and 
provides the reaction with a major driving force towards elimination of this 
species.235  
 
2.2.1 Chemoselectivity of Diaryliodonium Salt Fluorination 
 
As mentioned above, nucleophilic attack on an asymmetric diaryliodonium salt can 
provide a number of products that are a direct result of the substituents featured on 
the precursor. In the absence of a transition-metal catalyst and with substrates 
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without functionality in the ortho- positions, the more electron-deficient aryl ring will 
be fluorinated in preference.251  
Here, the aryl group that predominantly occupies the equatorial position is the 
species that is transferred to the nucleophile during ligand coupling, which in the 
ground state is the more electron-poor aryl group (Scheme 47), given its ability to 
help alleviate the build-up of negative charge in the transition state (113).252  
 
 
Scheme 47: Berry pseudorotation of diaryliodonium salt during [18F]fluorination and the preference 
for electron-poor aromatic occupation in the equatorial position. 
 
Similarly, the transition state exhibits a build-up of positive charge on iodine, which 
can be stabilised by the presence of an electron donating aryl group situated in the 
apical position and lower the energy of the transition state associated with this 
pathway, hence providing a major preference for the products highlighted above 
(Scheme 47). However, favouring of this reaction pathway is in spite of complex 110 
displaying higher stability than complex 111, since an electronegative species in the 
apical position is preferred to stabilise the hypervalent 3c-4e bond, but transitioning 
between the two “T-shaped” complexes is afforded by rapid Berry pseudorotation 
(ψ), allowing for a fluxional equilibrium between the species; however, there is also 
evidence to suggest that this pathway may be of too high energy to be realistic.253,254 
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As well as electronic influences, steric factors also provide a major contribution to the 
regiochemistry of diaryliodonium salt fluorination, whereby aryl groups bearing steric 
bulk in the ortho- position see that group take preference for the equatorial position 
over the apical one.255 This observation is an artefact of the equatorial position being 
less hindered than the apical counterpart and often provides an overriding effect that 
facilitates fluorination of the electron-rich aryl ring when both arenes are of equal 
electron-density; an extremely useful tool for radiochemists looking to produce 
electron-rich [18F]fluoroaromatics, commonly referred to as the ortho-effect (Scheme 
48).256 
 
 
Scheme 48: Demonstration of the ortho-effect on [18F]fluorination of a diaryliodonium salt bearing 
ortho-bulk  
 
A fully comprehensive study of nucleophilic reactions of diaryliodonium salts with 
regards to electronic factors versus steric factors has yet to be published, although 
our group has described some interesting observations in this area previously.257 
Largely the ortho-effect appears to have a substantial effect over product selectivity 
when the arenes on iodine are of similar electronic character,255,256 however, there 
are examples of aryl groups bearing ortho- bulk that were not transferred to the 
nucleophile where carbon nucleophiles were employed,258 as such as the work by 
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Ochiai and co-workers in their use of chiral diaryliodonium salts in the asymmetric 
transfer of aryl groups (Scheme 49).259 
 
 
Scheme 49: Asymmetric α-phenylation of β-keto ester enolates using chiral diaryliodonium salts 
 
Aside from the substituents on the aromatic rings of diaryliodonium salts, the choice 
of counter-ion has also been shown to have a remarkable effect on the outcome of 
radiofluorinations on such λ3-iodanes. Work by Ross et al developed an 
understanding on the influence of different counter-ions on [18F]fluorinations using 2-
methoxyphenyl(2-thienyl)iodonium salts 121 as model compounds (Scheme 50), 
finding that the application of a bromide counter-ion afforded superior RCYs (Figure 
31).221 Although the low nucleophilicity of organic counter-ions would be expected to 
benefit the [18F]fluorination of diaryliodonium salts, they also exhibit a more 
pronounced covalent interaction with the iodonium centre versus their inorganic 
counterparts, which can result in steric and electronic hindrance; whilst the 
application of the bromide counter-ion can promote formation of arylbromide by-
products, which may be difficult to separate from the arylfluoride product.  
 
 
Scheme 50: [18F]Fluorination of 2-methoxyphenyl(2-thienyl)iodonium salts with different counter-
ions 
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Figure 31: The influence of counter-ion selection on the [18F]fluorination RCYs of various 2-
methoxyphenyl(2-thienyl)iodonium salts221 
 
Hence a balance is struck between counter-ions that provide better stabilisation of 
the hypervalent 3c-4e bond but display increased nucleophilicity which supplements 
the competing substitution reaction; and counter-ions that are less strongly bound to 
iodine and thereby dissociated, allowing for increased [18F]fluoride interaction with 
the electrophilic centre.221 Despite the relatively high nucleophilicity of the 
trifluoroacetate anion, the counter-ion sees frequent use in this application because 
of the convenience of preparing diaryliodonium trifluoroacetates.260,261 
The performance of diaryliodonium salt fluorination reactions is also highly 
dependent on a number of other factors - as expected reaction times, substrate 
concentration and temperatures play major roles, but the choice of solvent also 
greatly effects the RCY of [18F]fluoroaromatics produced. SNAr chemistry employed 
for [18F]fluorinations typically rely on aprotic, polar solvents for success, where DMSO 
sees regular application. However, the Sδ+–Oδ– dipole demonstrated by the solvent 
often negates its effectiveness for chemistry with diaryliodonium salts, possibly as 
result of cation solvation.262  
The use of acetonitrile  (CH3CN) and dimethylacetamide (DMAA) have also shown to 
achieve very limited RCYs,221 whereas the use of dimethylformamide (DMF) has 
displayed drastically better results for diaryliodonium salt [18/19F]fluorinations across 
multiple studies, 263 which has been demonstrated by Wüst et al in the fluorination of 
symmetric 4,4’-diiododiphenyliodonium salts (Table 5).222  
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Counter-ion Rxn 
Conditions 
Solvent Yield of 4-[18F]fluoroiodobezene 
Cl– 80 °C CH3CN 0.5–1.0% 
Cl– 120 °C CH3CN 1.3–2.8% 
Cl– 100 °C DMF 3–12% 
Cl– 160 °C DMF 15–52% 
TsO– 100 °C CH3CN 0.5–2.5% 
TsO– 140 °C DMF 21–46% 
TfO– 100 °C CH3CN 2.5–5% 
TfO– 140 °C DMF 11–22% 
TfO– 140 °C DMSO 0.5–1.0% 
Cl– MW DMF 15–70% 
 
Table 5: Reaction conditions for the preparation of 4-[18F]fluoroiodobenzene from 4,4'-
diiodophenyliodonium salts with various counter-ions and conducted in a range of solvents 
 
The above summary table not only describes the benefits of using DMF over other 
solvents in these reactions, as well as the improvement seen by utilising triflate or 
tosylate counter-ions, but also the scope for the higher reaction temperature 
afforded by DMF, which appear to be greatly beneficial for high RCYs from 
diaryliodonium salt [18F]fluorination;264 however, error ranges remain consistently 
large. This trend of increasing RCYs could be extended through higher temperatures, 
however, are limited by the physical properties of DMF, which is known to 
decompose to dimethylamine and carbon monoxide at temperatures exceeding 160 
°C,265 a clear limitation of conducting these reactions in non-closed systems. 
Microwave-assisted heating has seen fairly frequent use in [18F]fluorination 
chemistry,169 including some diaryliodonium salts,180,266,267 but has yet to be applied 
to a wide range of diaryl-λ3-iodane systems. In the above table, the application of 
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microwave heating offers greatly reduced reaction times, a very welcome benefit for 
radiochemists, and does see an improvement in the maximum achievable RCY, 
however, the range of RCYs is also markedly wider, which raises a reproducibility 
concern (Table 5).222  
Similarly, the use of chloride counter-ion versus other anions also displays a large 
amount of deviation in the RCY output, an issue that commonly observed in the 
[18F]fluorination of diaryliodonium salts, until a strategy was developed by Carroll and 
co-workers that greatly improved the robustness of the chemistry.261 Here the group 
attributed this inconsistency to the unprompted and random formation of aromatic 
radical species, produced by homolytic cleavage of the aryl-iodine bond when 
subjected to heating. They found that the application of various radical scavengers 
(Table 6), such as butylated hydroxytoluene (BHT), galvinoxyl and 2,2,6,6-
tetramethylpiperidine-1-oxyl (TEMPO) 124 (Scheme 51) could halt further 
propagation by the radical species and thereby reduce the inconsistency seen over 
multiple [18F]fluorination runs (Table 6) and reduce the formation of side products 
formed by this competing radical mechanism.261  
 
 
Scheme 51: Application of radical scavenger TEMPO to improve reproducibility of diaryliodonium 
salt fluorinations  
 
 
 
 
 
 
 92 
Radical Scavenger Yield Average yield 123:124 
none <5% <5% 1.1:1 
BHT 14-28% 21% 1.3:1 
Galvinoxyl 22-29% 26% 1.3:1 
TEMPO 24-26% 25% 1.3:1 
 
Table 6: [19F]Fluorination of diaryliodonium salt 122 with and without various radical scavengers 
(10 mol%), whereby TEMPO provided the most reproducible results261 
 
2.2.2 Applications of Diaryliodonium Salts 
 
Aside from their applications as hypernucleofuge centred precursors to 
[18F]fluoroarenes, aryl-λ3-iodanes also have a number of other chemistries at their 
disposal, allowing employment into a number of very varied applications.178  The 
aforementioned exchange of heteroatomic ligands is common and although the 
substrate scope is exceptionally wide, the general transformation is the same. In 
contrast, the numerous reactions encompassed under the umbrella of ‘reductive 
eliminations’ can be categorised into a number of sub-types, consisting of: reductive 
α-elimination, reductive β-elimination, hypernucleofuge reductive elimination, 
reductive elimination with fragmentation, reductive elimination with substitution, 
reductive elimination with rearrangement, homolytic cleavage and ligand.235  
With regards to diaryl-λ3-iodanes, these reagents have seen substantial success in a 
variety of organic transformations, including use as arylation reagents for a wide 
range of substrates,268,269,270,271 including heteroatomic nucleophiles;272,273 as metal-
catalysed and metal-free cross-coupling reagents;274,275, as efficient Lewis acid 
catalysts (e.g. for three component Mannich reactions),276 precursors to biaryl and 
benzyne systems;277278 strategies to macromolecule syntheses;279 and applications in 
photochemistry and polymerisation.178,280,281 Scheme 52 provides a pictorial summary 
of some of the applications of diaryl-λ3-iodanes outside of [18F]fluoroaromatic 
preparations. 
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Scheme 52: A summary of some of the transformations possible with diaryl-λ3-iodanes outside of 
[18F]radiofluorinations 
 
2.3 Synthesis of Diaryliodonium Salts 
 
The literature presents a number of strategies for the preparation of diaryliodonium 
and aryl(heteroaryl)iodonium salts from commercially available starting material, 
many of which involve the oxidation of an iodoarene to an intermediary ArIL2 λ
3-
iodane compound, which undergoes ligand exchange with a nucleophilic aryl 
compound to achieve the target diaryliodonium salt compound;282 and if desired, a 
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counter-ion exchange reaction can be undertaken to yield a diaryliodonium salt with 
an anion more suited to its purpose.283 This very versatile and convenient method 
provides a clean, two-step route to diaryliodonium salts and is tolerant of a wide 
range of functionalities (Scheme 53). Here some commonly utilised oxidants include 
hydrogen peroxide,284 sodium periodate,285 mCPBA286 and sodium perborate,287 all of 
which allow for preparation of functionalised λ3-iodanes under mild conditions.288  
 
 
Scheme 53: Preparation of diaryliodonium salts via aryliodobis(acetate)s 
 
The subsequent transformation is, again, very adaptable, with most procedures 
utilising organic acids such as triflic acid, tosylic acid or trifluoroacetic acid to activate 
the λ3-iodane towards nucleophilic attack; where arylstannane reagents, arylboronic 
acids and arylsilanes are commonly employed to afford the diaryl-λ3-iodane under 
mild, substrate tolerant conditions, whilst providing regiochemical control.178 This 
method came as a much needed improvement over the dated application of 
iodosylarenes (ArI=O) and iodoxyarenes (ArIO2), which typically afford poor yields, 
required lengthy preparations and are inherently explosive.289   
Koser’s reagent 107 (Figure 29) and its derivatives have seen regular use as a mild 
and convenient routes to diaryl-λ3-iodanes since their deployment, but were largely 
limited by modest yields. However, Kita et al demonstrated the use of 2,2,2-
trifluoroethanol (TFE) as a superior solvent for coupling the ArIL2 reagent with 
electron-rich arenes (Scheme 54), providing high yielding route to diaryliodonium 
salts that easily adapted for a variety of substrates.290 Koser’s reagent and related 
compounds also allow for the incorporation of electron-deficient arenes, again by 
utilising boronic acid, silyl- and stannyl- based precursors.291,292,293  
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Scheme 54: High yielding preparation of diaryl-λ3-iodanes using Koser’s reagent and its derivatives 
 
Alkenyl-λ3-iodanes, despite their instability, have also seen multiple applications as 
precursors to both symmetrical and unsymmetrical diaryl-λ3-iodanes, often providing 
good yields. However, their highly reactive nature comes at the cost of the need for 
delicate reagent pre-synthesis using strong bases and low temperatures.178 
Traditional uses of unstable iodanes in this application demanded highly acidic 
conditions, which not only limits substrate scope but also deactivates functionality 
susceptible to protonation such as heteroarenes, however Beringer and Nathan 
defined a method for using the reagent class that allowed diaryliodonium salts 
formation under basic conditions.294,295 Here the group prepared trans-
chlorovinyliodoso dichloride 129 from ethyne 128, then immediately treated the 
reagent with a variety of lithiated arenes to afford diaryliodonium chlorides in modest 
to excellent yields (Scheme 55).294 
 
 
Scheme 55: Preparation of diaryl-λ3-iodane chlorides via a highly reactive alkenyl-λ3-iodane reagent 
 
A number of other research groups have also looked to exploit the high reactivity of 
unstable λ3-iodanes to achieve a rapid route to diaryliodonium salts, for which 
inorganic hypervalent iodine(III) reagents, (i.e. a λ3-iodane bearing no ligands that 
are bound to iodine via a carbon atom) are often very applicable. Iodosyl sulfate,296 
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Iodosyl triflate297 and tris(trifluoroacetoxy)-λ3-iodane 130 (Scheme 56)298,299 have all 
been investigated as suitable inorganic iodine(III) precursors that yield symmetrical 
diaryliodonium salts from electron-rich (hetero)aromatics and electron-deficient 
arenes activated with stannyl-, silyl- or boronic acid functionality. However, as with 
alkenyl-λ3-iodanes, their frequent application is limited by the difficulty of their 
syntheses and their potentially explosive character.  
 
 
Scheme 56: Preparation of symmetrical electron-rich diaryliodonium salts using iodine(III) 
trifluoroacetate 
 
Recently some more direct, one–pot strategies for diaryliodonium salts preparation 
from arenes and iodoarenes have also been developed (Scheme 57),178 however, 
although these approaches offer very high yields at small scale, larger scale 
production via these routes proved to be problematic and substantially lower yielding 
in practice, many also have rather specific substrate requirements.  
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Scheme 57: Multiple one-pot approaches to diaryl-λ3-iodane synthesis, a),300 b),301 c),302 d),303 e)304 
and f)305 
 
2.4 A Strategy for 4-[18F]Fluorophenol Production 
 
Of the numerous strategies discussed in Section 2.3, aryliodobis(acetate)s were 
employed as robust and adaptable precursors to a range of diaryliodonium 
trifluoroacetates (Scheme 53) that deliver a n.c.a. route to 4-[18F]fluorophenol. This 
strategy for diaryliodonium trifluoroacetate preparation has been well developed 
within the group,260,261  and has seen successful application to a number of 
diaryliodonium salts, including precursors for 4-[18F]fluorobenzaldehyde], N-(4-
[18F]fluorophenylmaleimide, 2-, 3-, and 4- regioisomers of ethyl [18F]-fluorobenzoate, 
[18F]DAA1106, [18F]SFB and [18F]3-fluoro-5-[(2-methy-1,3-thiozol-4-yl)ethynyl] 
benzonitrile ([18F]MTEB). Here the general approach begins with preparation (and 
protection if necessary) of the target aryl halide, whilst preparation of the “non-
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participating ring” (n.p.r.) aryliodobis(acetate)s from a simple, usually electron-rich 
iodoarene is conducted in tandem. After stannylation of the target aryl halide, 
convergent coupling of the activated aryliodobis(acetate)s with the aryl stannane 
affords the target diaryliodonium trifluoroacetate; hence providing a versatile 
strategy to the preparation of diaryliodonium salts that yield 4-[18F]fluorophenol on 
radiofluorination and deprotection (Scheme 58).  
 
 
Scheme 58: General route for the preparation of diaryl-λ3-iodane precursors that yield 4-
[18F]fluorophenol on treatment with [18F]fluoride 
 
Although the use of organotin chemistry presents a serious toxicity concern, careful 
purification of the product diaryl-λ3-iodane from the reaction mixture, either by 
column chromatography or multiple recrystallisations eliminate any detectable 
amounts organotin precursor of by-products.  
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2.5 Preparation of Aryliodobis(acetate)s 
 
Numerous research groups have published a range of strategies that permit 
oxidation of iodoarenes to aryliodobis(acetate)s under mild conditions in modest to 
good yields,284,285,286 Here the procedure developed by McKillop et al 287,306 was 
utilised because the method allows for broad substrate scope, a simple work up 
procedure and utilises sodium perborate tetrahydrate (NaBO3·4H2O) as a cheap 
oxidant, allowing for the production of aryliodobis(acetate)s 132-137 (Scheme 59).  
 
 
Scheme 59: Preparation of aryliodobis(acetate)s via oxidation of iodoarenes with NaBO3·4H2O 
 
McKillop and Sanderson have proposed that the active species in this reaction is an 
oxidative peracetoxyborane species, formed in situ by the mixing of sodium 
perborate tetrahydrate, known to be the disodium salt of 1,4-borate dianion 138,307 
with acetic acid (Scheme 60).306  
 
 100 
 
Scheme 60: Formation of a reactive peracetoxyboron species expected to be the active oxidant in 
the preparation of aryliodobis(acetate)s via oxidation of iodoarenes using sodium perborate 
tetrahydrate  
 
In the above scheme, it is speculated that the species reacting in step C may be the 
same as that in step B, or that an intermediary solvolysis of the first BOOB linkage 
may have occurred. It was also considered that the numerous species bearing 
BOOAc units could also potentially act as oxidants on organic substrates, in tandem 
with or in place of the peracetoxyboron species afforded by the final acid-catalysed 
hydrolysis.306   
In practice, monitoring the progress of the reaction proved to be a challenge, as 
analysis via chromatographic methods (TLC) could not be utilised and the literature 
provides few examples of accurate reaction times, which can vary substantially 
depending on the electronic character of the substrate. Here the most practical 
method of judging the reaction progress of a aryliodobis(acetate) preparation was by 
visual observation of the reaction mixture, the homogenous starting mixture 
gradually yields an off-white precipitate, where a higher opacity typically correlated 
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to a higher yield. With extended reactions times (> 5 h) the reaction mixture was 
seen to revert to homogeneity and in these instances a drastically lower yield was 
afforded, and hence for lack of a better method, reaction progress was monitored by 
the proportion of precipitate in the reaction mixture, with optimal reaction times 
ranging between 4 and 5.5 hours. Given that aryliodobis(acetate)s are useful 
precursors to diaryliodonium salts, multiple batch-based productions of 
aryliodobis(acetate)s not only provided information on the achievable yields of the 
oxidation reaction (Figure 32), but also allowed for stock-piling of the synthetic 
precursor providing the λ3-iodane was correctly stored. 
 
 
Figure 32: Yields of aryliodobis(acetate)s preparations via oxidation of iodoarenes with sodium 
perborate tetrahydrate. Ar = phenyl (132), 2-thienyl (133), 4-anisyl (134), 2-anisyl (135), 4-tolyl 
(136) and mesityl (137); n = 3 minimum 
 
It was found that the most electron-deficient phenyl system 132 in the series 
exhibited the highest yield and the oxidation of 4-iodotoluene to 136 afforded a 
similarly high yield, both with relatively good reproducibility. However, with 
increasingly electron-rich iodoarenes, yields were seen to lower accordingly and 
become less consistent. In particular, the 2-thienyliodobis(acetate) 133, afforded 
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yields that were not only very inconsistent, but also even at best, were markedly 
lower than the other (diaceoxy)iodoarenes in the series.  
In an effort to optimise the preparations of the most commonly utilised 
aryliodobis(acetate)s and to study the effect of substrate electronics on the reaction 
time, the reaction progress for the formation of 132, 133, 134 and 135 was 
monitored by 1H NMR in 30 min increments for 7 h. Here an expected downfield shift 
of protons ortho- to the iodine centre from 7.3 – 7.5 ppm for aryliodide starting 
materials to 7.7 – 8.0 ppm for ArI(OAc)2 species could be observed and was utilised 
to determine the conversion progress of the reaction.261 This experiment highlighted 
the dependence reaction time has on electronic character of the substrate, note that 
complete consumption of the starting material is rarely seen and even with optimised 
reaction times, substantial starting material remained, attributing to the relatively 
poor conversions seen above (Figure 32).  
 
Aryliodobis(acetate) Ar Time Product: SM ratio 
132 phenyl 5.5 h 6:1 
133 2-thienyl 4.0 h 3:1 
134 4-anisyl 4.5 h 4:1 
135 2-anisyl 4.5 h 4:1 
 
In general, it was found that substrates endowed with electron-donating groups in 
ortho- or para- positions provided higher yields with shorter reactions times, as did 
the electron-rich heteroarene 133, which is in line with initial findings by McKillop 
and co-workers, who found that arenes bearing electron-withdrawing meta-
substituents also exhibited accelerated oxidation, whereas systems with ortho- or 
para- electron-withdrawing groups required longer reaction times.287  
The decomposition of the aryliodobis(acetate)s when exposed to atmospheric 
conditions, when stored in solution over distinct periods of time and when heated 
has been studied in detail using electrospray ionisation mass spectrometry (ESI-MS) 
Table 7: Optimal reaction times for production of aryliodobis(acetate)s 132-135 
 103 
by Silva et al,308  a feature of this compound class that was also noted in this work. 
Here ESI-MS was performed on a freshly prepared sample of phenyliodobis(acetate) 
132 (Figure 33, A) dissolved in acetonitrile, a sample of 132 stored in acetonitrile at 
room temperature for 24 h (Figure 33, B) and a freshly prepared sample of 132 
heated to 80 °C in acetonitrile prior to analysis (Figure 33, C).  
 
             
Figure 33: Decomposition products of (diacetoxy)iodobenzene 132 when subject to B: extended 
period in solvent (MeCN, 24 h at RT) and C: when heated (MeCN, 80°C) versus A: a freshly prepared 
solution of 132 (MeCN, RT) as observed by ESI-MS 
A 
B 
C 
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The ESI-MS study emphasised the potential that aryliodobis(acetate)s have for rapid 
decomposition when stored in solution for relatively short periods of time and when 
heated in solution, to afford the numerous dimeric and iodosyl species highlighted 
above. It is expected that a degree of decomposition to these species also occurs 
during the reaction conditions, which competes with the formation of the desired 
oxidation product and hence further limits the resulting yields of aryliodobis(acetate) 
production. Despite the unreliability and relatively poor yields afforded by McKillop 
and co-workers’ general method for aryliodobis(acetate) production,287 the procedure 
does provide a simple route for batch preparation of the valuable λ3-iodanes when 
performed in relatively large scale (60 mmol), whilst utilising cheap, commercially 
available starting materials and an oxidant that allows for mild reaction conditions 
and affords non-toxic by-products. 
A further improvement was made on the yield for the most commonly employed 
aryliodobis(acetate), 134, by utilising an Asynt ReactoMate CLR jacketed reactor 
system (Figure 34), which provided more efficient heat distribution through the use 
of an overhead stirrer coupled with Julabo temperature control circulator.309 The 
simple reaction set up allows for easy extraction of the product aryliodobis(acetate) 
through a filter port at the bottom of the vessel, a practically useful feature for when 
the preparation is conducted at large scale. Not only was a noteworthy increase in 
the average yield of this reaction observed (>15% increase), but the consistency of 
yields also saw drastic improvement (± 3% with the jacketed reactor system versus 
± 18% with a standard round bottomed flask and magnetic stirrer). 
 
 
Figure 34: Asynt ReactoMate CLR Jacketed system (pictured left) and the scheme for improved 
production of aryliodobis(acetate) 134 (right) 
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Here the optimisation of the aryliodobis(acetate) preparation protocols for the λ3-
iodanes described in this section (132–137) provided a relatively reliable and quick 
to synthesise source of the diaryliodonium salt precursors largely bearing the desired 
electron-rich character. Once prepared, these reagents were stored in a freezer, in 
the dark for a limited period (maximum of 2 weeks) before being utilised in the 
subsequent coupling reaction, once the corresponding arylstannane had been 
produced. The oxidising nature of aryliodobis(acetate) synthesis denies the 
incorporation of sensitive functionalities and hence our general approach entails the 
preparation of the arylstannane component as the more functionalised ‘target’ 
aromatic ring, rather than the reverse.  
 
2.6 Preparation of Arylstannanes  
 
The use of arylstannane reagents in this application (and as in many other 
applications) provide a means for nucleophilic coupling of the stannylated aryl group 
on an electrophilic centre, being the aryliodobis(acetate) hypervalent iodine centre in 
this case. Other commonly utilised applications of the reagent class include 
carbonylation reactions,310 and Stille coupling reactions,311 but these methods often 
involve a different substrate scope to those discussed in this work. The benefits of 
using arylstannane reagents here over the alternative boronic acids or silane based 
reagents not only includes improved reactivity towards electrophilic species, but in 
addition their preparation is generally very tolerant to the inclusion of multiple 
sensitive functionalities, hence being beneficial to our general approach to 
diaryliodonium salt formation. 
A forgoing requirement to stannylation of the phenol halides is protection of phenolic 
functionality, for which two simple approaches, benzylation (Scheme 61) and 
acetylation (Scheme 62) provided robust means to protect the alcohol functionality 
whilst allowing for simple and quick deprotection of the target fluoroarene. 
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Scheme 61: Simple benzylation protection of 4-iodophenol and 4-bromophenol 
 
 
Scheme 62: Simple acetylation protection of 4-iodophenol and 4-bromophenol 
 
These easily scalable protocols provided access to substantial amounts of the 
required protected aryl halide starting materials, that were not only simple to purify 
but also sufficiently stable for long term storage. Here both bromo- and iodo- 
derivatives of the fluorination target were prepared to determine which provided the 
superior substrate for stannylation and whether or not use of 4-iodophenol over 4-
bromophenol outweighed the substantial difference in starting material cost (£41.27 
for 25 g312 versus £28.50 for 100 g313 respectively).  
In development of this protection strategy, it is important to consider the subsequent 
deprotection required after the prospective [18F]fluorination of the diaryliodonium 
salts; here this cleavage step must be fast to avoid loss of RCY, must be high 
yielding to avoid loss of protected-4-[18F]fluorophenol of which concentrations might 
be low, and must yield easily separable by-products. For the two protection methods 
described above (Scheme 61 and Scheme 62), methods of achieving rapid and high 
(chemical) yielding deprotection have previously been described (Scheme 63 and 
Scheme 64).314,315 
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Scheme 63: Rapid cleavage of benzyl protecting group via the in situ generation of molecular 
hydrogen through the addition of triethylsilane to palladium on charcoal314 
 
 
Scheme 64: Rapid cleavage of the acetyl protecting group using sodium perborate, providing a 
clean and highly selective procedure315 
 
A number of routes to arylstannanes from arylhalides are available and here more 
traditional approaches including palladium mediated stannylation (Scheme 65)316 and 
stannylation via halogen-lithium exchange (Scheme 66)317 were initially considered.  
 
 
Scheme 65: Preparation of arylstannanes via palladium catalysed stannylation 
 
 
Scheme 66: Preparation of arylstannanes via halogen-lithium exchange 
 
However, these methods of arylstannane synthesis proved to have a number of 
associated limitations. Although the tetrakis(triphenylphosphine)palladium (0) 
catalysed process produces good yields and is tolerant of a wide range of reactive 
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functionalities, use of the costly transition metal at the significantly high catalyst 
loading described above; coupled with the requirement for two equivalents of the 
considerably toxic hexa-n-butylditin reagents; and the high potential for biaryl 
formation through homo-coupling makes this approach relatively unattractive.316 
Similarly, stannylation achieved via halogen-lithium exchange can provide a fast, 
simple and low-cost route to arylstannanes, however, the use of n-butyllithium 
considerably limits the substrate scope, making this approach an inadequate method 
for preparation of arylstannane precursors with acidic protons and/or remotely 
electrophilic functionality.317  
An alternative method for trialkylstannanyl arene production that evades some of the 
constraints of the two approaches described above, includes the work of Gosmini and 
co-workers,318 which has demonstrated broad substrate scope, without the need for 
an expensive catalyst and without calling for two equivalents of a ditin reagent; all 
whilst affording good stannylation yields under mild conditions.319,320 This innovative 
conversion of arylhalide to arylstannanes proceeds with acidic activation of zinc dust 
to facilitate the reduction of cobalt (II) bromide, which then leads into the catalytic 
cycle depicted below (Scheme 67). The catalytic process continues via oxidative 
insertion of the resulting cobalt (I) bromide species into the substrate aryl bromide 
C-Br bond (or aryl iodide C-I bond), affording a trivalent arylcobalt dibromide 
complex. The subsequent transmetallation (provided by excess zinc in the system) 
accounts for the formation of the reactive organozinc species and simultaneous 
regeneration of cobalt (II) bromide (Scheme 67).320  
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Scheme 67: Cobalt (II) bromide catalysed formation of arylzinc species in Gosmini and co-workers’ 
preparation of arylstannanes 
 
Administration of the substrate arylhalide in tandem with the stannylating reagent, 
tributylstannyl chloride, allowed for in situ formation and reaction of the key 
organozinc reagent, affording one-step preparation of the desired 
tributylstannylarene products in 3-16 h with gentle heating (50 °C).  
Small modifications to the stoichiometry of the original procedure provided an 
optimised, simple-to-follow, one-step route to tributylstannylarenes from simple 
arylhalide substrates bearing various protected phenol functionality, affording yields 
of 53-91% (Scheme 68).  
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Scheme 68: One-step preparation of tributylstannylarenes from protected 4-halophenols via cobalt 
catalysed in situ arylzinc preparation 
 
Despite the increased reactivity offered by aryliodides versus the bromide 
counterparts, they suffer from notably lower yields across the series, which is mostly 
likely an artefact of competing by-product formation via homo-coupling,319 however, 
compared to methods described earlier (Scheme 65 and Scheme 66) this route 
provides comparable yields without the need for costly catalysts or more forcing 
reaction conditions. 
Initial preparations of arylstannanes by this adapted method highlighted potential 
difficulty in the separation of the stannylated product and other tributylstannyl by-
products, believed to be oxidised organostannanes such as Bu3SnO and Bu3Sn-O-
SnBu3. Although purification by column chromatography on SiO2 did, on occasion, 
afford the desired purified arylstannanes on one attempt, often multiple purifications 
were required and similarly, the potential for destannylation of the product on the 
acidic sorbent afforded reduced yields. This challenge was overcome by utilising 
reverse phase chromatography with neat acetonitrile as the eluent, a purification 
method that would otherwise prove to be grossly expensive on moderate/large scale, 
however, in this case flash chromatography allowed for rapid purification with 
reduced volumes of solvent. Likewise, the risk of destannylation was mitigated by 
employing flash reverse phase chromatography and provided the good yields 
described above (Scheme 68).  
This work demonstrates the scope of cobalt catalysed/organozinc mediated 
tributylstannyl arene preparation as an excellent alternative to conventional 
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approaches, via an easy to replicate, one-pot process, further supported by an ultra-
simple purification protocol.  
 
2.7 Preparation of Diaryliodonium Salts for 4-[18F]Fluorophenol 
Production 
 
As outlined in Section 2.3 the literature presents a number of diverse routes to 
diaryliodonium salts with various advantages and limitations. A general approach that 
could facilitate the production of electron-rich diaryliodonium systems; utilised the 
preferred trifluoroacetate counter-ion; and was tolerant of potentially sensitive 
protecting groups and/or other functionality was desired. In this work, a general 
procedure developed by Pike and co-workers321 was modified to meet this demand 
and was found to permit coupling of arylstannanes and aryliodobis(acetate)s 
activated with trifluoroacetate to yield the product diaryliodonium trifluoroacetate 
under very mild conditions (Scheme 69).  
 
 
Scheme 69: General method for the preparation of diaryliodonium trifluoroacetates from 
aryliodobis(acetate)s and arylstannanes 
 
Although the method is uncomplicated, there are a number of crucial finer points 
that must be followed stringently to achieve successful diaryliodonium salt formation, 
firstly preparation under anhydrous conditions using dried solvent and reagents is 
strongly recommended.  Dropwise addition of trifluoroacetic acid (2 eq.) to the cold 
(–30 °C) solution of aryliodobis(acetate) (as prepared in Section 2.5) is also vital for 
the in situ formation of a reactive aryliodo bis(trifluoroacetate) species, which when 
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subjected to an appropriate arylstannane (as prepared in Section 2.6, also 
administered at –30 °C affords the objective diaryliodonium trifluoroacetate after a 
period of stirring (10-17 h) in the dark, at room temperature.321 Unlike alternative 
approaches, this method avoids the necessity for heating the reaction, which can to 
some extent result in a reduced yield given the heat sensitive nature of hypervalent 
iodine compounds.300,305   
The nucleophilic character of the arylstannane C-Sn bond facilitates its attack on the 
electrophilic aryl-λ3-iodane (Scheme 70), a feature greatly enhanced by incorporation 
of the trifluoroacetates ligands. There is more evidence to suggest that this attack on 
the hypervalent species proceeds by an associative mechanism,322 rather than a 
dissociative mechanism (introduced in Section 2.2), however both mechanisms 
require elimination of a ligand in the equatorial position, which can only occur via the 
conformational interchange of a dimeric species provided by Berry pseudorotation 
(ψ) in the example below (Scheme 70).254 Note that up until this point, only 
monomeric models have been considered, however, as more is discussed it will 
become apparent many postulations rely on the existence of dimeric and polymeric 
species for them to occur. 
 
 
Scheme 70: A proposed mechanism for the formation of diaryliodonium trifluoroacetates, including 
consideration of an associative pathway in the mechanism 
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Practically, the formation of the diaryliodonium salt product could be monitored by 
TLC, as could the consumption of the arylstannane and aryliodobis(acetate) starting 
materials; and the subsequent product extraction procedure involved removal of 
~75% of the solvent e.g. DCM and addition of a lower polarity solvent e.g. petrol 40-
60 to afford crystallisation of the product.  
To promote crystallisation of the product diaryliodonium salt over remaining 
aryliodobis(acetate), preparations utilising a slight excess of arylstannane reagent 
were trialled.  1H NMR of the crude reaction mixture typically highlighted the success 
of the conversion as well as the proportion of arylstannane reagent remaining, 
however, when this impurity was present in substantial amounts, crystallisation of 
the product often proved challenging. In these circumstances column 
chromatography effectively removed these contaminants to yield purified 
diaryliodonium trifluoroacetates, however, this extended period of exposure to 
moisture, light, silica and potential nucleophiles understandably reduced the yields 
obtained, as did the inherent instability of the compound class, given the electron-
rich nature of the diaryliodonium salts’ arene substituents, versus diaryliodonium 
salts bearing electron-poor aromatics.  
Hence the above procedure (Scheme 69), was used to prepare diaryliodonium salts 
149-153 (Figure 35), with special care taken to ensure molar equivalency of the 
arylstannane and aryliodobis(acetate) reagents employed. 
 
 
Figure 35: Diaryliodonium trifluoroacetates prepared from arylstannanes and aryliodobis(acetate)s 
 
The challenges in product isolation (as well as product instability) resulted in 
inconsistent yields for all diaryliodonium salts prepared (n ≥ 3), but particularly for 
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products bearing the 2-thienyl functionality. In an attempt to improve the yields of 
some diaryliodonium salts through the application of an alternative solvent (of which 
options are limited), acetonitrile, was trialled in place of DCM and was also found to 
have a notable effect on the resulting yields (Table 8).  
 
Bu3SnAr (Ar =) ArI(OAc)2 (Ar =) Solvent Product Yield 
146 (4-(BnO)C6H4)
 134 (4-anisyl) DCM 149 39-71% 
146 (4-(BnO)C6H4)
 134 (4-anisyl) MeCN 149 52-67% 
146 (4-(BnO)C6H4)
 133 (2-thienyl) DCM 150 29-55% 
146 (4-(BnO)C6H4)
 133 (2-thienyl) MeCN 150 44-56% 
146 (4-(BnO)C6H4) 132 (phenyl) DCM 151 70-78% 
147 (4-(AcO)C6H4) 134 (4-anisyl) DCM 152 32-47% 
147 (4-(AcO)C6H4) 133 (2-thienyl) DCM 153 14-33% 
 
These findings highlight the enhanced instability afforded when the 2-thienyl moiety 
is incorporated into diaryliodonium salts, regardless of the protecting group on the 
other aromatic or the solvent used; likely to be a consequence of the arene’s 
increased electron density versus the other two non-participating ring (n.p.r.) 
systems. By the same rational, it was found that the integration of a phenyl n.p.r. 
into diaryliodonium salts such as 151 over the electron-rich arenes afforded higher 
yields, an expected observation given the preference for electronegative ligands in 
apical positions of diaryliodonium salts when compared to the other diaryliodonium 
systems, which bearing two electron-rich arenes are unable to provide stabilisation to 
the hypervalent 3c-4e bond.235  
Diaryliodonium salt 151, albeit more stable, is not a useful substrate for the 
production [18F]fluorinated protected phenol derivatives, as [18F]fluorobenzene is 
likely to be the major product given that is more electron-deficient than the other 
Table 8: A series of unsymmetrical protected phenoxy-iodonium trifluoroacetates prepared from 
coupling arylstannane and aryliodobis(acetate) reagents 
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arene, however, this diaryliodonium will be retained in the series as it provides 
support to the methodology of diaryliodonium salt fluorination.   
Another clear observation provided by the results in Table 8 includes the notable 
benefit to yields achieved with benzylated arylstannanes over acetylated 
arylstannane substrates, most likely owing to the improved resistance to nucleophilic 
species within the reaction mixture, given that acetate groups are prone to in situ 
hydrolysis. Provisionally, this work suggest that substituting DCM for acetonitrile 
provided more consistent yields, such as diaryliodonium salts 149 and 150, 
however, further work on the conversion would be required to fully validate that 
claim.  
1H- and 13C-NMR spectra of diaryliodonium salts 149–153 were generally as 
expected and comparable to previously published derivatives,260,261 displaying a 
downfield shift of protons ortho- to the iodane between 8.0 – 8.3 ppm, relative to 
the protons in the same position on aryliodobis(acetate) starting materials, which 
typically exhibited a shift between 7.7 – 8.0 ppm. 1H-NOESY NMR also provided a 
means to discriminate proton environments experiencing very similar electronic 
influences, by collecting resonances from nuclei that are spatially close, as 
exemplified below for diaryliodonium salt 149.  
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Figure 36: 1H-NOESY NMR of diaryliodonium salt 149 
 
The general method for the preparation of electron-rich diaryliodonium salts 
described above (Scheme 69) proved to yield the desired target compounds 149–
153 of sufficient purity for radiofluorination (as deemed by 1H NMR, 13C NMR, HR-MS 
and elemental analysis), where amounts of contamination considered to be 
insignificant can lead to reduced RCYs and poor SAs. Further structural information 
of the electron-rich diaryliodonium salts was desired and hence a simple procedure 
for obtaining crystalline product suitable for crystallographic analysis was required. 
Multiple recrystallisation methods and various solvent combinations were examined, 
of these, recrystallisation via slow vapour diffusion using acetonitrile as the sample 
solvent and 50:50 diethyl ether:petrol as nucleation inducing solvent system, with 
two week freezer storage afforded crystals of sufficient quality for x-ray 
crystallography (Figure 37). 
HB HD HC PhCH2 OCH3 
Ph 
HA 
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Figure 37: X-ray crystal structures of diaryliodonium salts 149-151, prepared via slow vapour 
diffusion recrystallisation from acetonitrile and 50:50 diethyl ether:petrol 
 
As briefly discussed in Section 2.5, aryl and diaryliodonium salts are known to form 
numerous polymorphs; with dimers, trimers and polymeric structures frequently 
observed. Dimerism and polymeric interactions were also seen for diaryliodonium 
salts prepared within the 149-153 series (Figure 38). 
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Figure 38: X-ray crystal structures of dimeric polymorph of diaryliodonium salt 150 and polymeric 
polymorph of diaryl iodonium salt 153 
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At this stage, it is worth noting that very few published monomeric crystal structures 
of diaryliodonium salts are true representations of the ground-state structure of the 
species, as they are often extracted from dimeric or polymeric structures like those 
shown in Figure 39. For example, the orientation of the ring systems within the 
dimeric crystal structure of 150 (Figure 38) could be interpreted in two different 
ways (Figure 39), where arenes exchange between pseudo-equatorial and pseudo-
apical positons is facilitated by the dimeric nature of species.  
 
 
Figure 39: Ground-state conformation can be elucidated differently depending on which portion of 
the unit cell is selected 
 
The optimised procedures for the production of diaryliodonium salts (via Scheme 69) 
and the parent aryliodobis(acetate)s (Section 2.5) and arylstannanes (Section 2.6) 
allowed for the routine production of diaryliodonium salts suitable for the 
[18/19F]fluorinations described in the upcoming sections. However, an alternative 
route to some of these diaryliodonium salts, which negates the need for 
arylstannanes or other aromatic activated to nucleophilic attack, was also found to 
be useful. Investigations by Pike et al,321 highlighted the application of this route for 
preparing a variety of substituted electron-rich diaryliodonium triflates and 
trifluoroacetates, from simple electron-rich arenes (Scheme 71). 
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Scheme 71: Preparation of electron-rich diaryliodonium salts from aryliodobis(acetate)s and simple 
electron-rich arenes321 
 
This route does appear to be markedly simpler than our method involving 
arylstannanes, and omits the need for the toxic reagent and the associated stringent 
diaryliodonium salt purification required to ensure removal of organostannanes 
residues. For the production of diaryliodonium triflates incorporating simple (4-anisyl, 
4-tolyl, 2,4,6-trimethylphenyl) electron-rich arenes, this method afford good to 
excellent yields (60–85).321 However, for the production of more desirable 
diaryliodonium trifluoroacetates, yields reported via this route are limited to 30–60% 
for simple systems; and replication of this procedure for the synthesis of marginally 
more complex diaryliodonium trifluoroacetates such as 149 and 152 produced 
unsatisfactory results (Scheme 72). 
 
 
Scheme 72: Production of diaryliodonium trifluoroacetates via direct coupling of 
aryliodobis(acetate)s and protected phenols 
 
This more direct route to simple, electron-rich diaryliodonium trifluoroacetates, albeit 
convenient, suffers from very poor yields and hence the use of arylstannane reagents 
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outweighs its application, particularly when preparing more intricate diaryliodonium 
salts. In addition, use of the arylstannane route allows for the preparation of a 
variety of regioisomers, unlike the simple route which affords on certain regioisomers 
as dictated by electronics. 
 
2.8 [19F]Fluorination of Diaryliodonium Salts 
 
Prior to conducting [18F]fluorinations of the diaryliodonium salts prepared in Section 
2.7, it was deemed wise to conduct provisional [19F]fluorination experiments of the 
precursors, with an aim to quickly validate the relative magnitude of fluorination of 
the target ring versus the non-participating ring. As previously mentioned, the more 
electron-deficient arene of a diaryliodonium salt sees preferential fluorination over 
electron-rich counterparts.323 Hence for diaryliodonium salts 149–153, where the 
electron density of the two arenes on all examples is near equivalent, a 50:50 
selectivity profile between the target ring and the n.p.r. can be considered an 
encouraging outcome, and will aid selection of the most suitable diaryliodonium salts 
for the subsequent radiofluorination work.  
A simple protocol for [19F]fluorination of diaryliodonium salts was adapted from Shah 
and co-workers’ method;324 here the reactions were conducted on a small scale with 
deuterated DMF as the solvent of choice, since most radiofluorinations of this 
manner exploit DMF for its reagent compatibility and extended temperature range 
(up to 130 °C). Furthermore, application of the isotopologue allows for observation 
of the reaction progress in real time via 1H and 19F NMR.  
Caesium fluoride was selected as the model [19F]fluorination reagent, despite the 
actual species used for radiofluorination being different, however, work by Nairne et 
al has elucidated that caesium fluoride provides superior yields and the most 
suitability for these model [19F]fluorination experiments (Table 9).261 
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Fluoride source (“F ”) Yield  Ratio 155:156 
CsF 25% 1.3:1 
TBAF < 5% n/a 
KF < 5% n/a 
KF/K222 9% 1.3:1 
KF/18-crown-6 13% 1.3:1 
 
Table 9: Assessment of [19F]fluorination reagents using model diaryliodonium 154 to observe the 
selectivity profile between products 155 and 156261 
 
In this work, dynamic 1H- and 19F-NMR [19F]fluorination studies were completed on 
diaryliodonium salts 149–153, using one equivalent of the parent diaryliodonium 
salt and two equivalent of caesium fluoride in deuterated DMF within a NMR tube. 
The reactions mixtures were heated up to 140 °C from room temperature in 20 
degree increments over 2 h, whilst being monitored by 1H- and 19F-NMR, providing 
insight on the fluorination selectivity profiles of each diaryliodonium salt (Scheme 
73). 
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Scheme 73: Dynamic 1H- and 19F-NMR [19F]fluorination study with diaryliodonium salts 149-153, 
highlighting the potential fluoro- and iodoarene products 
 
After each reaction had been maintained at 140 °C for a minimum of 10 min, each 
was administered with a small amount of the desired fluoroaromatic product 
reference standard, analysed by 1H- and 19F-NMR, and then also co-injected with 
authentic standards of the other expected fluoroaromatic product before being 
analysed by 1H- and 19F-NMR once more, as shown for precursor 149 below (Figure 
40 and Figure 41). [19F]Fluorination of diaryliodonium salts 149–153 via this method 
provided a simple means to rapidly assess the effectiveness of each precursor 
candidate without expending excessive amounts of material. 
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Figure 40: Dynamic 1H-NMR experiment following the fluorination of (4-benzyloxy)phenyl)(4-
methoxyphenyl)iodonium trifluoroacetate (149) 
 
 
Figure 41: Dynamic 19F-NMR experiment following the fluorination of (4-benzyloxy)phenyl)(4-
methoxyphenyl)iodonium trifluoroacetate (149), spiked with 4-fluoroanisole (164) and 4-
benzyloxy)-1-fluorobenzene (157) 
21 °C 
40 °C 
60 °C 
80 °C 
100 °C 
120 °C 
140 °C 
Formation of new aromatic species after 100 °C (1 h 20 min) and 
the change in diagnostic diaryliodonium salts peaks (> 8.0 ppm) 
120 °C 
140 °C 
With 4-(benzyloxy)-1-
fluorobenzene 157 
with 4-fluoroanisole 164 
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[19F]Fluorination of diaryliodonium salts 149–153 were conducted as depicted above 
and can be summarised by the following observations (Table 10). In all cases a 
decrease in the amount of diaryliodonium salt as the reaction proceeds above 100 °C 
could be observed; and the formation of new aromatic multiplets for substrates 149 
and 151 was also recorded, corresponding to the expected formation of fluoro- and 
iodoarenes as per the anticipated fluorination outcome (Scheme 73).  
 
Diaryliodonium salt Fluoroarenes observed (19F-NMR shift) Ratio  
149 157 (-124.9 ppm); 164 (-125.6 ppm) 1:1 
150  157 (-124.9 ppm) - 
151 165 (-114.4 ppm) - 
152 none observed - 
153 158 (-118.92 ppm) - 
 
Table 10: Summary of dynamic 1H- and 19F-NMR study following the [19F]fluorination of 
diaryliodonium salts 149–153 
 
Diaryliodonium salt 149 provided the expected 50:50 selectivity profile 
corresponding to fluoroarenes 157 and 164, unsurprising given the electronic 
similarity between the target ring and n.p.r. Whereas precursor 150, anticipated to 
be relatively unstable due to the incorporation of the 2-thienyl n.p.r., saw loss of the 
characteristic diaryliodonium salt proton shift of 8.2 ppm for the protons ortho- to 
the iodine centre after reaching 80 °C (1 h), suggesting that much of the material 
decomposed prematurely. However, a very small amount of the target fluoroarene 
157 was detected, yet the corresponding fluorinated product, 2-fluorothiophene 165 
was not observed. Although it is conceivable that 157 was produced in preference 
over 165, it is also likely that relatively low boiling 2-fluorothiophene (bp = 82 °C)325 
was produced to some extent but not detected, given that the reaction was not 
performed within a closed system, thus a selectivity profile ratio could not be 
assigned. This highlights a clear limitation in this method of diaryliodonium salt 
fluorination selectivity analysis for precursors bearing the 2-thienyl n.p.r., in that 
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many small fluoro- and iodoarenes will not be retained in the reaction mixture and 
thereby cannot be observed by 1H/19F-NMR. Another limitation of this method 
includes the loss of resolution seen for NMR spectra obtained at higher temperatures, 
where line broadening occurs as a result of poor NMR probe shimming at elevated 
temperatures. 
The control diaryliodonium salt, 151, bearing the markedly less electron-rich phenyl 
n.p.r. behaved as predicted, yielding fluorobenzene 165 as the sole fluorinated 
aromatic and appeared to avoid decomposition of the parent diaryliodonium salt, a 
hallmark of its improved stability over the more electron-rich diaryliodonium salts in 
the series. Note that fluorobenzene also has a similarly low boiling point (84 °C) to 2-
fluorothiophene, however 2-fluorothiophene exhibits a remarkably higher vapour 
pressure than that of fluorobenzene and hence detection of the fluorobenzene was 
possible. 
Acetyl-protected diaryliodonium salts 152 and 153 provided less conclusive 
outcomes in this study, possibly as an artefact of increased susceptibility to 
nucleophiles afforded by this protection strategy; here no peaks corresponding to 
fluoroaromatics were seen in the 19F-NMR spectra for the [19F]fluorination of 
precursor 152, however, 1H-NMR revealed the formation of new para-substituted 
aromatic species. Despite bearing the instability inducing 2-thienyl n.p.r, 
[19F]fluorination of diaryliodonium salt 153, did yield evidence of new aromatic 
compounds in the 1H-NMR as well as 19F-NMR peak corresponding to 4-(acetoxy)-1-
fluorobenzene 158, albeit these peaks were miniscule in proportion versus the 
fluoroaromatic products seen for the rest of the series. 
Table 10 captures many of the key outcomes from this dynamic [19F]fluorination 
study, most importantly, diaryliodonium salt stability at elevated reaction 
temperatures is directly affected by electronics of the aryl substituents attached to 
iodine and as a consequence, in situ decomposition of the parent diaryliodonium salt 
ultimately results in a loss of product fluoroarene(s). Similarly, application of the 
acetyl protection strategy (152 and 153) also suffers from stability concerns and 
provides a lower proportion of fluoroarene products versus diaryliodonium salts 
baring the benzyl protection strategy 149–151, possible as a result of oxidisable 
phenol generation as an artefact of acetyl group hydrolysis. Table 10 also describes 
the expected selectivity profiles for diaryliodonium salts 149 and 151, whereby more 
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electron-deficient arenes are preferably fluorinated over electron-rich arenes, and in 
the absence of any substantial difference in electron density the resulting fluorinated 
target ring and fluorinated n.p.r. ratio is approximately 1:1.  
In summary, although dynamic 1H- and 19F-NMR observation of diaryliodonium salts 
149–153 has provided valuable insight into the stability and [19F]fluorination 
selectivity profiles of the precursors, it is apparent that prolonged, gradual heating of 
the sensitive reagents is far from an ideal reaction environment. Conducting such 
fluorinations at higher temperatures (180 °C+) under a drastically shorter timeframe, 
within a closed system vessel would likely afford superior results, and also allow for 
analysis of low boiling aromatics such as 2-fluorothiophene via an in-line 
chromatography system and UV detector.  
 
2.9 Improving Selectivity 
 
As mentioned, diaryliodonium salts bearing two electron-rich arene components are 
limited to a maximum yield of 50% (with respect to the target fluoroarene product) 
when subject to [18/19F]fluorination conditions. This section describes efforts to 
combat the limitation associated with diaryliodonium salts as precursors to electron-
rich fluoroaromatics, where two new strategies for the preparation of 4-(benzyloxy)-
1-fluorobenzene were envisaged, since benzyl protection of the phenol functionality 
has already proven to generate diaryliodonium salt precursors stable under the 
reaction conditions. Firstly, it was proposed that production of a symmetrical 
diaryliodonium salt would negate the concern of n.p.r. fluorination which was 
prepared as below (Scheme 74); and secondly a precursor diaryliodonium with 
additional electron density upon the n.p.r., with the intention of driving fluorination 
to the less electron-rich target ring, was also designed and synthesised (Scheme 75). 
Both of the strategies depicted below involved preparation of protected phenoxy 
aryliodobis(acetate) 166, an inversion of our usual method of diaryliodonium salt 
production. For the preparation of the below arylstannane compounds (141 and 
169), the corresponding bromoarenes were utilised over the iodoarene counterparts 
because they were dramatically cheaper as starting materials. 
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Scheme 74: Synthesis of symmetrical diaryliodonium salt 167 
 
 
Scheme 75: Synthesis of diaryliodonium salt 170, bearing trimethoxyphenyl n.p.r. 
 
The overall synthetic yields for 167 and 170 were very poor, largely due to the 
limited yield associated with the oxidation of 4-(benzyloxy)-1-iodobenzene to 
aryliodobis(acetate) 166. Similarly, purification of arylstannane 169 proved 
challenging, requiring multiple purification steps and typically saw destannylation of 
over 50% of the crude material during column chromatography (as compared to the 
estimated crude product yield assessed by 1H-NMR of the crude material). Despite 
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these poor yields, preparation of these unique diaryliodonium salts demonstrated the 
versatility of the general route to electron-rich diaryliodonium salts described in 
Section 2.7 and provided sufficient material for [19F]fluorination testing.  
As before, dynamic 1H- and 19F-NMR [19F]fluorination studies were conducted on 
both diaryliodonium salts 167 and 170 as a means to rapidly obtain an 
understanding of their stability under the reaction conditions, as well as the 
selectivity outcome of fluorination. Here it was anticipated that symmetrical 
diaryliodonium salt 167 would afford a single fluoroarene (19F-NMR peak 
corresponding to 4-(benzyloxy)-1-fluorobenzene 157). Diaryliodonium salt 170 was 
also expected to largely yield the same fluoroarene (157) over the unlikely formation 
of 3,4,5-trimethoxy-1-fluorobenzene, although it was also considered that the 
distinctly electron-rich diaryliodonium salt may be poorly stable to the reaction 
conditions.  
Analysis of the [19F]fluorination reaction of 167 by 1H-NMR displayed the formation 
of para-substituted aromatics species from 100 °C (1 h 20 min) as per the previous 
diaryliodonium salts 149–151 (Figure 42). However, observation of the reaction by 
19F-NMR also highlighted the formation of an unexpected fluorinated product X (-
79.36 ppm, suggesting a CF3 group), as well as a prominent peak for corresponding 
to the formation of 4-(benzyloxy)-1-fluorobenzene 157 (-125.13 ppm).  
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Figure 42: [19F]Fluorination products of symmetrical diaryliodonium salt 167 
 
It was initially considered that X represented the formation of the counter-ion 
addition product 171 (Scheme 76), an outcome that should be avoided given the 
non-nucleophilic nature of the trifluoroacetate counter-ion; however this suggests 
that the fluorination reaction proceeds slowly for electron-rich diaryliodonium salts 
(versus diaryliodonium salts bearing one or more electron-deficient arene), whilst 
decomposition of electron-rich diaryliodonium occurs at a faster rate. 
 
 
Scheme 76: Conceivable formation of counter-ion addition product 171 through the decomposition 
of symmetrical diaryliodonium salt 167 
X 
157 
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However, on preparation and 19F-NMR of counter-ion addition product 171, the 
compound was found to have a notably different shift (-75.1 ppm) to X, furthermore 
the literature provided no insight into any potentially generated fluorinated 
compounds that provided a 19F-NMR shift around -79 ppm and hence the identity of 
species X remains unknown.  
Tailored diaryliodonium salt 170 also provided disconcerting results when subjected 
to our [19F]fluorination procedure, as 19F-NMR shifts for the desired fluoroarene 4-
(benzyloxy)-1-fluorobenzene 157 (recorded as -125.13 ppm) and for formation of 
the less favoured 3,4,5-trimethoxy-1-fluorobenzene species (expected around -113.6 
ppm)416 were both absent. This is despite dynamic 1H-NMR observation of the 
fluorination reaction suggesting that the formation of a para-substituted aromatic 
entity had been achieved. Given the ambiguity surrounding the [19F]fluorinations of 
diaryliodonium salts 167 and 170 at this stage, they were considered as secondary 
substrates for [18F]fluorination, behind the more successful precursor candidates of 
the foremost series 149–153.  
 
2.10 Chapter 2 Summary 
 
This chapter describes the successful development of a simple and highly versatile 
method for the preparation of electron-rich diaryliodonium salts, afforded by 
optimised aryliodobis(acetate) preparation coupled with a modified method for 
arylstannane synthesis and purification. With a robust protocol in place, this process 
was utilised to produce a series of diaryliodonium trifluoroacetates, including novel 
examples, that are capable of affording [18F]fluorophenol when subject to 
[18F]fluorination and subsequent deprotection. Further information on the structural 
details, relative stabilities and [19F]fluorination outcomes for these diaryliodonium salt 
precursors were obtained though x-ray crystallography and dynamic 1H- and 19F-NMR 
[19F]fluorination of the compounds. This work has provided a number of lead 
candidates deemed suitable for the radiofluorination studies described in the 
subsequent section.  
  
 132 
3 Microfluidic Radiofluorination of Diaryliodonium Salts 
 
Chapter 2 describes preparation of electron-rich diaryliodonium salt precursors, 
intended on providing a route to the valuable prosthetic group 4-[18F]fluorophenol 
after radiolabelling with nucleophilic [18F]fluoride. The chapter also specifies the 
limitations in performing [19F]fluorination of diaryliodonium salts in open vessels at 
elevated temperatures, imposed by the solvent, DMF, which begins to decompose at 
137 °C326 and boils at 152 °C and hence prevents performing the reactions at higher 
temperatures. It is thereby speculated that conducting fluorinations of diaryliodonium 
salts within closed systems at higher temperatures (190 °C) should allow better 
conversion of the precursors into the daughter fluoroarene(s). The use of sealed 
microfluidic systems, capable of operating at remarkably high pressures (over 20 
bar) permits the use of solvents well above their boiling points (Table 11) and also 
provide some distinct benefits over traditional glassware based approaches when 
applied to radiochemical transformations, as is discussed in this chapter.  
 
 Boiling point (°C) at 
Solvent 1 bar 6.9 bar 17.0 bar 
Dichloromethane 41 109 153 
Methanol 65 138 185 
Tetrahydrofuran 66 140 186 
Isopropanol 82 159 207 
Acetonitrile 82 159 207 
Water 100 181 231 
1,4-Dioxane 101 182 234 
Dimethylformamide 153 244 301 
Dimethylacetamide 165 259 318 
 
Table 11: Variation of common solvent boiling points with pressure calculated according to 
Trouton’s rule327 
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3.1  Automated Radiochemistry 
 
The last twenty years have seen the use of automated synthesis platforms and 
microfluidic reactor systems rapidly develop, with applications spanning robust 
chemical syntheses to niche academic projects yielding novel reaction conditions. For 
detailed information on these developments the reader is directed to some well 
written reviews,328,329,330 whilst key points are summarised below.  
The most obvious benefit provided by using automated apparatus for radiochemical 
transformations includes the reduced handling (and hence radiation dose to the 
operator) required for radioisotope manipulation. Typically, once the radioisotope has 
been transferred from the cyclotron to the synthesis platform, shielding (i.e. by 
housing the equipment inside a ‘hot’ cell) can negate any further radiation exposure 
to the radiochemist, allowing the user to remotely operate the apparatus safely. A 
host of markedly different types of radiosynthesis platforms are now commercially 
available, as well as many reaction–specific bespoke systems; encompassing batch 
systems, lab-on-a-chip devices, and microfluidic platforms. 
Batch-based radiosynthesis systems are the most commonly seen in PET centres and 
are often designed for easy-operation, routine production of multi-dose, high-
demand PET imaging agents, however, these are typically limited to performing 
chemistry similar to that particular radiotracer/ligand. More adaptable modular 
systems, like the Eckert and Ziegler Modular-Lab (Figure 43)331 allow for 
incorporation of microwave systems, multiple reaction vessels, in-line SPE 
purification, etc. facilitating their application in R&D as well as the clinical setting;332 
Others are often even self-shielded,333 owing themselves to cartridge-based 
radiosynthesis in clean-room facilities, with aims of integrating radiolabelling, 
purification, formulation and QC, providing a complete radioisotope to patient-ready 
imaging agent workflow, reducing radiosynthesis time and maximising RCY.  
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Figure 43: Eckert and Ziegler Modular-Lab Standard, a customisable radiosynthesis platform for 
batch production of PET imaging agents 
 
Micro-scaled lab-on-a-chip (LOC) devices provide a contrasting view on 
radiopharmaceutical production, where efforts are based on minimising the 
apparatus with a view of minimising potential fluorine-19 contamination from tubing, 
glassware and the atmosphere in a bid to maximise SA; as well as potentially 
reducing the considerable costs that accompany radiosynthesis platforms; and 
provide to a more streamlined approach to radiolabelling through automations, 
hence removing the need for extensively trained radiochemists in clinical settings. In 
addition, cheaply manufactured LOC devices can be used as disposable, single-use 
items, reducing the sometimes lengthy post-radiosynthesis cleaning and validation 
protocols 
Although these approaches currently remain in the early stages of their development, 
they have already seen some success in affording miniaturised multi-step 
radiosyntheses, such as the work by Quake and co-workers on the routine micro-
production of [18F]FDG (Figure 44),334 via a five step protocol, integrating 
[18F]fluoride concentration, water evaporation, radiofluorination, solvent exchange 
and hydrolytic deprotection, all within a single, digitally–controlled device.  
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Figure 44: A schematic representation of micro-scaled production of [18F]FDG (top, A); an optical 
micrograph of the central area of the circuit (bottom, B); with an image of the device next to a 
penny (inset, B); and the resulting microPET/CT image of a tumour-bearing mouse using a 375 µCi 
dose of [18F]FDG produced via this method.334,335  
 
Micro-structured devices for LOC radiosynthesis provide an exciting new avenue of 
research for radiochemists and could potentially deliver an ultra-low cost, efficient 
means for single–dose radiopharmaceutical production, imaginably achievable by the 
patient’s side since they employ drastically reduced amounts of shielding when 
compared to more cumbersome batch-scale radiosynthesis platforms.336 The current 
major limitation inhibiting further development of chip based devices involves the 
polydimethylsiloxane (PDMS) from which they are fabricated. The versatile 
viscoelastic material allows for high precision injection moulding of micro-channels 
and simple, high-strength bonding protocols, however, PDMS is poorly resistant to 
most organic solvents, seriously limiting its application in a variety of radiochemical 
applications.337 
Microfluidic capillary systems, such as the Advion NanoTek (Figure 45), provide a 
convenient intermediate between adaptable modular systems and robust batch-
C) 
 136 
based synthesis platforms, whilst maintaining the benefits of microfluidic chemistry 
utilised by LOC devices.  
 
Figure 45: Advion NanoTek microfluidic radiosynthesis system338 
 
Exploiting microfluidics to conduct chemical transformations not only provides faster 
and more reproducible reaction protocols, as well as the elevated solvent 
temperatures described earlier, but also allows for more controlled solvent mixing 
through uniform, fluid dynamics. Narrowing the channels of a microfluidic reactor, 
results in a monumental increase in the surface area:volume ratio of the reaction 
vessel (Table 12), assisting the heat loss from the channel and conversely, allowing 
for ultra-fast heating (as well as cooling) of the system and more accurate 
thermostatic control.339  
 
Reactor type Surface area:volume ratio (cm2/cm3) 
1 m3 reactor 0.06 
100 ml rb flask 1 
1.0 mm ID channel 40 
100 µm ID microchannel 400 
 
Table 12: Relative surface area:volume ratio of different reactor vessels with the same internal 
volume 
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Microfluidic systems are often expected to operate under laminar flow (Figure 46), 
which induces atypical reaction environments often affording improved yields and 
reduced by-product formation,340 a major advantage in radiochemistry where 
extended chromatographic purification can significantly limit the RCY.  
 
 
 
Laminar flow (an alternative to turbulent flow which occurs within a standard round 
bottom flask) affords mixing of the two reagent streams through radial diffusion as 
the fluidic bolus rapidly disperses through the microchannel, a form of mixing that is 
not only highly reproducible but also very fast when applied to channels with very 
small dimensions (hence encouraging rapid and reproducible mixing). Again, as an 
artefact of channel based fluidics, the reaction mixture bolus adopts a parabola-like 
shape as the fluid closest to the inner wall of the channel experiences friction.328 The 
properties of a flow system can be characterised by calculating the system’s 
Reynolds number (Re), a dimensionless quantity that describes the interactions 
between fluid speed, the diameter of the channel and the internal viscosity of the 
fluid, as defined by the equation:  
 
𝑹𝒆 =  
𝒊𝒏𝒆𝒓𝒕𝒊𝒂𝒍 𝒇𝒐𝒓𝒄𝒆𝒔
𝒗𝒊𝒔𝒄𝒐𝒖𝒔 𝒇𝒐𝒓𝒄𝒆𝒔
=  
𝒎𝒆𝒂𝒏 𝒇𝒍𝒖𝒊𝒅𝒊𝒄 𝒗𝒆𝒍𝒐𝒄𝒊𝒕𝒚 𝒙 𝒅𝒊𝒂𝒎𝒆𝒕𝒆𝒓
𝒌𝒊𝒏𝒆𝒕𝒊𝒄 𝒗𝒊𝒔𝒄𝒐𝒔𝒊𝒕𝒚
=  
𝛖𝒔𝑳
𝒗
 
 
It is expected that a fluidic system that provides a Reynolds number below 2500 is 
operating under laminar flow and hence behaves as described above. However, 
some microfluidic systems intentionally incorporate elements of turbulent mixing 
Dispersion 
Diffusional mixing Parabolic flow 
Radial 
mixing 
Figure 46: Diagrammatic representation of laminar flow, whereby mixing 
occurs by radial diffusion rather than turbulent flow 
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through static mixer geometries,341 providing a hybrid laminar–turbulent flow 
system.342  
Microfluidic reactor systems also provide a number of benefits relevant to 
radiochemistry, including the ability to conduct a series of reactions utilising just 
milligram quantities of precursor material, avoiding the waste of material associated 
with batch-based radiosynthesis, imperative when working with precursors that 
require lengthy syntheses, are expensive, or only available in trace amounts, such as 
bespoke peptides. Similarly, a single provision of [18F]fluoride can provide enough 
radioisotope to complete a series of radiofluorinations, again thanks to the micro-
scaling of vessels and tubing, and the nature of flow processes. The nature of 
microfluidic synthesis lends itself to rapid optimisation studies given that many 
platforms allow for specific control of multiple reaction parameters, such as 
temperature, reaction time, system pressure, reagent stoichiometry; providing a 
means to rapidly screen parameters of a process still under development.  
 
3.2  Radiosynthesis with the Advion NanoTek Microfluidic System 
 
The previous section highlights a number of key advantages offered by remotely 
controlled microfluidic radiosynthesis platforms, owing to the selection of the Advion 
Nanotek as the primary tool for [18F]fluorination of diaryliodonium salts in this 
chapter of work. The modular synthesis system boasts microscale radiolabelling 
capability, versatile operation software, as well as temperature and pressure 
monitoring, making the platform an excellent choice for R&D-type [18F]fluorination 
optimisation as well as potential upscaling for PET imaging studies.343  
Other researchers have demonstrated the capability of Advion’s radiosynthetic 
hardware through microfluidic production of multiple fluorine-18 labelled PET 
imaging agents, including tau radioligand [18F]T807 for Alzheimer’s disease,344 
metabotropic glutamate receptor subtype type 5 (mGluR5) imaging agent,345 and 
[18F]fallypride which has seen application in a US clinical trial, imaging dopamine D2 
and D3 receptors for the treatment of psychosis in Alzheimer's disease.
346 
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Figure 47: Examples of desirable PET imaging agents prepared by microfluidic [18F]fluorination 
 
In order to conduct radiofluorination of the diaryliodonium salts prepared in Section 2 
with a commercially available Advion NanoTek a number of augmentations were 
required (Figure 48), including the coupling of an auto-injector for transferral of 
reaction mixtures to a radio-HPLC for in-line purification and characterisation, as well 
as numerous radioactivity counters, SPE cartridges and the development of bespoke 
operation macros.  
 
Figure 48: Advion NanoTek base module (BM), concentrator module (CM) and reactor module (RM) 
coupled with an auto-injector (Knauer Smartline Valve Drive), radio-HPLC (Agilent Technologies 
1200 series with a LabLogic Flow Count) and activity counter (Capintec CRC ® -25PET Dose 
Calibrator); all allowing for in-line radiolabelling, purification and activity characterisation 
BM CM RM Radio-HPLC 
Activity counter Auto-injector 
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As depicted by the image above, the Advion Nanotek system comes with a number 
of core components, including a base module (BM) which provides reagent solutions 
to the reactor from reagent loops via two syringe pumps (P1 and P2); a concentrator 
module (CM) which provides removal of the [18O]H2O from the [
18F]fluoride solution 
via azeotropic distillation; and reactor module (RM) which houses up to four 
microreactors (Figure 49) within an aluminium heating block.  
 
 
Figure 49: Advion NanoTek microreactor coil, normally housed within the reactor module of the 
system within an aluminium heating block 
 
For this work, silica glass capillary microreactors as 4 metre coils, with an internal 
diameter of 0.1 µm, coated in a red thermoresist polymer and a brass shell for 
protection as seen above (Figure 49) were selected because of their resilience to the 
reaction medium, their convenient temperature range (up to 200 °C) and for their 
scope as closed system vessels which allows for detection of volatile products which 
would otherwise remain undetected.347  
[18F]Fluorination of diaryliodonium salts typically commenced with loading the Advion 
NanoTek with all non-decaying reagents, SPE cartridges and anhydrous solvents 
required for radiolabelling, prior to loading the [18F]fluoride onto the system. This 
highlights the necessity for a judicious and well-orchestrated system preparation 
procedure, as well as a timely delivery of the radioisotope, produced in-house using 
the ABT cyclotron. Here production of n.c.a. [18F]fluoride in [18O]H2O, via 
bombardment of the target [18O]H2O for 1 hour, with a proton beam current of 4 µA, 
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set at a target angle of 5° typically yielded between 1 and 2 GBq of [18F]fluoride in 
250 µL of [18O]H2O per run.  
After transferral of the ‘wet’ isotope to the Advion NanoTek CM and careful 
application of a syringe line to the [18F]fluoride vessel to ensure full isotope uptake 
the ‘hot cell’ access ports can closed, completely safeguarding the user from the 
radiation. Our bespoke macro-dictated drying procedure then utilised the CM’s low 
pressure, six-way valve to transfer and trap the [18F]fluoride onto a quaternary 
ammonium resin (QMA) cartridge whilst eluting the [18O]H2O into a receiving vial for 
recycling. A solution of tetraethylammonium bicarbonate is then utilised as a phase 
transfer agent (PTA) to liberate the [18F]fluoride from the QMA cartridge into a vial 
housed in the CM heating block. Three iterations of azeotropic distillation with 
acetonitrile completes the drying process, affording a dry [18F]fluoride/TEA•HCO3 
complex, which is then extracted from the CM using anhydrous DMF (Figure 50).  
 
        
Figure 50: Preparation of radiofluorination-ready 'naked' [18F]fluoride via a trap and release 
mechanism on a QMA cartridge, facilitated by a phase transfer agent and followed by azeotropic 
drying. QMA image from the manufacturer’s website348 
 
As mentioned in Section 1.5.3, the use tetraethylammonium bicarbonate provides a 
means of yielding an organic solvent soluble [18F]fluoride complex, whilst 
simultaneously providing sufficient basicity to release the [18F]fluoride from the QMA 
resin, a highly convenient method developed within the research group.110 Use of this 
PTA over traditional cryptands and longer chain tetraalkylammonium reagents greatly 
reduced the risk of microreactor blocking, a problem often seen when working with 
microreactor channels of 0.1 µm internal diameter or less.110   
[18F]KF in [18O]H2O [
18F]TEAF in DMF 
1) [18F]fluoride trapped on QMA 
2) Sequestered with TEA•HCO3 PTA 
3) MeCN azeotropic distillation 
4) DMF extraction 
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The resulting [18F]TEAF/DMF mixture is transferred to the RM where pump 3 (P3) 
facilitates loading of the radioisotope solution into loop 3, ready for administration 
into the microreactor (Figure 51). From here the microreactor can be simultaneously 
charged with precursor diaryliodonium salt from loop 1 and [18F]TEAF from loop 3, 
with flow rates, temperature, reaction time and stoichiometry pre-set by the user.  
 
 
Figure 51: Schematic of bespoke [18F]fluorination set-up using the Advion NanoTek coupled with an 
auto-injector and in-line radio-HPLC. Image adapted from publication by Reed et al110  
 
After the desired reaction time, anhydrous DMF is used to sweep the crude reaction 
mixture towards the Knauer Smartline Valve Drive auto-injector, which harbours a 
large loop to store the reaction mixture whilst the 4 m microreactor is emptied. The 
auto-injector is then directed to transfer the reaction mixture onto the pre-
equilibrated HPLC column (C-18 Phenomenex or C-Phenyl Phenomenex) for analysis 
of the products.  
 
3.3  Radiosynthesis of Protected-4-[18F]fluorophenol 
 
The [19F]fluorination studies of diaryliodonium salts 149—153, 167 and 170 
prepared in Chapter 2 were used to select the more stable and more fruitful 
precursors for [18F]fluorination. Here diaryliodonium salts 149, 150, 151 and 152 
[18F]TEAF 
CM 
BM 
RM 
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were selected as primary substrates for this work, where it was expected that 149, 
150 and 152 would afford higher radiochemical yields (RCYs) of protected-4-
[18F]fluorophenol over the other diaryliodonium salts in the series and it was deemed 
that precursor 151 would provide an excellent control substrate which should see 
formation of mainly [18F]fluorobenzene [18F]165 on treatment with [18F]TEAF 
(Scheme 77).  
 
 
Scheme 77: Radiofluorination of diaryliodonium salts 149-152 using [18F]TEAF in a microreactor 
 
Prior to radiofluorination of the selected diaryliodonium salt series 149—152, each 
precursor required development of a detailed HPLC method, which allowed for 
identification (based on the relative retention times) of each potential component of 
the reaction mixture in real-time. Consider diaryliodonium salt 149, which when 
treated with [18F]TEAF can potentially yield the desired [18F]157 protected-4-
fluorophenol species, as well as 159, 162, [18F]164 and the parent diaryliodonium 
salt itself. Hence a development method for the HPLC analysis of [19F]157, 159, 
162, [19F]164 and 149 was sought, most of which were commercially available, or 
were synthesised when unavailable. Ideally, separation of the fluoro- and iodoarene 
products and the starting material should be achieved within a timely manner, given 
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time sensitivity of decaying species, and should afford baseline separation between 
all components, as can be seen for the HPLC spectrum of diaryliodonium salt 149 
and its potential products (Figure 52).  
 
     
Figure 52: HPLC chromatogram of diaryliodonium salt 149 and potential fluoro- and iodoarene 
products yielded when fluorinated, HPLC method achieved using a C-phenyl reverse phase silica 
HPLC column (Phenomenex, Kinetex) 60:40 MeCN:H2O eluent system at 1.1 ml/min, Agilent 1200 
Series 
 
Establishing the retention times of fluoroarenes and iodoarenes greatly assisted in 
the identification of the products for the [18F]fluorination reactions of diaryliodonium 
salts 149—152, however, on occasion, other non-radioactive by-products were 
observed, which were shown to be protio-derivative decomposition products when 
compared to commercially available reference standards.  
Preliminary [18F]fluorination reactions on diaryliodonium salts 149—152 together 
with the [19F]fluorination work discussed in Chapter 2, as well as prior work on the 
[18F]fluorination of diaryliodonium salts within the research group349 has determined 
that temperature has the greatest effect on the yield of these reactions, hence other 
parameters were kept constant for the entirety of this work (Table 13). Here a 
temperature range between 110 °C and 190 °C was deemed appropriate, taking into 
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account that fluoroarene formation was inadequate and poorly measurable below 
110 °C and that the integrity of the microreactor is limited to 200 °C.  
 
Parameter Optimal conditions 
microreactor dimensions coil ID 0.1 µm, 31.41 µL volume    
diaryliodonium salt concentration 10 mg/mL 
[18F]TEAF volume 10 µL 
P1:P3 injection volume ratio 1:1 
reagent loading flow rate 10 µL/min 
Reaction time 5 min 23 sec 
Reaction bolus transfer rate 60 µL/min 
 
Table 13: Parameters to be held constant as temperature is varied for [18F]fluorination reactions of 
diaryliodonium salts 149-152. In addition, P1 loop volume, load line volume and collection line 
volumes were maintained at 386, 39 and 88 µL respectively; P2 loop volume, load line volume and 
collection line volumes were maintained at 220, 21, 71 µL respectively; the microreactor to auto-
injector line volume was maintained at 32 µL; and the auto-injector to radio-HPLC line volume was 
maintained at 30 µL 
 
[18F]Fluorination of each diaryliodonium salt in the series at each temperature 
increment was completed in triplicate (at least) and the upper and lower RCYs 
achieved for each is displayed by error bars in the forthcoming graphs (Figure 54, 
Figure 55, Figure 56 and Figure 57).  Note, that the focus of this chapter’s work was 
to screen reaction conditions and study the outcome of [18F]fluorination for 
diaryliodonium salt precursors 149—152, whilst reviewing the effect of protecting 
groups and n.p.r. selection of [18F]fluorination selectivity, hence isolation of individual 
[18F]fluoroarenes was not conducted. Instead RCYs were reported as the amount of 
radioactivity of the product [18F]fluoroarenes as a percentage of the total 
radioactivity in the reaction mixture, as detected by radio-HPLC, validated by 
frequent calibration against known samples. An example of a typical radio-HPLC 
trace of a [18F]fluorination reaction is shown below (Figure 53), the spectrum is 
superimposed with the corresponding UV HPLC chromatogram for the 
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radiofluorination of diaryliodonium salt 149. It is important to note, that all RCYs 
reported in this Chapter are delivered as non-decay corrected, analytical RCYs. 
 
 
Figure 53: HPLC spectrum of product mixture yielded by the reaction of diaryliodonium salt 149 
with [18F]TEAF, bearing the radio-HPLC trace overlain with UV HPLC trace, validating the identity of 
the [18F]fluoroarene products. HPLC conditions: C-18 reverse phase silica column (Phenomenex), 
60:40 MeCN:H2O, 0.1% formic acid, flow rate = 1.1 mL/min. [
18F]fluorination reaction conducted at 
190 °C 
 
Optimised HPLC conditions were achieved through the application of an alternative 
column type (C-18 rather than C-Phenyl), as well as the introduction of 0.1% formic 
acid additive, which allowed for elution of the desired [18F]fluoroarene [18F]157 
within 5 min. This reduction of retention times, whilst maintaining clean separation of 
products can be highlighted as a highly beneficial outcome given the necessity for 
fast product purification, especially important when further post-radiofluorination 
steps are required, such as deprotection to yield the target 4-[18F]fluorophenol as in 
this case. Note also, the rapid elution of unreacted [18F]fluoride, which was observed 
across radiofluorination reactions of all diaryliodonium salts within the series 149—
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152. As the lead candidate from the [19F]fluorination study, the [18F]fluorination of 
diaryliodonium salt 149 {(4-(Benzyloxy)phenyl)(4-methoxyphenyl)iodonium 
trifluoroacetate} was the first to be studied in detail (Figure 54). 
 
 
Figure 54: [18F]Fluorination of diaryliodonium salt 149, with the structure of the precursor 
highlighting the two arenes fluorinated and corresponding RCYs of each resulting [18F]fluoroarene 
 
As seen with the [19F]fluorination experiments (Chapter 2), the [18F]fluorination of 
diaryliodonium salts bearing two electron-rich arenes, such as 149, displayed near 
1:1 selectivity between the target ring system and the n.p.r. The dramatic increase in 
RCY afforded at the elevated temperatures (>170 ⁰C) demonstrates the need to 
formation radiolabelling within closed system reaction systems, since batch based 
systems would limit the maximum temperature to 130 ⁰C with this solvent and hence 
limit the maximum RCY achievable. The relatively high RCY (47%, n = 3, s = 4.93) 
achieved for the target [18F]fluoroarene, 4-[18F]fluoro-1-(benxyloxy)benzene 157, 
justifies the utility of diaryliodonium salt precursor 149 for the production of 
[18F]fluorophenol, as does the short retention time required to elute 157 (tr = 4 min 
22 s), allowing the subsequent deprotection reaction to be conducted promptly, 
hence reducing the detriment to RCY that would be caused by lengthy HPLC 
purification (although deprotection could also be conducted prior to purification to 
remove the need for a second purification stage).  
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Diaryliodonium salt 150 also performed as anticipated, given that the 2-thienyl n.p.r. 
bears more electron density than the target ring system, [18F]fluorination was 
directed to the ipso-carbon of the benzyoxyphenyl moiety, affording [18F]157 in 
preference over [18F]165 (Figure 55). However, as noted before (Chapter 2), 
application of the electron-rich 2-thienyl n.p.r, when the other arene is also electron-
rich does appear to result in destabilisation of the diaryliodonium salt, and hence the 
RCYs reported here are notably lower than those observed for precursor 149 (Figure 
54). 
 
 
Figure 55: [18F]Fluorination of diaryliodonium salt 150, with the structure of the precursor 
highlighting the two arenes fluorinated and corresponding RCYs of each resulting [18F]fluoroarene 
 
Again, the elevated temperatures, only achievable through employment of a closed-
system reactor like the Advion Nanotek, provided drastic improvement on the 
incorporation of [18F]fluoride into precursor 150, a feature also seen with control 
diaryliodonium salt 151 (Figure 56). Here the incorporation of comparably electron-
deficient phenyl moiety in place of an electron-rich n.p.r. saw direction of 
[18F]fluorination towards this ring system, rather than the target arene. And as seen 
previously, the majority product observed on [18F]fluorination of 151 proved to be 
[18F]fluorobenzene [18F]166. Note that with an electron-deficient arene in place, 
[18F] fluorination of diaryliodonium salt 151 afford a markedly higher combined RCY 
(near 90%) than the other precursor in the series. 
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Figure 56: [18F]Fluorination of diaryliodonium salt 151, with the structure of the precursor 
highlighting the two arenes fluorinated and corresponding RCYs of each resulting [18F]fluoroarene 
 
[18F]Fluorination of precursor 151 not only provided a clear control substrate, but 
the majority formation of [18F]166 supported findings similar to those reported 
formerly,260,324 and to some extent this observation was also noted in the 
[18F]fluorination of 152 (Figure 57), since the acetyl protection strategy in place here 
will reduce some electron density applied by the phenoxy- moiety through resonance 
withdrawal. Although [18F]fluorination of 152 does see some preference for the 
formation of [18F]158 over [18F]164, the precursor exhibits questionable stability, 
as RCYs a markedly lower than those for diaryliodonium salt 149, as was observed 
for the [19F]fluorination of this precursor. However, [18F]fluorination of 
diaryliodonium salt 152 did provide markedly superior results than [19F]fluorination 
of the precursor, probably owed to the ability to reach higher temperature much 
more quickly. 
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Figure 57: [18F]Fluorination of diaryliodonium salt 152, with the structure of the precursor 
highlighting the two arenes fluorinated and corresponding RCYs of each resulting [18F]fluoroarene 
 
At this stage, it is worth noting that although achieving a high RCY is always of high 
importance, the resulting radioactivity of a radiolabelled product is heavily reliant on 
the starting radioactivity of the cyclotron-produced [18F]fluoride used. Classically, 
radiosynthesis of PET imaging agents utilises large, powerful cyclotrons, capable of 
producing 20—50 GBq of activity per [18F]fluoride production run; and hence even 
with relatively poor RCYs (~5%) the resulting radiopharmaceutical formulation will 
afford sufficient activity for clinical PET imaging, even if transport to a remote PET 
centre is required. However, with smaller cyclotrons, such as the ABT system in place 
here, [18F]fluoride production is limited to a maximum of 2 GBq, which after 
radiolabelling, purification and formulation is likely to yield a radiopharmaceutical in 
lower levels of radioactivity (100—200 MBq), barely sufficient for  and of limited use 
for preclinical clinical imaging with a rodent model because of the large volume of 
product generated. However, as with this work, the smaller, more conveniently 
placed cyclotrons are seeing substantial application in methodology development and 
with further optimisation and streamlining of radiosynthetic procedures, radiolabelled 
products with sufficient activity for on/near-site PET imaging could conceivably be 
produced utilising ultra-compact cyclotrons like the ABT biomarker generator. Hence, 
production of 4-[18F]fluoro-1-(benzyloxy)benzene [18F]157 from precursor 
diaryliodonium salt 149 and [18F]TEAF within 10 min (5 min 24 sec for radiolabelling 
and 4 min 22 sec for purification) presents a notable achievement.  
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3.4 Chapter 3 Summary 
 
Chapter 1 highlighted a need for electron-rich [18F]fluoroarenes both as complete 
radiopharmaceutical or as simple prosthetic groups, 4-[18F]fluorophenol being a 
target of particular value for the latter; the subsequent chapter described a robust 
route to electron-rich diaryliodonium salts that could be used to prepare such 
[18F]fluoroarenes, unhindered by the limitations of SNAr chemistry. In this third 
chapter, rapid production and purification of [18F]fluoroarenes has been 
demonstrated though the unique benefits provided by microfluidic radiolabelling 
diaryliodonium salts and an optimised  in-line HPLC method, in particular 4-
[18F]fluoro-1-(benzyloxy)benzene was prepared in an average RCY of 47% (s = 
4.93%, non-decay corrected) within 10 min. The [18F]fluorination of other electron-
rich diaryliodonium salts was also explored via these means, with results strongly 
supporting prior research in the area, as well as the benefits of employing 
microfluidics in the radiolabelling of these precursors. 
Although further development of this work, through deprotection of 4-[18F]fluoro-1-
(benzyloxy)benzene to afford 4-[18F]fluorophenol and ultimately application of the 
prosthetic group to radiolabel macromolecules is desired, limitations in the R&D 
grade cyclotron limited the availability of [18F]fluoride and hence work discussed in 
the later chapters of this thesis discuss findings on further explorations with 
diaryliodonium salts and more complex precursors to electron-rich [18F]fluoroarenes.  
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4 Diaryliodonium Routes to 6-[18F]Fluoro-m-tyramine  
 
Since the introduction of PET into the clinical setting, there has been considerable 
interest into the development of fluorine-18 labelled imaging agents capable of 
imaging the human dopaminergic projections, which are neural pathways that 
transmit the neurotransmitter dopamine from one area of the brain to another.350 6-
[18F]Fluoro-3,4-dihydroxyphenyl-L-alanine ([18F]FDOPA) has seen a huge amount of 
attention for the imaging of dopamine metabolism and has seen successful PET 
imaging for a wide number of applications, including Parkinson’s disease, 
neuroendocrine tumours and cerebral gliomas,351 which will be discussed further in 
Chapter 5.  
However, the development of analogues, derivatives and metabolites of [18F]FDOPA, 
such as 6-[18F]-L-meta-tyrosine,352,353 4-[18F]fluoro-3-hydroxyphenylacetic acid,350 6-
[18F]fluorodopamine,354 and regioisomers of 6-[18F]fluoro-meta-tyramine354 have also 
seen substantial attention as PET imaging agent targets. Of these 6-[18F]fluoro-meta-
tyramine (6-[18F]fluoro-m-tyramine) provides a target, that to the author’s 
knowledge, has yet to be investigated fully with regards to preparation using n.c.a. 
nucleophilic [18F]fluoride, although some provisional methodology work has been 
conducted within the group355  and hence in this chapter we look to utilise the 
diaryliodonium salt precursor methodology developed in chapter 2 to provide a 
robust, n.c.a. route to high SA 6-[18F]fluoro-m-tyramine. Not only does this work 
provide a new route to a desirable fluorine-18 labelled tracer, but successful 
application of the diaryliodonium salt strategy for this precursor also demonstrates its 
potential for more complex electron-rich [18F]fluoroarene imaging agents, such as 
[18F]FDOPA.  
Current routes to 6-[18F]fluoro-m-tyramine employ an electrophilic approach either 
using carrier added [18F]F2 or use reagents derived from [
18F]F2 and hence are 
restricted to low SAs, making realistic application of 6-[18F]fluoro-m-tyramine via 
these routes unlikely. 
One approach, developed by Garnett and co-workers,350 utilises anhydrous HF as 
reaction medium for direct [18F]fluorination carrier of the precursor m-tyramine using 
cyclotron produced [18F]F2 (Scheme 78). Here they found that use of strong acid, 
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rather than more commonly seen solvents such as TFA or CH3CN/BF3 provided a 
cleaner, more selective conversion than previous approaches, however, after 
separation of product regioisomers the resulting RCY of the 6-regioisomer was 
relatively poor.350  
 
 
Scheme 78: Preparation of 6-[18F]fluoro-m-tyramine [18F]173 via direct electrophilic 
[18F]fluorination of 172 with [18F]F2 
 
However, as with many routes involving direct electrophilic [18F]fluorination, the use 
of [18F]F2 proved to be too unselective, and the extensive separation time required to 
separate mono-fluorinated and multi-fluorinated regioisomers failed to outweigh the 
benefits of such simple, one-step conversions. 
A more regioselective preparation 6-[18F]fluoro-m-tyramine was afforded by 
[18F]fluorodestannylation of a protected arylstannane precursor (Scheme 79), 
providing a drastically more useful procedure with improved RCYs.354,356 Although this 
route does exploit the toxic trimethylstannyl moiety to ensure regioselectivity, the 
research group found that tin concentrations within the radiolabelled product could 
be as low as <15 ppb through standard HPLC purification alone. However, this 
method is again, still restricted by the limitations associated with electrophilic [18F]F2  
fluorination, such as low SA. 
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Scheme 79: Preparation of 6-[18F]fluoro-m-tyramine via [18F]fluorodestannylation of 174, followed 
by a subsequent acid hydrolysis deprotection 
 
Note that precursor 174 also exploits the acetyl group for phenol protection, as with 
some of the diaryliodonium salts developed in Chapter 2, hence demonstrating that 
this strategy does occasionally see application in the radiolabelling of electron-rich 
[18F]fluoroarenes. 
 
4.1  Diaryliodonium Salt Precursors to 6-[18F]Fluoro-m-tyramine 
 
It was envisioned that preparation of a diaryliodonium salt precursor for the 
production of 6-[18F]fluoro-m-tyramine would overcome the problems described in 
prior section, particularly by employing a strategy suited to late-stage 
radiofluorination with n.c.a. nucleophilic [18F]fluoride to ascertain high RCYs and high 
SA, although it was appreciated that post-radiofluorination deprotection step would 
be essential (Scheme 80).  
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Scheme 80: Planned synthesis route for the production of 6-[18F]fluoro-m-tyramine via the 
standard protocol developed in Chapter 2 
 
Here, a simple synthesis strategy involving tandem installation of robust protecting 
group chemistry was adapted from previous work on the preparation of deuterium 
labelled phenethylamine derivatives by Xu and Chen,357 which allowed preparation of 
the protected m-tyramine substrate three steps (Scheme 81). Augmentations were 
made to this general route to allow for straightforward installation of the 
diaryliodonium salt hypernucleofuge, built on knowledge obtained through the work 
discussed in Chapter 2 in that, although very low yielding, diaryliodonium salts can 
be prepared be reacting aryliodobis(acetate)s directly with appropriately substituted 
electron-rich arenes, without the need to prepare an arylstannane species. Failing 
this, it was deemed that iodination of electron-rich arene 179 could allow access to 
the iodoarene required for the subsequent stannylation, should that be necessary.  
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Scheme 81: Successful synthesis strategy for the preparation of protected m-tyramine 179, 
precursor to diaryliodonium salts for the preparation of 6-[18F]fluoro-m-tyramine 
 
The Henry reaction allowed for near quantitative conversion of commercially 
available benzaldehyde 176 to the corresponding β-nitrostyrene 177, affording the 
product as a pale yellow solid without the need for any additional purification.358,359 
Also known as the ‘nitro-aldol’ reaction, this very useful C-C bonding forming reaction 
proved to be a convenient method of installing the required length side-chain, with 
an in situ dehydration, utilising the buffer system generated by combining 
ammonium acetate and acetic acid to provide the synthetically useful nitroalkene 
177.  
Treatment of 177 with lithium aluminium hydride afforded phenylethylamine 178 via 
complete reduction of the nitroalkenyl moiety, although conversion to the 
hydrochloride salt afforded a cleaner product, immediate use of free amine 178 
proved to be the most convenient substrate for subsequent conversion and further 
purification was deemed unnecessary.  
At this stage it was decided to employ a phthalimidyl protection strategy, selected for 
its particularly high robustness under a variety of conditions and complimentary to 
the sturdiness of the methoxy protected phenol moiety. Although deprotection of 
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these groups requires harsh conditions (e.g. H2NNH2), typically not compatible with 
radiosynthetic equipment, for this work they provided a clear method of ensuring 
diaryliodonium salt stability.360 In addition, it was believed that doubly protecting the 
amine functionality within an extendedly conjugated system would drastically reduce 
the nucleophilicity of the amine, hence reducing the risk of homo-attack on the 
highly electrophilic diaryliodonium salt product, which could bring about the 
formation of a neutral cyclic species (Figure 58). 
  
 
Figure 58: Neutral cyclic iodine (III) species which could potentially be formed if the m-tyramine 
amine is not doubly protected, particularly because of the optimum ring size afforded. 
 
Initial efforts in producing 179 from phenylethylamine 178 and phthalic anhydride 
proved challenging, as both very poor conversions coupled with challenging 
purification resulted in exceptionally poor yields (0—25%). A number of small 
modifications were trialled, including the addition of 3 Å molecular sieves into the 
reaction mixture, alternative solvents and use of Dean-Stark apparatus,361 of these, 
use of the latter followed by recrystallization from acetone:ethanol (1:9) proved to be 
the most successful method, although yields were still limited to 49%. 
As with previous preparations of diaryliodonium salts, it was considered that the non-
participating ring (n.p.r.) could be varied to control selectivity through relative 
electronics of the resulting protected m-tyramine diaryliodonium salt and hence three 
different aryliodobis(acetate)s, prepared as previously discussed (Section 2.5), were 
utilised in the preparation of diaryliodonium salts 180, 181 and 182 (Scheme 82).  
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Scheme 82: Preparation of diaryliodonium trifluoroacetates 180-182 for the production of 6-
[18F]fluoro-m-tyramine using aryliodobis(acetate)s as λ3-iodane precursor reagents 
 
As anticipated, direct reaction of aryliodobis(acetate)s 133-135 with electron-rich 
arene 179 proved to be poor in all cases, in particular, isolation of diaryliodonium 
salt 180 could not be achieved via this route. Formation of a diaryliodonium species 
corresponding to 180 was observed by 1H-NMR (doublet above 8.0 ppm consistent 
to previously observed protons ortho- to the iodine centre) of the crude reaction 
mixture, however, recrystallization failed to yield the desired product. Multiple 
attempts at column chromatography of crude reaction mixtures of 180 also failed to 
afford the product, presumably as a result of diaryliodonium salt instability as an 
artefact of the high electron density of both aryl substituents attached to the iodine 
centre as well as over exposure of the sensitive material to heat, light, solvent, silica, 
etc.  
This direct method of diaryliodonium salt formation did, however, successfully afford 
both 181 and 182 via recystallisation from DCM:ether:petrol, with material amounts 
sufficient for the subsequent [18/19F]fluorination experiments. Numerous efforts were 
also made to produce crystals of 181 and 182 of suitable quality for x-ray 
crystallography including via slow vapour diffusion as discussed in Section 2.7, 
however, only sufficiently large crystals of 181 were obtained and on 
crystallographic analysis the structure still exhibited substantial disorder (Figure 59).  
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Figure 59: Attempted x-ray crystallography of diaryliodonium salt 181 afforded the above 
disordered structure.  
 
Despite the inability to obtain high quality x-ray crystal structure date of 
diaryliodonium salts 181 and 182, the other supporting data (1H-NMR, 13C-NMR, 
HR-MS, elemental analysis) validated successful preparation of both targets. This 
encouraging result not only confirms the varied substrate scope of this method of 
diaryliodonium salts, but also two valuable diaryliodonium salt precursors have been 
afforded, useful for the preparation of 6-[18F]fluoro-m-tyramine. Given the small 
amounts of material needed for [18/19F]fluorination studies, attempts to optimise the 
preparation of 180—182 via incorporation of yield-improving arylstannane 
functionality was deemed unnecessary, but could be attempted in future work.  
 
4.2 [19F]Fluorination of 6-Fluoro-m-tyramine Precursors 
 
As with the diaryliodonium salts designed for 4-[18F]fluorophenol (Chapter 2), initial 
fluorination work on diaryliodonium salts 181 and 182 was conducted using ‘cold’ 
[19F]fluoride, to again assess the selectivity profile of each diaryliodonium salt under 
our artificial fluorination conditions, whilst monitoring the reaction progress by 1H- 
and 19F-NMR in real-time. As before, each diaryliodonium salt was dissolved in 
deuterated DMF before the addition of caesium fluoride and the reaction mixtures 
were heated up to 140 ⁰C, heated in 20 ⁰C increments every 30 min, whilst 
monitoring the change in the 1H- and 19F-NMR spectra (Scheme 83).  
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Scheme 83: Dynamic 1H- and 19F-NMR [19F]fluorination study with diaryliodonium salts 181-182, 
highlighting the potential fluoro- and iodoarene products 
 
As before, the identities of fluoroarene products were elucidated by adding an 
authentic sample of the relevant fluoroarenes to the complete reaction mixture, then 
re-analysing the mixture via 1H- and 19F-NMR with the expectation of seeing the 
corresponding peaks increase in intensity. Samples of protected 6-fluoro-m-tyramine 
183, 4-fluoroanisole 164 (expected to be seen for the fluorination of 181) and 2-
fluoroanisole 186 (expected to be seen for the fluorination of 182) were available 
for product validation. Fortunately, the formation only two fluoroarene products were 
observed during [19F]fluorination reactions of both 181 and 182, making analysis of 
the [19F]fluoroarene products straight forward (Figure 60 and Figure 61). 
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Figure 60: Dynamic 19F-NMR experiment following the fluorination of 2-(2-(3-
Methoxyphenethyl)isoindoline-1,3-dione)(4-methoxyphenyl)iodonium trifluoroacetates 181. 
 
 
Figure 61: Dynamic 19F-NMR experiment following the fluorination of 2-(2-(3-
Methoxyphenethyl)isoindoline-1,3-dione)(2-methoxyphenyl)iodonium trifluoroacetates 181.  
100 ⁰C 
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140 ⁰C 
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The dynamic [19F]fluorination experiments portrayed by the 19F-NMR spectra above 
demonstrate some interesting selectivity outcomes for the reactions of 181 and 182 
with caesium fluoride. In both cases it appears that fluorination was heavily directed 
towards formation of protected 6-fluoro-m-tyramine species 183, caused by the so-
called ortho-effect, discussed in Section 2.2.1, not surprising given the electron-
density exhibited by the target ring versus the n.p.r. Here, congestion around the 
axial positions of fluorination transition state promotes occupation of the pseudo-
equatorial by the arene bearing the most sterically demanding, and hence this 
species sees preferential fluorination.  
As with the [19F]fluorination studies discussed earlier, the material yield of these 
conversions under these reactions conditions is very low, therefore the experiments 
are used to purely assess the selectivity profile observed for the [19F]fluorination of 
each diaryliodonium salt. This is distinctly similar to the [18F]fluorination of 
diaryliodonium salts discussed herein, since RCY and material yield are independent 
of one another, and it is the RCY that is most important in radiochemical 
transformations. 
The table below (Table 14) summaries the findings of the above dynamic 
[19F]fluorination studies and provides approximate selectivity ratios determined by 
integration of the above 19F-NMR peaks, as well as corresponding shifts for the 
[19F]fluoroarene products detected.  
 
Precursor Fluorinated Products Selectivity 19F-NMR Shift 
181 protected 6-fluoro-m-tyramine 
183 
80% -130.3 ppm 
4-fluoroanisole 164 20% -125.6 ppm 
182 protected 6-fluoro-m-tyramine 183 75% -130.3 ppm 
2-fluoroanisole 186 25% -135.3 ppm 
Table 14: Summary of dynamic [19F]fluorination experiments on [18F]fluoro-m-tyramine precursor 
diaryliodonium salts 181 and 182, including 19F-NMR shifts and approximate selectivity profiles of the 
[19F]fluoroarene products 
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It was anticipated that diaryliodonium salt 182 would provide a poor substrate for 
the preparation of 186, given that both aryl substituents on iodine not only hold 
similar electron-rich quality, but also both bear functionality in the ortho position. 
Interestingly however, Table 14 highlights the lack of dissimilarity between the 
[19F]fluorination selectivity profiles of 181 and 182, despite this potentially poor 2-
anisyl n.p.r. on precursor 182. Seemingly the markedly bulkier functionality in the 
ortho position of target ring system heavily outweighs the effect of the ortho-
methoxy group on the n.p.r. of diaryliodonium salt 182. However, this only considers 
a monomeric model, where the extremities of the side chain are too distant to cause 
influence, whereas consideration of a dimeric model may see the side chain 
functionality providing additional interactions to neighbouring diaryliodonium salts. 
This positive outcome demonstrates how the ortho-effect can be exploited to 
override the disadvantages associated with the fluorination of diaryliodonium salts 
bearing two electron-rich arene substituents, a potentially invaluable tool for the 
fluorination of other [18F]fluoroarenes bearing steric bulk in the ortho- position, such 
as [18F]FDOPA. Although the ortho-effect has been studied for simple diaryliodonium 
salts previously,98,169 the application of ortho- substituted aromatics within 
diaryliodonium salts here fortifies the understanding of this advantageous effect and 
how it can provide highly selective late-stage radiofluorination of electron-rich arenes 
bearing extended functionality.  
 
4.3 [18F]Fluorination of 6-Fluoro-m-tyramine Precursors  
 
Chapter 3 describes the numerous benefits associated with microfluidic 
radiofluorination, as well as certain features specific to [18F]fluorination of 
diaryliodonium salts, such as the ability to operate radiolabelling within a closed 
system, providing access to higher than normal temperatures where RCYs are 
maximised. Similarly, the work therein also demonstrated how [18F]fluorination 
reactions of electron-rich diaryliodonium salts benefit from reaching elevated 
temperatures rapidly to avoid decomposition of the sensitive precursor during 
prolonged heating, again another feature supplied by microfluidics. 
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Despite these key benefits, simple-to-operate batch-based radiosynthesis platforms 
remain more popular than microfluidic systems within the PET community,362 
particularly within the clinical setting329 where radiosynthesis is still often conducted 
by non-chemically trained personnel and hence procedures are designed to be as 
simple as possible. Batch-based systems allow for the routine production of larger 
scale quantities (both in terms of material quantity and radioactivity) of fluorine-18 
labelled tracers and ligands, which permits transportation of the PET imaging agent 
to a distance location, or does splitting between multiple patients. However, to 
achieve optimal [18F]fluorination conditions on batch platforms, prior development on 
research grade microfluidic systems may be beneficial, followed by translation of 
those optimised parameters to the batch based system of choice, which can be 
complicated given the intrinsic differences between the radiosynthesis methods.  
A collaborative project with radiochemists at Edinburgh University Clinical Research 
Imaging centre (CRIC)363 provided the opportunity to conduct [18F]fluorination of 
electron-rich diaryliodonium salts within a batch radiolabelling platform, namely the 
GE TRACERlab FX FN platform (Figure 62, left),364 developed specifically for 
nucleophilic substitution with [18F]fluoride. GE have developed a number of batch-
based systems based around this model, encompassing electrophilic [18F]F2 
fluorination chemistry, carbon-11 labelling and systems intended for immediate 
clinical application utilising pre-developed, robust protocols, such as the GE FASTlab 
(Figure 62, right). 
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Figure 62: Batch based radiosynthesis platforms, the GE TRACERlab FX FN platform for research 
purposes (left)364 and the GE FASTlab platform designed for routine multi-tracer production of 
radiopharmaceuticals for clinical application (right)365 
 
In this pilot study, we aimed to trial the [18F]fluorination of diaryliodonium salt 
precursors to 6-[18F]fluoro-m-tyramine, namely precursor 181 prepared in Section 
4.2, to primarily investigate the translatability of diaryliodonium salt fluorination 
chemistry to the batch-based system, as well as to develop understanding of how 
the dominating the ortho-effect is outside of microfluidic radiofluorination. It is 
important to recall that [18F]fluorination via batch-based synthesis was always likely 
to yield limited results compared to the findings from microfluidic radiofluorination, 
given the lack of a closed system environment and hence temperatures above 130 ⁰C 
could not be accessed.  
The precursor diaryliodonium salt 181 was loaded into the GE TRACERlab FX FN 
platform, dissolved in a mixture of anhydrous DMF and anhydrous diglyme. The 
precursor was then transferred to the reaction vessel along with GE cyclotron 
produced [18F]fluoride, dried and re-administered as [18F]KF.K222 in anhydrous DMF, 
following which the reaction mixture was heated to 155 ⁰C for 30 min before being 
transferred to a semi-preparative radio-HPLC system for analysis of the reaction 
mixture (Figure 63).  
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Figure 63: UV/radio-HPLC chromatograms of the [18F]fluorination of diaryliodonium salt 181 
providing formation of protected 6-[18F]fluoro-m-tyramine [18F]183 , using a batch-based 
radiosynthesis platform (GE TRACERlab FX FN).  
 
Although extensive testing and parameter alterations were not conducted, the pilot 
[18F]fluorination of diaryliodonium salt 181 using the batch reactor platform proved 
highly successful, formation of the desired protected 6-[18F]fluoro-m-tyramine 
species [18F]183 was achieved with high selectivity for target arene over the 
[18F]fluorination of the n.p.r., over three [18F]fluorination runs an average RCY of 66 
% (s = 4.66, non-decay corrected) was achieved. Most importantly, this 
demonstrates the translatability of diaryliodonium salts as precursors to electron-rich 
[18F]fluoroarenes, given that platform translation proved to be relatively straight 
forward in this case. This bodes well for further development of electron-rich 
diaryliodonium salt precursors, since they can be applied to both microfluidic 
radiosynthesis platforms as well as the commonly seen batch-based systems, thus 
supporting simpler conversion to the preferred clinical format. However, the benefits 
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provided by microfluidic systems should not be overlooked and as the development 
of more hybrid microfluidic, batch-scale systems continues it is likely that 
radiochemists will look to utilising the advantages offered by microfluidic systems for 
clinically licensed fluorine-18 labelled targets.  
 
4.4 Chapter 4 Summary 
 
Chapter 4 demonstrates the potential application of diaryliodonium salt precursors for 
the preparation of dopaminergic system imaging agent 6-[18F]fluoro-m-tyramine, 
which also presents itself as a derivative of high valued target [18F]FDOPA. Here the 
strategy for producing electron-rich diaryliodonium salts was adapted to permit the 
formation of a series of, to the author’s knowledge, previously unreported protected 
m-tyramine diaryliodonium trifluoroacetates, providing a distinct advantage over 
previous efforts involving low SA electrophilic [18F]F2 fluorination chemistry. 
[19F]Fluorination studies on these precursors exposed how valuable manipulation of 
the ortho-effect can be for driving [19F]fluorination towards the target ring system, 
and preliminary [18F]fluorination using batch reactor system demonstrated the high 
level of translatability held by diaryliodonium salts of this type, drastically improving 
the chances of clinical application.  
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5 Diaryliodonium Routes to [18F]FDOPA 
 
Chapter 4 exemplifies how diaryliodonium salts can provide precursors for late-stage 
radiofluorination allowing access to n.c.a. electron-rich [18F]fluoroarenes produced as 
complete radiopharmaceuticals; herein we aim to extend that methodology to 3,4-
dihydroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA), a highly valuable 
dopaminergic system imaging agent that still lacks a robust and reliable nucleophilic 
route to production. The multiple labile protic functionalities on the molecule, as well 
as the inclusion of function-critical stereocentre and a need for highly regiospecific 
fluorine-18 incorporation make radiolabelling this small molecule a challenge (Figure 
64). 
 
 
Figure 64: Structure of 3,4-dihdroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA) 
 
Investigations into suitable protecting groups that supply compatibility with the 
[18F]fluorination conditions and accommodate the conditions required for 
diaryliodonium salt formation is required, as is a simple and crucially very fast 
method for complete deprotection in order to maintain a high RCY. As with the 
production of 6-[18F]fluoro-m-tyramine, precursor design should also consider the 
current trends and formats in the production of fluorine-18 labelled imaging agents 
and as such, translation of the diaryliodonium salt precursor into a format compatible 
with a ‘plug and play’ cassette is also explored. 
 
5.1  Introduction to [18F]FDOPA 
 
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) has seen extensive application in the PET 
imaging of a wide number of cancers, allowing for detailed identification of malignant 
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tissue and accurate assignment of stage and restage tumours.366 Even with 
continued development into other fluorine-18 labelled radiopharmaceuticals, more 
than 90% of all clinical PET scans are still conducted with [18F]FDG, despite the huge 
scope for PET imaging using alternative radiotracers and radioligands (Figure 65).367 
This setback in PET imaging agent diversity can, in part, be attributed to poor 
translation of successful PET tracers and ligands from bespoke R&D PET imaging 
studies to robust and widely accepted formats; although radiochemistry developers 
are constantly striving to bring successful pre-clinical candidates to market using 
simple-to-operate multi-tracer radiosynthesis platforms.365 
 
 
Figure 65: Infographic describing the importance of [18F]FDG in oncological PET, as well as other 
facts related to the clinical applications of fluorine-18 labelled PET imaging agents.367 
 
However, for many applications, the high uptake of [18F]FDG exhibited by 
energetically demanding tissue, such as the brain, heart, regions of inflammation and 
other heavily glycolytic processes often renders the radiotracer unsuitable for 
identification of abnormalities in these regions. [18F]FDOPA is widely regarded as a 
versatile yet highly selective radiotracer for the evaluation of presynaptic 
dopaminergic function, which holds influence over a number of diseases and 
conditions, making [18F]FDOPA a highly desirable tool for clinicians across the globe.  
Good understanding of the un-labelled derivative, L-3,4-dihydroxyphenylalanine (L-
DOPA), has seen therapeutic application of the L-tyrosine derivative for the treatment 
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of Parkinson’s disease (PD) for over 40 years.368 As a precursor to the integral 
neurotransmitter dopamine (as well as norepinephrine and epinephrine), 
administration of L-DOPA sees the molecule cross the blood-brain-barrier and raises 
dopamine concentrations as it is metabolised by aromatic L-amino acid 
decarboxylase, aiding patients with dopamine deficiency such as those suffering from 
Parkinsonian symptoms or dopamine-responsive dystonia.369 
 
 
Figure 66: [18F]FDOPA PET scans highlighting the loss of dopamine storage capacity in the putamen 
of a patient with Parkinson's disease (left) versus normal dopamine distribution within a healthy 
brain (right) 
 
Initial efforts into the incorporation of fluorine-18 into L-DOPA sought to use the 
radiotracer to image the underlying pathophysiology of PD (Figure 66) and related 
central motor disorders, however, continued exploration into other uses of 
[18F]FDOPA over the last 15 years has unveiled the ever expanding spectrum of 
applications the radiotracer can be benefit.370 Amongst these new emerging uses, 
the most frequently researched is the imaging of neuroendocrine tumours (NETs),371 
a collective of cancers including pancreatic β-cell hyperplasia, pheochromocytoma, 
carcinoid tumours and medullary thyroid cancers (MTCs); 372,373 as well other related 
diseases such as hyperinsulinism, cerebral gliomas and bronchopulmonary cancer.374  
 
 171 
 
Figure 67: A demonstration of the superior sensitivity offered by [18F]FDOPA PET (right) over 
[18F]FDG PET (middle) and MRI (left) for newly diagnosed tumours of (A) glioblastoma and (B) 
grade II oligodendroglioma374 
 
As shown in above (Figure 67) imaging of gliomas using [18F]FDOPA benefits from 
high tumour-to-background ratio and high sensitivity, which is crucial when seeking 
to image non-aggressive metastatic cancers like NETs and gliomas.375 For many of 
the tumour types under the NET umbrella, [18F]FDOPA affords a very similar mode of 
action, as depicted below (Figure 68), whereby the uptake of [18F]FDOPA is mediated 
by the sodium-independent large amino acid transporter (LAT1) protein. [18F]FDOPA 
then undergoes metabolism facilitated by L-amino acid decarboxylase (AADC), 
affording [18F]fluorodopamine, which no longer being able to pass out of the cell 
membrane provides a cellular retention mechanism and helps promote successful 
PET imaging. After the metabolite is transported into neurosecretory vesicles via a 
vesicular mono-amine transported, further metabolism mediated by dopamine-β-
hydroxylase affords [18F]fluoro-norepinephrine.375 
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Figure 68: Schematic representation of the uptake mechanism of [18F]FDOPA in neuroendocrine 
cells375 
 
In essence, uptake of [18F]FDG increases as tumour aggressiveness increases, 
making the radiotracer invaluable for rapid diagnosis of life threatening cancers, 
however, radiolabelled amino acids like [18F]FDOPA hold particular value in imaging 
slower metastasising cancer types.372 Whilst the mortality rate of patients suffering 
from NETs is relatively low, patients can experience serious detriments to their health 
when afflicted by NETs over extended periods of time; and the last 30 years have 
seen a 500% increase in the incidence of NETs, hence a reliable route to diagnosis, 
through non-invasive PET imaging is very much required.  
 
5.2  Current Routes to [18F]FDOPA 
 
The ever increasing demand for a robust method of [18F]FDOPA production has 
brought considerable attention to the preparation of this challenging fluorine-18 
labelled target, and hence there are a number of diverse approaches known, 
however, all of which come with limitations that potentially hinder their application in 
the clinical setting. Traditional routes utilise electrophilic [18F]F2 or reagents derived 
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from [18F]F2 to achieve late-stage radiofluorination of a protected precursor, but are 
as expected, limited by the inherently low SA associated with carrier added [18F]F2. 
Unselective direct electrophilic [18F]fluorination with [18F]F2 provides a mixture of 
regioisomers that are difficult to separate quickly,376,377 hence subsequent efforts 
focussed on the incorporation of much more efficient directing metal groups (Scheme 
84).  
Cleavage of the carbon-silicon bond of precursor 187 to afford 188 and 
subsequently [18F]FDOPA was first conducted by Diksic and co-workers, although 
benefitting from the omission of any toxic organometallic precursors, the resulting 
RCY and SA were relatively poor.378  Note the use of Freon-11 (CCl3F) in this 
radiosynthesis as an inert and easily removable solvent, ideal for electrophilic 
[18F]fluorination chemistry, however, later work that found that substitution of the 
environmentally damaging chlorofluorocarbon for deuterated solvents afforded better 
results,379 as applied for the [18F]fluorination of precursor 189. The 
[18F]fluorodestannylation approach to [18F]FDOPA via 190 has received more 
attention than alternative demetallation methods largely because of the improved 
conversion, affording typically higher RCYs (Scheme 84).380  However, use of more 
nucleophilic trimethylstannylarene precursors rather than less toxic 
trialkylstannylarenes presents unfavourable toxicity concerns.  
Organomercury381 191 and organosilver122 193 precursors have also been utilised to 
achieve highly selective radiosynthesis of [18F]FDOPA, but similarly suffer from poor-
modest yields, low SAs and are also relatively toxic in character, which again 
hampers adoption of such precursors by clinical radiopharmacies.   
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Scheme 84: Electrophilic routes to [18F]FDOPA involving [18F]fluorodemetallation of protected 
precursors 
 
Isotopic exchange using nucleophilic [18F]fluoride has also been utilised in the 
preparation of [18F]FDOPA in attempts to capitalise on the improved SA offered by 
[18F]fluoride, as demonstrated by the radiosynthesis developed by Wagner et al. 
(Scheme 85).382 This three-step, one-pot protocol benefitted from the use of n.c.a. 
[18F]fluoride, as reflected by an improved SA (1.2–2.5 GBq/µmol), whilst achieving 
enantiomeric purity of 99% yet a modest RCY of 22%, as limited by the 
incorporation method.  
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Scheme 85: Radiosynthesis of [18F]FDOPA via isotopic exchange of 195 using nucleophilic 
[18F]fluoride 
 
A number of poorly effective attempts at producing [18F]FDOPA from 
enantiomerically pure chiral precursors or chiral auxillaries have been attempted, 
however they are typically limited to very low RCY (5-10%) and hence have limited 
application.383,384 More effectively, efforts have been taken to install fluorine-18 into 
simple, protected arenes bearing electron-withdrawing functionality ortho- to the 
fluorination site via SNAr chemistry using [
18F]fluoride, hence needing multiple post-
radiofluorination steps to convert the electron-withdrawing moiety into the required 
chiral DOPA side chain, usually by way of chiral phase transfer catalyst385,386,387 or via 
an enzymatic route.388 The later has been shown to provide access to [18F]FDOPA 
from simple [18F]fluoroarenes like [18F]201 in a single step, a conversion of 
particular significance to the work discussed in Chapters 2 and 3 (Scheme 86).389 
Despite the poor RCY achieved for this preparation, Kaneko et al. were able to 
achieve an exceptionally high SA of >200 GBq/µmol and presumably an enantiomeric 
excess of 100% given the enzymatic control of the reaction.389 
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Scheme 86: Radiosynthesis of [18F]FDOPA using enzymatic installation of the side functionality 
 
Optimised asymmetric routes to [18F]FDOPA have proven to be capable of affording 
excellent enantiomeric purity as well as drastically improved SA (>720 Gq/µmol) 
versus electrophilic routes, such as the recent work by Lemaire and co-workers 
(Scheme 87).390 This elegant approach represents one of the currently the most 
refined routes to [18F]FDOPA via automated radiosynthesis and with use of an 
optimised chiral phase-transfer catalyst, However, as seen previously the extended 
post-radiofluorination chemistry limits the product RCY. Other very similar automated 
production kits for [18F]FDOPA have been developed by Trasis Pharmacy 
Instruments,391 and Neptis.392  
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Scheme 87: Automated radiosynthesis of [18F]FDOPA using a chiral phase-transfer catalyst 203 
 
Recently, other more creative routes to [18F]FDOPA have also been developed, for 
example, the work by Brady and co-workers393 utilised solid-supported precursor 
206 to improve the efficiency of the electrophilic radiofluorination discussed earlier, 
the procedure utilises a simultaneous [18F]fluorination and cleavage mechanism to 
afford [18F]207 whilst retaining all toxic organostannane species on the resin 
(Scheme 88).393 
 
 178 
 
 
Scheme 88: Preparation of [18F]FDOPA via a solid-supported precursor (RCY not provided) 
 
As discussed in Section 1.6.2.4, metal mediated nucleophilic [18F]fluorination routes 
can provide access to electron-rich [18F]fluoroarenes which are otherwise 
unachievable by SNAr chemistry, and methods involving copper catalysed 
[18F]fluorination of pinacol-derived aryl boronic esters (Scheme 89),394 as well as 
nickel-mediated oxidative [18F]fluorination (Scheme 90)176 have been utilised to 
prepare [18F]FDOPA. 
 
 
Scheme 89: Preparation of [18F]FDOPA via copper-mediated nucleophilic [18F]fluorination of a 
protected pinacol-derived boronic ester precursor 
 
In this approach, Tredwell and co-workers implement successful enantioselective (ee 
> 99%) preparation of [18F]FDOPA with a rapid two-step radiofluorination of simple 
to prepare precursor, using high SA [18F]fluoride.394 However, no RCY was reported 
for the production of [18F]FDOPA and the use of a potentially toxic copper catalyst in 
the penultimate step of preparation potentially negates scope of the process in 
medical applications.  
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Scheme 90: Preparation of protected-[18F]FDOPA via nickel-mediated oxidative [18F]fluorination 
 
The above method for [18F]FDOPA, developed by the Ritter research group provides 
an interesting new approach to the preparation of the high value target, utilising 
aqueous [18F]fluoride, i.e. removal of any lengthy drying time, as well as an intricate 
nickel based precursor and λ3-iodane oxidant to afford ultrafast [18F]fluorination.176 
Despite these benefits, their reported modest RCY omits the essential subsequent 
deprotection reaction to afford [18F]FDOPA and hence the RCY is likely to suffer 
further. Other disadvantages include the extended organometallic synthesis required 
for the preparation of precursor 209, that has yet to be repeated by another 
research entity, as well as the high likelihood of protolysis of the Ni-C bond, resulting 
in the formation of the protio-derivative of 210, which may very difficult to separate 
from [18F]210. 
[18F]Fluorination of a protected DOPA iodonium ylid precursor 213 has demonstrated 
potential as a high yielding route to the [18F]fluoroarene. It has been shown that on 
reaction with [18F]fluoride in a polar aprotic, the ylid directs [18F]fluorination towards 
the aryl substituent (Scheme 91),395 however again this method comes with a distinct 
limitation. Preparation of the precursor iodonium ylid requires the potentially 
challenging preparation of λ3-iodane 212, an oxidation that in practise can be 
difficult to conduct in the presence of multiple sensitive functionality as with 211. As 
with the routes involving complex organometallic precursors described earlier, 
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reproducibility in the preparation of elaborate aryliodonium ylid precursors like 213 
may also prove to become a challenge in practice.  
 
 
Scheme 91: Preparation of [18F]FDOPA via an iodonium ylid precursor (RCY not provided) 
 
Scott and co-workers have also developed an interesting diaryliodonium salt 
precursor based strategy that utilises a mesityl n.p.r. in the presence of a copper 
catalyst which results in inversion of the usual [18F]fluorination regiochemistry.396 
Unlike typical [18F]fluorinations of diaryliodonium salts bearing sterically hindered 
aromatic components, the addition of a copper catalyst not only reduced the required 
reaction temperature but also inverted the radiofluorination selectivity, yielding 
preferred [18F]fluorination of the arene bearing less ortho- bulk. The group applied 
this approach to a wide range of electron-poor and electron-rich targets, including a 
protected [18F]FDOPA substrate (Scheme 92), however, as with the related strategies 
described earlier, widespread adoption of this approach may still be hindered by the 
challenge of preparing electron-rich diaryliodonium salt precursors.  
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Scheme 92: Preparation of a protected [18]FDOPA species via copper-catalysed [18F]fluorination of a 
(mesityl)(aryl)iodonium salt precursor 
 
 
5.3  [18F]FDOPA Diaryliodonium Salt Precursor Strategy 
 
The former section provides a short review of the existing strategies for the 
radiosynthesis of [18F]FDOPA, as well as the concerns that limit the application of 
each method for use in routine clinical production. This section describes efforts in 
designing a diaryliodonium salt precursor suitable for late-stage radiofluorination 
using n.c.a. [18F]fluoride to afford [18F]FDOPA in high RCYs and high SA, via a 
clinically viable format.   
Prior chapters have demonstrated how the diaryliodonium salt approach ensures 
complete regioselectivity on [18/19F]fluorination, an essential criterion for the 
preparation of [18F]FDOPA, as in vivo studies has shown that alternative regioisomers 
of 6-[18F]FDOPA exhibit accelerated O-methylation and hence installation of fluorine-
18 into the 6-position of [18F]FDOPA to ensure prolonged in vivo stability is 
absolutely crucial.397 Similarly, enantiomeric purity is also essential and hence 
chirality should be incorporated into the molecule well before radiofluorination. The 
ideal [18F]FDOPA diaryliodonium salt precursor should also allow for rapid, global 
deprotection, without requiring any further transformations to reach the target 
radiotracer (Scheme 93).  
 
 182 
 
Scheme 93: Planned radiosynthesis of [18F]FDOPA via a diaryliodonium salt and global deprotection 
strategy 
 
This planned approach should be generate a number of key benefits: a high RCY as 
a result of late-stage radiofluorination; high SA attributed to the use of n.c.a 
[18F]fluoride; and the sole post-radiofluorination step should afford high product 
purity, high radiochemical purity and simpler purification. This route also avoids use 
of any toxic organometallic precursors or catalysts within the radiosynthesis, aiding 
the likelihood of clinical approval. In addition, this two-step approach 
(radiofluorination followed by acid hydrolysis deprotection) mimics the radiosynthesis 
of the most commonly prepared PET tracer in use, [18F]FDG (Scheme 94). 
 
 
Scheme 94: Typical radiosynthesis of [18F]FDG, involving two step (radiofluorination and acid 
hydrolysis deprotection) approach 
 
As mentioned before, adapting to suit current trends in clinical radiopharmaceutical 
production appears to the best manner for improving the success of a radiotracer 
production method, hence why developing a protocol for [18F]FDOPA radiosynthesis 
that is similar to current protocols used to prepare the world’s leading PET 
radiotracer is a wise strategy.  
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As part of this rationale, a collaborative project was initiated with Advanced 
Biomarker Technologies (ABT) (the manufacturers of the compact cyclotron used for 
[18F]fluoride production discussed in Chapter 3)  to develop a means to produce an 
operator-friendly route to [18F]FDOPA, based around the synthesis cassette 
approach. It was noted that whilst synthesis cassettes are currently available for 
[18F]FDG, [18F]NaF for bone/skeletal imaging, [18F]FMISO for imaging hypoxic cells 
and proliferation tracer [18F]FLT,398 but not for [18F]FDOPA, representing a clear 
avenue for commercial viability. Such synthesis cassettes are usually intended for use 
with specific synthesis platforms, like the GE FASTlab Multi-Tracer Platform 
mentioned in Chapter 4, or the ABT Chemistry Production Module (CPM) (Figure 69). 
 
  
Figure 69: The ABT Chemistry Production Module (CPM), a self-shielded radiosynthesis platform 
developed for cassette-based radiotracer production399 
 
Conceptualisation of a [18F]FDOPA dose synthesis card (DSC), compatible with the 
above system, involved translating the knowledge and understanding on 
diaryliodonium salt [18F]fluorination chemistry developed in the prior chapters into a 
format suitable to this application. Reagents to be used within the cassette are 
purchased as miniature GMP-grade samples which can be stored within the synthesis 
platform, whereas diaryliodonium salt precursors will require freezer storage to 
ensure long-life. In this chapter efforts were made to yield a diaryliodonium salt 
precursor to [18F]FDOPA that exhibits some bench-stability. Chapter 4 has already 
validated that batch-based radiosynthesis with diaryliodonium salts precursors is 
certainly viable, hence that being a simpler and cheaper approach than microfluidics 
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will be utilised here, but future iterations of a [18F]FDOPA DSC could include a 
microfluidic reaction coil or chip. 
Minimising the complexity of components within the DSC is also imperative for 
ensuring the device is as small, as cheap and as robust as possible, so to facilitate 
this fluidic control will be dictated entirely the CPM, by fitting the back of the DSC 
with nitrogen/vacuum ports for fluid manipulation (Figure 70, A). Of course to 
guarantee that the device remains sterile during transport, these ports, as well as the 
[18F]fluoride entry port must remained sealed, until the DSC is inserted into the CPM, 
by way of one-way flow valves.  On-device purification (Figure 70, B) and 
formulation (Figure 70, C) is also essential to maintain a rapid, stream-lined process, 
thus the inclusion of silica (or other sorbent material) SPE cartridges are also 
required, there is also potential to lyophilise the required reagents within the 
appropriate channels (Figure 70, D) to again benefit the speed and smoothness of 
radiotracer production.  
For the radiosynthesis itself, the reaction vessel (if to be conducted as a one-pot 
preparation, otherwise two separate reaction vessels will be necessary) will need to 
protrude from the bottom of the DSC (Figure 70, E), so that it fits within a CPM 
miniature heating mantle. Finally, extraction of the purified and formulated 
[18F]FDOPA product directly into a sterile Luer-Lok syringe (Figure 70, F) will allow 
easy administration of the product to the multiple QC analyses that are required and 
ultimately delivery of the tracer to the patient.  
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Figure 70: Concept design for a [18F]FDOPA production cassette using a diaryliodonium salt 
precursor to provide late-stage radiofluorination as part of a two-step, one-pot protocol.  
 A = nitrogen/vacuum ports, B = SPE cartridge for product purification, C = formulation SPE 
cartridge, D = potentially reagents, including diaryliodonium salt precursor could be lyophilised 
within the device channels, E = reaction vessel, F = product extraction into sterile Luer-Lok syringe 
 
Synthesis cassettes like the [18F]FDOPA DSC design above are intended for single 
dose-single patient application, and hence are produced as sealed, sterile devices, 
negating the need for an expensive and difficult to maintain grade A clean room; 
instead a lower grade clean room can be utilised (as per EU GMP classifications).400 
One of the major benefits provided by single-dose single-patient radiosynthesis is 
that micro-scaling of the cassette allows easy and safe disposal of the cartridge once 
radiotracer production is compete, as well as eliminating the risk of reagent cross-
contamination.  
 
5.4 Initial Challenges in [18F]FDOPA Diaryliodonium Salt Development 
 
It was initially conceived that diaryliodonium salt precursors to [18F]FDOPA could be 
prepared as per the protocol utilised in Chapter 4, whereby a protected electron-rich 
arene could be reacted with an activated aryliodobis(acetate) to prepare the target 
diaryliodonium salt, without the need for activating groups, such trialkylstannane or 
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boronic acid functionality. Given that L-DOPA is commonly prescribed for the 
treatment of Parkinson’s Disease, the compound is commercially available with at 
high enantiomeric purity (> 98%, Sigma Aldrich), making it a logical starting material 
for the preparation of the following protected derivatives.  
Protecting groups were selected based on their ease of deprotection and the toxicity 
of their by-products on deprotection, as well as expected simplicity of removing 
these by-products from the product FDOPA. The Boc protecting group is commonly 
utilised for protection of the amine and catechol functionality of the molecule 
because of the scope for rapid deprotection using hydrochloric acid (6M), as seen 
with previous electrophilic and nucleophilic routes to [18F]FDOPA.393,395 Whereas the 
more robust protecting groups, such as the methyl or benzyl functionalities are 
commonly cleaved with hydrogen bromide (58%) or hydrogen iodide (57%) in a 
short amount of time.378,381 
Preparation of initial protected DOPA derivatives commenced with protection of the 
carboxylic acid functionality by treatment with thionyl chloride in methanol or ethanol 
to afford the corresponding DOPA methyl/ethyl ester, followed by protection of the 
amine functionality via Boc or trityl protecting groups with Boc anhydride or trityl 
chloride respectively, utilising trimethylamine to deprotonate the amine in both 
cases. Finally the catechol functionality was protected either by benzylation with 
benzyl bromide and potassium carbonate, or via Boc protection again utilising 
trimethylamine, Boc anhydride with prolonged heating to afford protected DOPA 
derivatives 219—224 (Figure 71).  
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Figure 71: Conversion of commercially available L-DOPA into six protected DOPA derivatives, 
prepared by the author and/or prepared within the research group. 
 
The substrates 219—224 were then utilised in a series of pilot experiments (0.25 
mmol), with the intention of validating their application for the preparation of a 
DOPA diaryliodonium salt precursor. Here three aryliodobis(acetate)s were selected 
for the scoping study based on their varying electron-density, phenyliodo bis(acetate) 
132, 2-thienyliodo bis(acetate) 133 and 4-anisyliodo bis(acetate) 134, prepared as 
described in Section 2.5. Activation of aryliodobis(acetate) reagents was realised 
using trifluoroacetic acid as per standard method (Section 2.7) as well as 
trifluoromethanesulfonic (triflic) acid to provide more forcing conditions through 
formation of a potentially more activated λ3-iodane species (Scheme 95).  
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Scheme 95: Pilot reactions to scope potential of [18F]FDOPA diaryliodonium salt formation under 
the selected conditions 
 
Across this scoping study reactions were monitored by TLC and 1H-NMR of the crude 
reaction mixture, where diaryliodonium salt formation was apparent (evident by the 
formation of 1H-NMR aromatic peaks exceeding 8.0 ppm) product extraction was 
attempted as per the standard method (Section 2.7), by recrystallisation from 
DCM/diethyl ether/petrol or via column chromatography on SiO2 with 4% methanol 
in petrol.  
 
 Protected DOPA Derivative 
ArI(OAc)2 Acid 219 220 221 222 223 224 
Phenyl (132) TFA Ar2I+X- 
132 
132 132 132 132 Ar2I
+X- 
 
Phenyl (132) TfOH - 132 132 - - - 
2-thienyl 
(133) 
TFA Ar2I+X- 
 
Ar2I+X- 
 
- - 
 
- Ar2I+X- 
133 
2-thienyl 
(133) 
TfOH - - - - - - 
4-anisyl (134) TFA Ar2I+X- 
134 
Ar2I+X- 
134 
- - Ar2I+X- 
134 
Ar2I+X- 
134 
4-anisyl (134) TfOH 134 - - - - - 
 
Table 15: Pilot experiments for the formation of [18F]FDOPA diaryliodonium salt precursors. Ar2I+X- 
indicates observation of an apparent diaryliodonium salt species in the reaction mixture as 
monitored by 1H-NMR, compound numbers indicates observation of the aryliodobis(acetate) 
starting material and - signifies the observation of a crude mixture of products 
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The pilot study highlighted the unsuitability of employing triflic acid for activation of 
the aryliodobis(acetate) precursors, presumably formation of the corresponding 
aryliodo bis(trfliate)s does occur but the resulting diaryliodonium triflate decomposes 
after formation. Another apparent trend seen is that the trityl protection strategy fails 
to endure the reaction conditions, since no product diaryliodonium was observed for 
the reactions of 221 and 222, an unsurprising observation given the acid sensitivity 
of the trityl functionality. 
Electron-rich protected DOPA derivatives 219, 220, 223 and 224 all appeared to 
afford, albeit very small, amounts of a diaryliodonium salt species, as detected by the 
formation of 1H-NMR peaks clearly above 8.0 ppm, however no distinct preferences 
for n.p.r. was seen across the pilot study.  
Reactions that appeared to yield some diaryliodonium salt product were then 
completed on a larger scale (≥5 mmol), however, all attempts to isolate a product 
diaryliodonium salt via this method of preparation failed to yield any of the desired 
product and on some occasions the protected DOPA arene starting material could be 
recovered. This outcome was possibly as a result of product instability and/or 
because the quantity of product formed was miniscule, making extraction of that 
material from a crude variety of compounds very challenging. It was considered that 
progression from the 6-fluoro-m-tyramine diaryliodonium salt to FDOPA 
diaryliodonium salt target was perhaps too large a step to take immediately, so 
development of an intermediate target, a diaryliodonium salt precursor for 6-
[18F]fluorodopamine was undertaken.  
 
5.5 Diaryliodonium Salt Precursor to 6-[18F]Fluorodopamine 
 
Preparation of a diaryliodonium salt precursor to 6-[18F]fluorodopamine not only 
provides a stepping stone to the high demand [18F]FDOPA diaryliodonium salt target, 
but [18F]fluoroarene is also a highly desirable PET tracer in itself, and currently the 
same issues involved with [18F]FDOPA production exist for 6-[18F]fluorodopamine. 6-
[18F]Fluorodopamine has previously been used for a number of in vivo PET imaging 
studies including imaging of cardiac sympathetic innervation,401 scanning for 
localisation of pheochromocytoma,402 and imaging brown adipose tissue (brown fat), 
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another hallmark of pheochromocytoma (Figure 72);403 however, many potential 
applications of the radiotracer are limited by its inability to cross the blood-brain-
barrier, hence the need for [18F]FDOPA. 
 
 
Figure 72: PET image of patient with pheochromocytoma exhibiting uptake of 6-
[18F]fluorodopamine uptake in the superclavicular brown fat (left) and the corresponding CT image 
(right) 
 
Preparation of the 6-[18F]fluoro-m-tyramine diaryliodonium salt precursor 181 was 
achieved through the reaction defined by Scheme 96 (in a yield of 20%), thus it was 
presumed that the 6-[18F]fluorodopamine could be prepared by the same route 
(Scheme 97), given that the sole difference between electron-rich arenes 179 and 
225 was an additional methoxy group, meta to the iodination position.  
 
 
Scheme 96: Preparation of 6-[18F]fluoro-m-tyramine diaryliodonium salt precursor 181 through the 
reaction of 134 and 179, facilitated by a ligand exchange of aryliodobis(acetate) 
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Scheme 97: Attempted preparation of 6-[18F]fluorodopamine diaryliodonium salt precursor 226 
through the reaction of 134 and 224, facilitated by a ligand exchange of aryliodobis(acetate). 
Protected dopamine derivative 225 was prepared by the same means as 179 
 
Despite multiple attempts at preparing diaryliodonium salt 226 via this route 
(Scheme 97), no product was obtained, and hence installation of a halogen in the 6-
position was required in order to convert electron-rich arene 224 into the 
corresponding arylstannane compound. Here iodine was installed via a very 
convenient method that utilises silica powder, iron (III) nitrate nonahydrate and 
iodine to afford iodination in good yields,404 and the subsequent stannylation was 
best achieved through palladium catalysed means (Scheme 98). Note that this 
iodination method was also utilised to afford clean iodination of 2,4,6-
trimthylbenzene and of benzylphenyl ether to yield iodinated products 138 and 242, 
which were utilised in Chapter 2.  
Then the target 6-[18F]fluorodopamine diaryliodonium salt 226 was successfully 
afforded by reaction of arylstannane 228 and aryliodobis(acetate) 134 (Scheme 99) 
as per the method discussed in Section 2.7.  
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Scheme 98: Preparation of arylstannane 228 via iodination of electron-rich arene 225 and palladium 
catalysed stannylation of the resulting iodoarene 227 
 
 
Scheme 99: Preparation of 6-[18F]fluorodopamine diaryliodonium salt precursor 226 by reaction of 
arylstannane 228 and aryliodobis(acetate) 134 
 
The 1H-NMR spectrum for diaryliodonium salt 226 (Figure 73) highlighted an 
interesting observation, the proton environment ortho- to the diaryliodonium salt 
ipso-carbon, whilst were still notably more downfield than the corresponding 
iodoarene (227) did not exhibit the expected downfield shift of over 8.0 ppm, 
normally representative of diaryliodonium salt formation. Other supporting data (13C-
NMR, HR-MS and elemental analysis) was in agreement of the expected 
characterisation for diaryliodonium salt 226. This disagreement with traditional 
interpretations is most likely an artefact of the increased electron-density of the 
diaryliodonium salt centre by the increased electron-rich nature of the target arene 
substituent. 
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Figure 73: 1H-NMR of aromatic protons for the conversion of protected dopamine 225 up to 6-
[18F]fluorodopamine diaryliodonium salt 226, validating the successful preparation of the target λ3-
iodane 
     
Successful preparation of 6-[18F]fluorodopamine diaryliodonium salt precursor 226 
via this method demonstrates that preparation of diaryliodonium salts bearing 
multiple electron-rich substituents is best achieved by the above method (Scheme 
99), whereby attack on the electrophilic diaryliodonium salt centre is directed by the 
arylstannane functionality of the electron-rich arene substrate. Hence to reach a 
diaryliodonium salt precursor to [18F]FDOPA a route involving arylstannane 
preparation will be required.  
 
 
 
5.6 Redesign of the [18F]FDOPA Diaryliodonium Salt 
 
HA 
HA 
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 194 
It was planned that late-stage incorporation of iodine could be achieved using the 
protected DOPA arenes 219—224 prepared in Section 5.4, however despite trialling 
a variety of iodination procedures404,405,406 229 could not be obtained. 
 
 
 
It was decided that early halogenation of L-DOPA would provide a better route to 
substrates like 230, and preparation of a bromo-arene would be preferred over the 
corresponding iodo-arene, given the difference in their relative Ar-X bond dissociation 
energies (346 and 240 kJ/mol respectively),407 bromoarenes should provide more 
stable precursors; a valuable characteristic given that further steps were required 
before stannylation could be conducted. 
In addition, initial work on the stannylation of electron-rich aryl halides (as discussed 
in Section 2.6) described how preparation of arylstannane reagents from 
bromoarenes rather than iodoarenes reduced the risk of homo-coupling and 
generally afforded superior yields. Hence, the new strategy for [18F]FDOPA precursor 
development was conducted as follows (Scheme 100), via direct bromination of L-
DOPA with bromine in acetic acid, followed immediately by conversion to the 
corresponding methyl ester 230 by treatment with thionyl chloride in methanol.408  
 
 
Scheme 100: preparation of bromo-DOPA methyl ester 230 from L-DOPA 
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Further protection of the L-DOPA derivative was achieved through sequential Boc 
protection, as 230 was treated with trimethylamine and Boc anhydride in degassed 
methanol at room temperature for 15 h.408 Validation of successful Boc protection of 
the amine group was then conducted on the intermediate before Boc protection of 
the catechol functionality, again using trimethylamine and Boc anhydride but with 
heating at 80 °C in anhydrous toluene for 7 h,176 to afford protection DOPA 
derivative 231. Simultaneous Boc protection of both the amine and catechol 
functionalities was attempted, but afforded a poorer yield, hence a step-wise 
protection method was preferred (Scheme 101). 
 
 
Scheme 101: Sequential Boc protection of aryl bromide 230 to afford protected aryl bromide 231 
 
In a bid to optimise conversion of protected DOPA bromide 231 to an arylstannane 
species (Scheme 102), a number of reaction conditions and catalyst systems were 
screened (Table 16). Preparation of the preferred tributylstannyl derivative 232, 
could not be achieved in synthetically useful yields, and hence the more reactive but 
toxic trimethylstannyl derivative 233 was utilised as the arylstannyl substrate of 
choice for [18F]FDOPA diaryliodonium salt preparation. 
 
 
Scheme 102: preparation arylstannanes 232 and 233 through catalysed stannylation of 231 
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Entry Catalyst system Stannane Reaction conditions Yield 
1 Zn, CoBr2, allyl 
chloride 
Bu3SnCl MeCN, 50 °C, 8 h 0%
1 
2 PdCl2(PPh3)2         
(10 mol%) 
Bu3SnSnBu3 1,4-Dioxane, 100 °C, 
16 h 
0%2 
3 Pd(PPh3)4
               
(10 mol%) 
Bu3SnSnBu3 1,4-Dioxane, 100 °C, 
16 h 
0%2 
4 Pd(PPh3)4                
(20 mol%) 
Bu3SnSnBu3 1,4-Dioxane, 100 °C, 
LiCl, 16 h 
6% 
5 (η3- C3H5)2Pd2Cl2 
(20 mol%) 
Bu3SnSnBu3 1,4-Dioxane, 100 °C, 
LiCl, 16 h 
3% 
6 Pd(PPh3)4                
(20 mol%) 
Me3SnSnMe3 1,4-Dioxane, 100 °C, 
LiCl, 16 h 
15% 
7 (η3- C3H5)2Pd2Cl2 
(20 mol%) 
Me3SnSnMe3 1,4-Dioxane, 100 °C, 
LiCl, 16 h 
34% 
 
Table 16: Optimisation of reaction conditions, catalyst type and catalyst loading for the preparation 
of protected DOPA arylstannanes 232 and 233. 1decomposition of starting material, 2starting 
material recovered 
 
Although optimisation of arylstannane preparations failed to achieve a high yielding 
process, literature examples also see yields limits to <40% for the preparation of 
very similar protected DOPA arylstannanes. Despite the inefficiency of the catalytic 
conversion, apparent by the very high catalyst loading required for successful 
formation of 232/233, sufficient material was available for attempted preparation of 
[18F]FDOPA diaryliodonium salt 234. However, despite use of the more reactive 
trimethylstannyl derivative 233, observation of the iconic doublet peaks 
corresponding to the protons ortho to the diaryliodonium salt centre (7.9 ppm) in the 
1H-NMR of the crude reaction mixture and multiple attempts at the preparation of 
234, no pure product could be isolated by this method (Scheme 103), although 5-
10% of the diaryliodonium salt was visible in the 1H-NMR of the reaction mixture.  
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Scheme 103: Attempted preparation of [18F]FDOPA diaryliodonium salt 234 
 
Here, preparation of a diaryliodonium trifluoroacetate designed to yield [18F]FDOPA 
was not afforded with the protection strategies described above, although further 
study into this work as well further protecting group screening was required to 
develop a better understanding of this challenge. 
Shortly after conducting the experiments described above, Wirth and co-workers 
published a similar route to diaryliodonium salts for the production of [18F]FDOPA, 
however they prepared the their diaryliodonium salts with tosylate counter-ion, 
before performing a counter-ion exchange conversion to afford diaryliodonium 
bromides.409 However, when reacted with tetramethylammonium fluoride as part of a 
‘cold’ [19F]fluorination study, these precursors afforded very poor chemical yields; 
similarly, when Wirth et al. conducted [18F]fluorination on leading precursor 235 
using a batch-based synthesis platform, they afforded a RCY of <1%, indicating a 
concern in their diaryliodonium salt strategy, potentially as a result of the use of a 
more nucleophilic counter-ion. 
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Scheme 104: Preparation of protected [18F]FDOPA 234 by [18F]fluorination of diaryliodonium salt 
233, usiing an automated Eckert & Zeigler batch radiosynthesis system. 
 
This result does, at least, provide proof of principle in the diaryliodonium salt 
approach to [18F]FDOPA production, however, it is clear that much refinement in the 
choice of counter-ion, [18F]fluorination conditions and, most crucially, the choice of 
protecting groups is required if a robust strategy for [18F]FDOPA is to be realised. 
Drawing from conclusions provided by Chapters 2 and 3, radiofluorination of 235 
may well have benefitted from [18F]fluorination utilising a microfluidic platform, such 
as our bespoke set-up described in Chapter 3 and given that it was observed that 
prolonged heating of diaryliodonium salts leads to precursor decomposition, and that 
[18F]fluorination conducted by rapid heating to 190° greatly improves the 
radiolabelling process, given that the above reaction was only conducted at 90 °C.  
Also included in the aforementioned publication from Wirth and co-workers,409 is a 
short assessment on some alternative protecting group approaches, in particular, the 
preparation of diaryliodonium salts with doubly protected amine functionality. Here 
they prepared di-Boc-amine and N-phthalimidyl derivatives of 235, as conducted in 
the preparation of 6-[18F]fluoro-m-tyramine (Chapter 4) and 6-[18F]fluorodopamine 
diaryliodonium salts, which has scope for nucleophilic attack on the nearby, highly 
electrophilic diaryliodonium salt centre. However, on [18F]fluorination of these 
diaryliodonium bromides bearing amine di-protection they observed no/very little 
[18F]FDOPA production. 
It was speculated that the large steric bulk associated with the phthalimidyl and di-
Boc protecting group strategies may be hindering attack on the λ3-iodane centre, 
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despite [18F]fluoride requiring relatively very little space to approach the electrophilic 
iodine centre. Given, this postulation we expected a DOPA diaryliodonium salt 
bearing a doubly protected amine group to exhibit high stability versus mono-
protected amine diaryliodonium salt derivatives. Hence we sought to prepare a 
diaryliodonium salt designed for [18F]FDOPA production that utilises a more compact 
strategy for doubly protecting the molecule’s amine functionality. Similarly, we aimed 
to utilise more electron-withdrawing protecting groups for protection of the 
catecholic functionality, by way of benzoyl protection, in a bid to reduce the overall 
electron-density of the target ring system (versus benzyl protected derivatives), 
potentially providing a more balanced and stable diaryliodonium salt, as well as 
improving the [18F]fluorination selectivity of that ring system over the n.p.r.  
Our adapted [18F]FDOPA diaryliodonium salt synthesis route was planned and 
implemented as shown below (Scheme 105), utilising the pre-prepared brominated 
DOPA methyl ester 230 followed by succinimidyl protection of the amino group to 
yield 237, followed by benzoyl protection and stannylation to yield arylstannane 
239.   
 
 
Scheme 105: Preparation of alternatively protected DOPA arylstannane 237 
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However, as with the previous efforts of diaryliodonium salt formation from protected 
DOPA arylstannanes and aryliodobis(acetate)s, the target diaryliodonium 
trifluoroacetate 240 was not isolated (Scheme 106). A white powder was obtained 
through crystallisation of the reaction mixture, which was later identified as the 
corresponding iodoarene, which suggests that diaryliodonium salt 240 was formed, 
but then underwent decomposition to afford aryliodide 241 (Figure 74) in situ. 
 
 
Scheme 106: Attempted preparation of [18F]FDOPA diaryliodonium salt 240 
 
 
Figure 74: 1H-NMR of iodoarene by-product 241 formed during the attempted preparation 
diaryliodonium salt 240, with the aromatic region expanded for clarity 
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Unfortunately this signifies the challenge in the preparation of a diaryliodonium 
trifluoroacetate precursor to [18F]FDOPA, with the a protection suite that allows for 
rapid, global deprotection. These findings, as well as the elucidation of by-product 
241 do validate that preparation of a [18F]FDOPA diaryliodonium salt is attainable, 
but further refinement in protection group chemistry, counter-ion choice and method 
may be required in order to achieve the target precursor molecule. 
 
5.4 Chapter 5 Summary 
 
This chapter sought to develop a route to a diaryliodonium salt precursor designed to 
yield [18F]FDOPA when reacted with n.c.a. [18F]fluoride, with a specific protecting 
group array that allowed for rapid, global deprotection to yield the radiotracer in high 
RCYs and SA. This precursor was intended for use within a bespoke radiosynthesis 
cassette to be developed by ABT, providing an easy-to-operate two-step procedure 
for the production of [18F]FDOPA, suitable for use within a clinical setting.  
Although a suitably stable diaryliodonium salt precursor to [18F]FDOPA has yet to be 
identified, although valuable insight was gained on potential routes to the target 
diaryliodonium salt, as well as a new diaryliodonium salt route to 6-
[18F]fluorodopamine, a valuable PET imaging agent with multiple applications within 
cancer imaging. In this preparation it was validated that the use of directing 
functionality, such the tributylstannyl moiety was essential for regioselective 
preparation of diaryliodonium salts that include arenes bearing multiple electron-
donating functionality.  
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7 Conclusions and Further Work 
 
The work herein has provided several key conclusions that benefit the development 
of diaryliodonium salts as precursors to electron-rich [18F]fluoroarenes: 
 A robust and versatile method for the preparation of electron-rich 
diaryliodonium trifluoroacetates has been developed and was utilised to 
prepare a series of precursors to 4-[18F]fluorophenol, a valuable prosthetic 
group for macromolecule labelling. 
 Dynamic [19F]fluorination experiments using these diaryliodonium salt 
precursors allowed for provisional assessment of the protecting groups and 
non-participating rings employed for each precursor, with the observed 
selectivity profiles supporting the understanding of the process. 
 Radiofluorination of lead candidate diaryliodonium salts for the production of 
4-[18F]fluorophenol were carried out with cyclotron produced n.c.a. 
[18F]fluoride, exploiting microfluidics to achieve excellent RCYs for 
[18F]fluorination of the target ring. 
 Superiority of the hypernucleofuge strategy provided by diaryliodonium salts 
for the late-stage radiofluorination of electron-rich arenes versus traditional 
approaches was confirmed. 
 The diaryliodonium salt precursor methodology was extended to the 
production of radiotracer 6-[18F]fluoro-m-tyramine, which exhibited excellent 
selectivity for the target ring system as a result of a combination of the 
“ortho-effect” and electronic control on [18/19F]fluorination. In addition, 
[18F]fluorination of 6-[18F]fluoro-m-tyramine diaryliodonium salt precursors 
was successfully conducted on a batch-based radiosynthesis platform, 
demonstrating the translatability of the [18F]fluorination approach. 
 A potential route to 6-[18F]fluorodopamine, another valuable radiotracer was 
also developed through the preparation of diaryliodonium salt precursors, 
further demonstrating the wide scope for electron-rich [18F]fluoroarene 
production exhibited by diaryliodonium salts.  
 Investigations into the preparation of a diaryliodonium salt precursor to 
[18F]FDOPA have provided key information on the functionality of protecting 
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groups, n.p.r.s and counter-ions, and their associated compatibility with the 
conditions of the various steps in the process, this should lead to a robust, 
viable precursor. 
 In this, we have also considered the requirements for incorporation of a 
[18F]FDOPA diaryliodonium salt precursor into a disposable, single-dose 
synthesis card, for a rapid and clinically compatible route to routine 
[18F]FDOPA production. 
 
To complete optimisation of diaryliodonium salt structures and radiofluorination 
conditions, further work should entail use of diaryliodonium salt precursors for batch 
production of 4-[18F]fluorophenol, including removal of protecting groups, to allow 
for prosthetic group labelling macromolecules and ultimately an imaging study. 
 
Further radiofluorination of 6-[18F]fluoro-m-tyramine should be conducted to further 
validate the diaryliodonium salt strategy in this application, similarly, batch and 
microfluidic [18F]fluorination of diaryliodonium salt precursors to 6-
[18F]fluorodopamine should be completed, given the high value of this radiotracer 
target. 
 
A full and comprehensive combined protecting group and n.p.r. study for the 
preparation of diaryliodonium salt precursors to [18F]FDOPA requires investigation to 
bring this important imaging agent into routine clinical use. Here efforts must focus 
on retaining a protection array that affords the required stability and selectivity, but 
also allows for rapid global deprotection, and ideally the precursor should be 
compatible with the automated reaction platforms currently in use and also, 
ultimately, integrated into a single-dose production cartridge, like the concept design 
described herein. 
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9 Experimental 
 
All manipulations involving air-sensitive materials were carried out using standard 
Schlenk line techniques under a nitrogen atmosphere, using oven dried glassware.410 
Anhydrous DCM and MeCN were prepared by refluxing over CaH2, whereas 
anhydrous toluene, THF and ether were prepared by refluxing over sodium, using 
benzophenone as an indicator. 1H and 13C NMR spectra were recorded on a Bruker 
300 MHz, JEOL 400 MHz, or a JEOL 500 MHz spectrometer at room temperature. 1H 
and 13C shifts were relative to tetramethylsilane (external standard). 19F spectra were 
recorded on either a JEOL 400 MHz, or a JEOL 500 MHz spectrometer at room 
temperature with 19F shifts relative to CFCl3 (external standard). Thin-layer 
chromatography was carried out on aluminum sheets pre-coated with silica gel 60F 
254, and performed using Merck Kieselgel 60. Melting points were determined with a 
Gallenkamp MF-370 and are uncorrected. Automated flash chromatography was 
performed using a Varian IntelliFlash 971-FP discovery scale flash purification 
system. Mass spectrometry data was obtained from the EPSRC National Mass 
Spectrometry Service Centre, Swansea and microanalysis data was obtained from the 
London Metropolitan University Elemental Analysis Service and Medac Ltd.  
 
9.1 Phenyliodobis(acetate) (132)261,412  
 
Iodobenzene (12.2 g, 60 mmol) was added to a solution of acetic acid (600 mL) at 
45 °C. Sodium perborate tetrahydrate (92.3 g, 600 mmol) was added sequentially 
over 1 hour. The solution was stirred at this temperature for a further 4–5.5 hours 
before the addition of cold water (500 mL) at which point the solution was allowed to 
cool to room temperature. The product was washed with water (500 mL), extracted 
into DCM (3 × 500 mL) and the organic layers concentrated in vacuo. Subsequent 
crystallisation was induced though addition of ether/petrol to give the product as a 
white crystalline solid (13.7 g, 42.6 mmol, 71%). Mp 149-151 °C (from DCM-ether-
petrol) (lit.412 mp 161.1-162.2 °C); IR νmax/cm
-1 (neat) 1646, 1574, 1486, 1351, 
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1288, 1249, 1189; 1H-NMR (300 MHz, CDCl3) δ 8.10 (2H, dd, H2/H6 J = 9.1 Hz), 
7.61 (1H, t, H4 J = 7.2 Hz), 7.51 (2H, tapp, H3/H5 J = 7.0 Hz), 2.02 (6H, s, OAc); 
13C-NMR (75 MHz, CDCl3) 176.4 (CO), 135.0 (C2/C6), 131.7 (C4), 131.0 (C3/C5), 
121.6 (C1), 20.4 (OAc). HR-MS (ESI) found: [M+Na]+, 344.9598. C10H11INaO4 
requires 344.9600. 
 
9.2 2-Thienyliodobis(acetate) (133)255,411 
 
 
Product prepared according to procedure outlined for 132. Product 133 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a pale yellow crystalline solid (6.30 g, 19.2 mmol, 32%). Mp 120-123 °C (from 
DCM-ether-petrol) (lit.411 mp 120-122 °C from CHCl3-hexane); IR νmax/cm
-1 (neat) 
3114, 1638, 1387, 1365, 1271, 1226, 1049, 1010; 1H-NMR (300 MHz, CDCl3) δ 7.80 
(1H, dd, H5 J = 3. Hz, J = 1.3 Hz), 7.66 (1H, dd, H3 J = 5.4 Hz, J = 1.2 Hz), 7.15 
(1H, dd, H4 J = 5.4 Hz, J = 1.2 Hz), 2.04 (6H, s, OAc); 13C-NMR (100 MHz, CDCl3) δ 
177.3 (CO), 139.6, 135.4, 129.0, 106.3 (C1), 20.5 (OAc); HR-MS (NSI positive) 
found: M+Na+, 350.9155. C8H9IO4SNa
+ requires 350.9158; Anal. Calcd. for C8H9IO4S: 
C, 29.28; H, 2.76. Found: C, 29.32; H, 2.69. 
 
9.3 4-Methoxyphenyliodobis(acetate) (134)255,412 
 
 
Product prepared according to procedure outlined for 132. Product 134 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (12.25 g, 34.8 mmol, 58%). Mp 91-93 °C (from DCM-
ether-petrol) (lit.412 mp 92.4-96 °C); IR νmax/cm
-1 (neat) 1639, 1582, 1570, 1490, 
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1291, 1251, 1182; 1H-NMR (400 MHz, CDCl3) δ 8.00 (2H, d, H2/H6 J = 9.0 Hz), 6.95 
(2H, d, C3/C5 J = 9.1 Hz), 3.85 (3H, s, OMe), 1.99 (6H, s, OAc); 13C-NMR (100 MHz, 
CDCl3) δ 176.5 (CO), 162.3 (C4), 137.2, 116.7, 111.7 (C1), 55.7 (OMe), 20.5 (OAc); 
HR-MS (NSI positive) found: [M+Na]+, 374.9701. C11H13IO5Na
+ requires 374.9705; 
Anal. Calcd. for C8H9IO4S: C, 37.52; H, 3.72. Found: C, 37.60; H, 3.66. 
 
9.4 2-Methoxyphenyliodobis(acetate) (135)255,412 
 
 
Product prepared according to procedure outlined for 132. Product 135 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (11.20 g, 31.8 mmol, 53%). Mp 144-146 °C (from 
DCM-ether-petrol) (lit.412 mp 146.9-150.1 °C from CHCl3-hexane); IR νmax/cm
-1 (neat) 
1639, 1478, 1432, 1267, 1049; 1H NMR (300 MHz, CDCl3) δ 8.15 (1 H, dd, H6 J = 
7.9, 1.5 Hz), 7.60 (1H, dtapp, J = 7.3, 1.4 Hz), 7.17 (1H, d, H3 J = 8.4 Hz), 7.04 (1H, 
dtapp, J = 7.7, 1.2 Hz), 3.99 (3H, s, OMe), 1.97 (6H, s, OAc); 
13C-NMR (75 MHz, 
CDCl3) δ 176.6 (CO), 156.3 (C2), 137.8, 134.5, 122.8, 113.5 (C1), 112.0, 56.9 
(OMe), 20.4 (OAc); HR-MS (NSI positive) found: [M+Na]+, 374.9710. C11H13IO5Na
+ 
requires 374.9705; Anal. Calcd. for C11H13IO5: C, 37.52; H, 3.72. Found: C, 37.69; H, 
3.76. 
 
9.5 4-Methylphenyliodobis(acetate) (136)261,412 
 
 
Product prepared according to procedure outlined for 132. Product 136 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (13.31 g, 39.6 mmol, 66%). Mp 108-110 °C (from 
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DCM-ether-petrol) (lit.412 mp 106-110 °C from CHCl3-hexane); IR νmax/cm
-1 (neat) 
2931, 1646, 1583, 1427, 1363, 1266, 1213, 1187, 1045, 1004; 1H-NMR (300 MHz, 
CDCl3) δ 7.97 (2H, d, H2/H6 J = 8.3), 7.29 (2H, d, H3/H5 J = 7.5), 2.44 (3H, s, p-
Me), 1.99 (6H, s, OAc); 13C-NMR (75 MHz, CDCl3) δ 176.3 (CO), 142.7 (C4), 135.0, 
131.8, 118.4 (C1), 21.5 (p-Me), 20.4 (OAc); HR-MS (NSI positive) found: [M+Na]+, 
358.9758. C11H13IO4Na
+ requires 358.9756; Anal. Calcd. for C11H13IO4: C, 37.52; H, 
3.72. Found: C, 37.20; H, 3.99. 
 
9.6 2,4,6-Trimethylphenyliodobis(acetate) (137)261,412 
 
 
Product prepared according to procedure outlined for 132. Product 137 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (12.45 g, 34.2 mmol, 57%). Mp 163-166 °C (from 
DCM-ether-petrol) (lit.412 mp 160-163 °C from CHCl3-hexane); IR νmax/cm
-1 (neat) 
2927, 1644, 1446, 1367, 1264, 1010, 999; 1H-NMR (300 MHz, CDCl3) δ 7.11 (2H, s, 
H3/H5), 2.72 (6H, s, o-Me), 2.37 (3H, s, p-Me), 1.97 (6H, s, OAc). 13C-NMR (75 MHz, 
CDCl3) δ 176.4 (CO), 143.2 (C4), 141.3 (C2/C6), 129.7 (C1), 129.0 (C3/C8), 26.7 (o-
Me), 21.2 (p-Me), 20.3 (OAc); HR-MS (NSI positive) found: [M+Na]+, 387.0070. 
C13H17INaO4
+ requires 387.0069; Anal. Calcd. for C13H17IO4: C, 42.87; H, 4.71. 
Found: C, 42.79; H, 4.62. 
 
9.7 4-(Benzyloxy)phenyliodobis(acetate) (166)221 
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Product prepared according to procedure outlined for 132. Product 166 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (1.33 g, 3.1 mmol, 32%). Mp 111-112 °C (from DCM-
ether-petrol) (lit.221 mp 113 °C from EtOAc/Ac2O); IR νmax/cm
-1 (neat) 1641, 1584, 
1571, 1490, 1290, 1253, 1181; 1H-NMR (400 MHz, CDCl3) δ 7.99 (2H, d, H2/H6 J = 
9.1), 7.43 – 7.34 (5H, m, ), 7.02 (2H, d, H3/H5 J = 9.2), 5.10 (2H, s, CH2), 1.98 (6 
H, s, OAc). 13C-NMR (100 MHz, CDCl3) δ 176.5 (CO), 161.0 (C4), 137.2, 135.9, 
135.5, 128.9, 128.5, 127.6, 117.5 (C1), 117.3, 70.5 (CH2), 20.5 (OAc); HR-MS (NSI 
positive) found: [M+Na]+, 451.0006. C17H17IO5Na
+ requires 451.0013; Anal. Calcd. 
for C17H17IO5: C, 47.68; H, 4.00. Found: C, 47.81; H, 4.04. 
 
9.8 4-(Benzyloxy)-1-iodobenzene (140)413,414 
 
 
To a solution of 4-iodophenol (6.60 g, 30 mmol) in acetone (200 mL) were added 
potassium carbonate (20.71 g, 149.87 mmol) and benzyl bromide (2.97 mL, 4.27 g, 
25.00 mmol) and the reaction mixture was heated under reflux for 16 h. The white 
reaction mixture was then allowed to cool to room temperature before being filtered 
to through filter paper and the solvent was removed under reduced pressure. The 
resulting yellow crude material was re-dissolved in diethyl ether (50 mL), washed 
with water (300 mL) and with brine (100 mL) before being extracted with diethyl 
ether (3×50 mL), dried with MgSO4 and concentrated in vacuo. Purification by 
column chromatography on SiO2, eluting with petrol, then 1:9 ethyl acetate:petrol) 
gave the product as a white solid (8.47 g, 27.32 mmol, 91%). Mp 61-63 °C (from 
ethyl acetate-petrol) (lit.413 mp 62-63 °C from DCM); IR νmax/cm
-1 (neat) 1599, 1120, 
973; 1H-NMR (400 MHz, CDCl3) δ 7.54 (2H, d, H2/H6 J = 8.6), 7.44 – 7.29 (5H, m, 
H8-H12), 6.74 (2H, d, H3/H5 J = 8.9), 5.02 (2H, s, CH2); 
13C-NMR (100 MHz, CDCl3) 
δ 158.7 (C4), 138.3 (C2/C6), 136.6, 128.7, 128.2, 127.5, 117.4 (C3/C5), 83.1 (C1), 
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70.1 (CH2); HR-MS (ESI positive) found: [M+H]
+, 309.9925. C13H12IO
+ requires 
309.9932. 
 
9.9 4-(Benzyloxy)-1-bromobenzene (141)413,414 
 
 
Product prepared according to procedure outlined for 140. The product was 
obtained as in previous example, however purification by column chromatography on 
SiO2 (1:8 ethyl acetate:petrol) afforded a white solid (4.76 g, 18.1 mmol, 94%). Mp 
58-59 °C (from ethyl acetate-petrol) (lit.414 mp 59-60 °C from ethyl acetate-hexane); 
IR νmax/cm
-1 (neat) 3058, 1853, 1587, 1487, 1289, 1248, 1170, 1070, 1041, 1026; 
1H-NMR (400 MHz, CDCl3) δ 7.39 (2H, d, H2/H6 J = 7.4), 7.37 – 7.30 (5H, m), 6.85 
(2H, d, H3/H5 J = 8.9), 5.03 (2H, s, CH2). 
13C-NMR (100 MHz, CDCl3) δ 158.8 (C4), 
132.7 (C2/C6), 136.7, 129.8, 128.2, 127.55, 118.4 (C3/C5), 115.4 (C1), 70.2 (CH2); 
HR-MS (ESI positive) found: [M+H]+, 262.0174. C13H12BrO
+ requires 262.0176 
 
9.10 4-Iodophenyl acetate (142)415,416 
 
 
To a solution of 4-iodophenol (8.40 g, 38.16 mmol) in DCM was added 
trimethylamine (6.11 mL, 4.44 g, 43.85 mmol), followed by the portion wise addition 
of acetyl chloride (2.72 mL, 3.00 g, 38.16 mmol) at room temperature. After stirring 
at room temperature for 14 h the reaction mixture was poured into distilled water 
(100 mL), the organic layer was then washed with 5% aqueous NaOH (100 mL), 
distilled water (50 mL) and dried with MgSO4. The solvent was removed in vacuo to 
yield a crude oil, which following purification by column chromatography on SiO2 
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(1:19 ethyl acetate:petrol) afforded a white solid (9.21 g, 35.18 mmol, 92%). Mp 
31–33 °C (from ethyl acetate-petrol) (lit.415 mp 32–32.5 °C from water-methanol); IR 
νmax /cm
-1 (neat) 3089, 1760, 1597, 1481, 1432, 1393, 1372, 1294, 1271, 1197, 
1164, 1098, 1054, 1010, 942, 915, 837, 791, 705, 671; 1H-NMR (400 MHz, CDCl3) δ 
7.66 (2H, d, H2/H6 J = 8.8), 6.84 (2H, d, H3/H5 J = 8.8), 2.27 (3H, s, OAc); 13C-
NMR (100 MHz, CDCl3) δ 169.2 (CO), 150.6 (C4), 138.6, 123.9, 90.0 (C1), 21.2 
(CH3); HR-MS (ESI positive) found: [M+H]
+, 261.9499. C8H8IO2
+ requires 261.9503 
 
9.11 4-Bromophenyl acetate (143)415 
 
 
Product prepared according to procedure outlined for 142. Product was obtained as 
in previous examples, however purification was achieved by distillation to afford the 
product as a colourless oil. (2.60 g, 12.1 mmol, 79%). Rf 0.40 (1:4 ethyl 
acetate:petrol); IR νmax/cm
-1 (neat) 1760, 1486, 1370, 1196, 1068, 1011, 909, 843, 
674; 1H-NMR (400 MHz, CDCl3) δ 7.47 (2H, d, H2/H6 J = 8.7), 6.97 (2H, d, H3/H5 J 
= 8.8), 2.28 (3H, s, OAc); 13C-NMR (100 MHz, CDCl3) δ 169.2 (CO), 149.8 (C4), 
132.6, 123.5, 119.0 (C1), 21.2 (CH3); HR-MS (ESI positive) found: [M+H]
+, 
213.9645. C8H8BrO2
+ requires 213.9649. 
 
9.12 4-(Benzyloxy)-1-fluorobenzene (157)416 
 
 
Product prepared according to procedure outlined for 140. The product was 
obtained as in previous examples however purification was achieved by column 
chromatography on SiO2 (petrol) to afford a crystalline white solid (0.53 g, 2.6 mmol, 
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79%). Mp 51-53 °C (from ethyl acetate-petrol) (lit.416 mp 49-50 °C from diethyl 
ether-pentane); IR νmax/cm
-1 (neat) 3064, 3052, 3040, 3036, 2888, 2856, 1598, 
1502, 1451, 1248, 1197; 1H-NMR (400 MHz, CDCl3) δ 7.45 – 7.28 (5H, m, H8-H12), 
6.96 (2H, tapp, H3/H5 J = 8.7), 6.92 – 6.88 (2H, tapp), 5.02 (2 H, s, CH2); 
13C-NMR 
(100 MHz, CDCl3) δ 158.6 (C1), 154.9 (C4), 136.9 (C7), 128.7, 128.1, 127.6, 116.0, 
115.8, 70.7 (CH2); HR-MS (APCI corona positive) found: [M-H]
+, 201.0710. 
C13H10FO
+ requires 201.0710; Anal. Calcd. for C13H11FO: C, 77.30; H, 5.49. Found: C, 
77.45; H, 5.58. 
 
9.13 4-(Benzyloxy)-1-tributylstannylbenzene (146)318,319,320 
 
 
A flask was charged with zinc dust (11.09 g, 169.20 mmol), followed by anhydrous 
MeCN (100 mL) and the dropwise addition of trifluoroacetic acid (1.53 mL, 2.36 g, 
20.71 mmol). After 5 minutes of stirring at room temperature, under nitrogen, cobalt 
dibromide (2.56 g, 11.70 mmol) was added, affording an immediate colour change 
from grey to blue. After a further 5 minutes of stirring at room temperature, allyl 
chloride (2.70 mL, 2.62 g, 34.22 mmol) was injected into the reaction vessel and the 
mixture was left to stir for a further 10 min. To the resultant red reaction mixture 
was then added 4-(benzyloxy)-1-iodobenzene (27.90 g, 90.00 mmol), followed 
immediately by tri-n-butylstannyl chloride (22.45 mL, 40.14 g, 123.30 mmol) and the 
reaction mixture was heated to 50 °C and monitored by TLC (5:95 diethyl 
ether:petrol) until all of the starting material had been consumed. After which the 
reaction mixture was allowed to cool to room temperature, poured into aqueous 
saturated ammonium chloride (80 mL) and extracted with diethyl ether (3 x 70 mL). 
The combined organic fractions were dried with MgSO4, filtered and concentrated in 
vacuo to afford a crude yellow/orange oil. Purification by column chromatography on 
SiO2 (petrol, then 10:90 diethyl ether:petrol) or alternatively by flash reverse phase 
chromatography (MeCN) which afforded the colourless oil product (32.38 g, 68.42 
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mmol, 86 %). Rf 0.68 (5:95 diethyl ether:petol); 
1H-NMR (400 MHz, CDCl3) δ 7.44 
(2H, d, H2/H6 J = 7.8), 7.41 – 7.30 (5H, m, Ph), 6.98 (2H, dd, H3/H5 J = 8.5), 5.05 
(2H, s, H13), 1.57 – 1.48 (6H, m, H16), 1.37 – 1.26 (6H, m, H15), 1.02 (6H, t, H14 J 
= 8.3), 0.88 (9H, t, H17 J = 7.3); 13C-NMR (100 MHz, CDCl3) δ 159.1 (C4), 137.6 
(C2/C6), 137.3 (C7), 132.5, 128.7, 128.0, 127.6, 114.9 (C3/C5), 69.8 (C13), 29.2 
(C15), 27.5 (C16), 13.8 (C14), 9.7 (C17); HR-MS (ESI positive) found: [M+H]+, 
473.1921. C25H37OSn
+ requires 473.1914; Anal. Calcd. for C25H38OSn: C, 64.44; H, 
8.09. Found: C, 64.50; H, 8.11. 
 
9.14 4-(Acetoxy)-1-tributylstannylbenzene (147)318,319,320 
 
 
Product prepared according to procedure outlined for 146 The product was obtained 
as in previous examples with purification by column chromatography on SiO2 (petrol, 
then 10:90 diethyl ether:petrol) which afforded the colourless oil product (6.18 g, 
14.53 mmol, 61 %). Rf 0.62 (5:95 diethyl ether:petol); 
1H-NMR (400 MHz, CDCl3) δ 
7.47 (2H, d, H2/H6 J = 7.6), 7.05 (2H, d, H3/H5 J = 8.3), 2.28 (3H, s, OAc), 1.62 – 
1.49 (6H, m, H9), 1.39 – 1.28 (6H, m, H8), 1.09 – 1.02 (6H, m, H7), 0.90 (9H, t, 
H10 J = 7.3); 13C-NMR (100 MHz, CDCl3) δ 169.7 (CO), 150.9 (C4), 139.3 (C1), 
137.5 (C2/C6), 121.2 (C3/C5), 29.2 (C8), 27.5 (C9), 21.3 (C7), 13.8 (C10), 9.7 
(COCH3); HR-MS (ESI positive) found: [M+H]
+, 425.1567. C20H33O2Sn
+ requires 
425.1579. Anal. Calcd. for C20H34O2Sn: C, 56.50; H, 8.06. Found: C, 56.52; H, 8.12. 
 
9.15 4-(Methoxy)-1-tributylstannylbenzene (148)318,319,320 
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Product prepared according to procedure outlined for 146 The product was obtained 
as in previous examples with purification by flash reverse phase chromatography 
(MeCN) which afforded the colourless oil product (8.81 g, 22.17 mmol, 91 %). Rf 
0.67 (5:95 diethyl ether:petol); 1H-NMR (300 MHz, CDCl3) δ 7.40 (2H, d,  H2/H6 J = 
8.5), 6.93 (2H, d, H3/H5 J = 8.5), 3.83 (3H, s, OMe), 1.62 – 1.49 (6H, m, H9), 1.35 
(6H, sx, H8 J = 7.2), 1.09 – 1.01 (6H, m, H7), 0.91 (9 H, t, H10 J = 7.3); 13C-NMR 
(100 MHz, CDCl3) δ 159.7 (C4), 137.6 (C2/C6), 132.1 (C1), 114.0 (C3/C5), 55.0 
(OMe), 29.2 (C8), 27.5 (C9), 13.8 (C7), 9.7 (C10); HR-MS (ESI positive) found: 
[M+H]+, 397.1861. C19H33OSn
+ requires 397.1872. Anal. Calcd. for C19H34OSn: C, 
57.46; H, 8.63. Found: C, 56.49; H, 8.59. 
 
9.16 (3,4,5-trimethoxy)-1-tributylstannylbenzene (169)318,319,320 
 
 
Product prepared according to procedure outlined for 146. The product was 
obtained as in previous examples with purification by column chromatography on 
SiO2 (petrol, then 10:90 diethyl ether:petrol) which afforded the colourless oil 
product (3.76 g, 8.22 mmol, 34 %). Rf 0.58 (5:95 diethyl ether:petol); 
1H-NMR (400 
MHz, CDCl3) δ 6.63 (2H, s, H2/H6), 3.86 (6H, s, m-OMe, m-OMe), 3.83 (3H, s, p-
OMe), 1.59 – 1.49 (6H, m, H9), 1.33 (6H, sx, H8 J = 14.4, 7.3), 1.08 – 1.01 (6H, m, 
H7), 0.88 (9H, t, H10 J = 7.3); 13C-NMR (100 MHz, CDCl3) δ 153.0 (C3/C5), 138.3 
(C4), 136.8 (C1), 112.8 (C2/C6), 60.9 (p-OMe), 56.2 (m-OMe, m-OMe), 29.2 (C8), 
27.5 (C9), 13.8 (C7), 9.9 (C10); HR-MS (ESI positive) found: [M+H]+, 344.0445. 
C13H21O3Sn
+ requires 344.0440. 
 
9.17 (4-(Benzyloxy)phenyl)(4-methoxyphenyl)iodonium trifluoroacetate 
(149) 
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4-Methoxyphenyliodobis(acetate) (134) (2.32 g, 6.60 mmol) was dissolved in DCM 
(40 mL). The solution was cooled to -30 °C. TFA (1.01 mL, 13.2 mmol) was added 
dropwise, the yellow solution was stirred at -30 °C for 30 minutes, followed by 1 
hour stirring at room temperature. The reaction mixture was then re-cooled to -30 
°C, 4-(benzyloxy)-1-tributylstannylbenzene (146) (3.12 g, 6.60 mmol) was added, 
and stirred for 30 minutes. The reaction was warmed to room temperature and 
stirred overnight. The solvent was removed in vacuo, affording a yellow oil, which 
was crystallised from DCM/petrol/ether to given the crude product as an off-white 
powder. (1.99 g, 3.76 mmol, 57%). Mp 149-151 °C (from DCM-ether-petrol); IR 
νmax/cm
-1 (neat) 3056, 3031, 1589, 1579, 1276, 1009; 1H-NMR (400 MHz, CDCl3) δ 
7.81 (2H, d, H2’/H6’ J  = 3.3), 7.79 (2H, d, H2/H6 J = 9.2), 7.39 – 7.32 (5H, m), 
6.95 (2 H, d, H3/H5 J = 9.2), 6.89 (2 H, d, H3’/H5’ J = 3.3), 5.05 (2 H, s, C7’’), 3.81 
(3 H, s, OMe); 13C-NMR (100 MHz, CDCl3) δ 162.5 (C4), 161.6 (C4’), 136.4 (C1’’), 
136.3 (C2/C6/C2’/C6’), 135.6, 128.9, 128.6, 127.6, 118.4 (C1’), 117.7 (C1), 70.5 
(C7’’), 55.7 (OMe); HR-MS (NSI positive) found: [M]+, 417.0339. C20H18IO2
+ requires 
417.0346; Anal. Calcd. for C22H18F3IO4: C, 49.83; H, 4.42. Found: C, 50.09; H, 3.52. 
 
9.18 (4-(Benzyloxy)phenyl)(2-thienyl)iodonium trifluoroacetate (150) 
 
 
Product prepared according to procedure outlined for 149. Product 150 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (1.06 g, 2.10 mmol, 52%).  Mp 162-164 °C (from 
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DCM-ether-petrol); IR νmax/cm
-1 (neat) 3044, 3021, 2861, 1600, 1584, 1301, 1013; 
1H-NMR (400 MHz, CDCl3) δ 7.88 (2H, d, H2’/H6’ J = 9.1), 7.66 (1H, d, H3 J = 4.9), 
7.58 (1H, d, H5 J = 6.4), 7.40 – 7.31 (5H, m), 7.05 (1H, dd, H4 J = 5.3, 3.8), 6.95 
(2H, d, C3’/H5’ J = 9.1), 5.04 (2H, s, C7’’); 13C-NMR (100 MHz, CDCl3) δ 161.5 (C1’), 
136.0 (C1’’), 135.5 (C2’/C6’), 129.8, 128.9, 128.6, 127.6, 118.4 (C3’/C5’), 109.7 
(C1’), 70.6 (C7’’); HR-MS (NSI positive) found: [M]+, 392.9801. C17H14IOS
+ requires 
492.9805; Anal. Calcd. for C19H14F3IO3S: C, 45.10; H, 2.79. Found: C, 45.23; H, 2.90. 
 
9.19 (4-(Benzyloxy)phenyl)(phenyl)iodonium trifluoroacetate (151) 
 
 
Product prepared according to procedure outlined for 149. Product 151 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (1.87 g, 3.74 mmol, 68%).  Mp 156-157 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3012, 2799, 1596, 1584, 1204, 1057, 1022; 
1H-NMR (400 MHz, CDCl3) δ 7.92 (2H, d, H2’/H6’ J = 8.4), 7.87 (2H, d, H2/H6 J = 
9.1), 7.60 – 7.51 (1H, m, H4), 7.47 – 7.42 (2H, m, H3/H5), 7.43 – 7.35 (5H, m), 
7.00 (2H, d, H3’/H5’ J = 8.4), 5.09 (2 H, s, H7”); 13C-NMR (100 MHz, CDCl3) δ 161.5 
(C4’), 137.8 (C1’’), 136.7 (C2’/C6’), 135.4 (C2/C6), 132.3, 132.1, 129.1, 128.7, 
128.4, 118.7 (C1), 117.7 (C1’), 106.3 (C3’/C5’), 70.2 (C7’’); HR-MS (NSI positive) 
found: [M]+, 387.0240. C19H16IO
+ requires 387.0236; Anal. Calcd. for C21H16F3IO3: C, 
50.42; H, 3.22. Found: C, 50.50; H, 3.29. 
 
9.20 (4-(Acetoxy)phenyl)(4-methoxyphenyl)iodonium trifluoroacetate 
(152) 
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Product prepared according to procedure outlined for 149. Product 152 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (0.95 g, 1.98 mmol, 41%).  Mp 147-149 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3070, 3023, 2956, 1702, 1423, 1403, 1130; 
1H-NMR (400 MHz, CDCl3) δ 7.89 (2H, d, H2/H6 J = 8.9), 7.85 (2H, d, H2’/H6’ J = 
9.2), 7.11 (2H, d, H3’/H5’ J = 9.2), 6.88 (2H, d, H3/H5 J = 8.9), 3.80 (3H, s, OMe), 
2.28 (3H, s, OAc); 13C-NMR (100 MHz, CDCl3) δ 168.7 (CO), 162.6 (C4), 153.2 (C4’), 
137.1 (C2/C6), 135.8 (C2’/C6’), 125.1 (C3’/C5’), 117.7 (C3/C5), 112.4 (C1’), 105.2 
(C1), 55.7 (OMe), 21.2; HR-MS (NSI positive) found: [M]+, 369.040. C15H15IO3
+ 
requires 369.0036; Anal. Calcd. for C17H14F3IO5: C, 42.34; H, 2.93. Found: C, 42.34; 
H, 2.82. 
 
9.21 (4-(Acetoxy)phenyl)(2-thienyl)iodonium trifluoroacetate (153) 
 
 
Product prepared according to procedure outlined for 149. Product 154 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (1.33 g, 2.90 mmol, 33%).  Mp 138-140 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3067, 3021, 2970, 1714, 1419, 1240; 1H-NMR 
(400 MHz, CDCl3) δ 7.96 (2H, d, H2’/H6’ J = 9.0), 7.71 (1H, dd, H3 J = 3.8, 1.2), 
7.60 (1H, dd, H5 J = 5.3, 1.2), 7.14 (2H, d, H3’/H5’ J = 9.0), 7.06 (1H, dd, J = 5.3, 
3.8), 2.28 (3H, s, OAc); 13C-NMR (100 MHz, CDCl3) δ 168.6 (CO), 153.2 (C4’), 140.1 
(C3), 136.3 (C1), 135.2 (C2’/C6’), 129.8 (C4), 125.1 (C3’/C5’), 115.3 (C1’), 21.2; HR-
MS (NSI positive) found: [M]+, 344.9441. C12H10IO2S
+ requires 344.9441; Anal. 
Calcd. for C14H10F3IO4S: C, 36.70; H, 2.93. Found: C, 36.77; H, 2.36. 
 217 
 
9.22 Bis(4-(benzyoxyl)phenyl)iodonium trifluoroacetate (155) 
 
 
Product prepared according to procedure outlined for 149. Product 155 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (2.75 g, 4.54 mmol, 23%).  Mp 156-157 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3054, 3016, 2960, 2201, 1429, 1268, 1211; 
1H-NMR (400 MHz, CDCl3) δ 7.80 (4H, d, H2/H6/H2’’/H6’’ J = 9.1), 7.41 – 7.29 (10H, 
m), 6.96 (4H, d, H3/H5/H3’’/H5’’ J = 9.1), 5.05 (4H, s); 13C-NMR (100 MHz, CDCl3) δ 
161.7 (C4/C4’’), 136.4 (C2/C6/C2’’/C6’’), 135.6 (C1’/C1’’’), 128.9, 128.6, 127.6, 118.5 
(C3/C5/C3’/C5’), 105.5 (C1/C1’’), 70.5 (C7’/C7’’’); HR-MS (NSI positive) found: [M]+, 
493.0645. C26H22IO2
+ requires 493.0659; Anal. Calcd. for C28H22F3IO4: C, 55.46; H, 
3.66. Found: C, 55.37; H, 3.74. 
 
9.23 (4-(Benzyloxy)phenyl)(3,4,5-trimethoxyphenyl)iodonium 
trifluoroacetate (170) 
 
 
Product prepared according to procedure outlined for 149. Product 170 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (1.20 g, 2.04 mmol, 16%).  Mp 158-159 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3099, 2971, 2966, 2954, 2210, 1423, 1261, 
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1210; 1H-NMR (400 MHz, CDCl3) δ 7.85 (2H, d, H2/H6 J = 9.1), 7.40 – 7.32 (5H, m), 
7.09 (2H, s H2’/H6’), 6.99 (2 H, d, H3/H5 J = 9.1), 5.07 (2H, s, H7’’), 3.83 (3H, s, p-
OMe), 3.80 (6H, s, m-OMe); 13C-NMR (100 MHz, CDCl3) δ 155.0 (C4), 136.8 
(C3’’/C5’’), 135.6 (C4’’), 128.9, 128.6, 127.6, 118.5 (C1’’), 112.0 (C1), 108.9 (C2/C5), 
105.3 (C2/C6’), 70.5 (C7’’), 61.1 (p-OMe), 56.7 (m-OMe); HR-MS (NSI positive) 
found: [M]+, 477.0621. C22H22IO4
+ requires 477.0624; Anal. Calcd. for C24H22F3IO6: 
C, 48.83; H, 3.76. Found: C, 48.79; H, 3.74. 
 
9.24 1-Methoxy-3-(2-nitrovinyl)benzene (177)417,418 
 
 
To a stirred solution of 3-methoxybenzaldehyde (1.77g, 13 mmol) and ammonium 
acetate (1.08g, 14 mmol) was added glacial acetic acid (200 mL) was treated with 
nitrostyrene (1.53 g, 25 mmol), and the mixture was heated to 110 °C for 4 h. The 
resulting dark green solution was cooled, diluted with cold water (500 mL) and the 
green precipitate was collected. Crystallisation from chloroform-hexane (1:1) 
afforded the product as a yellow solid 1.86 g 10.4 mmol, 80%). Mp 91-93 °C (from 
chloroform-hexane) (lit.417 mp 91-92 °C from ethanol); IR νmax/cm
-1 (neat) 3110, 
1634, 1578, 1509; 1H-NMR (400 MHz, CDCl3) δ 7.96 (1H, d, H8 J = 13.7), 7.56 (1H, 
d, H7 J = 13.6), 7.36 (1H, dd, H5 J = 9.0, 7.6), 7.25 (1H, s, H2), 7.16 – 7.11 (1H, m, 
H4), 7.03 (1H, dd, H6 J = 4.5, 2.3), 3.84 (3H, s, OMe); 13C-NMR (100 MHz, CDCl3) δ 
160.2 (C1), 139.12 (C7), 137.4 (C8), 131.34 (C3), 130.5 (C5), 121.8 (C4), 118.1 
(C6), 114.0 (C2), 55.5 (OMe); HR-MS (ESI positive) found: [M+H]+, 179.0674. 
C9H10NO3
+ requires 179.0671. 
 
9.25 2-(3-Methoxyphenyl)ethan-1-amine (178)417,418 
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A solution of 177 (4.00 g, 22.33 mmol) in anhydrous diethyl ether (100 mL) was 
added dropwise to a stirred suspension of lithium aluminium hydride (1.70 g, 44.67  
mmol) in anhydrous ether (100 mL) at room temperature. The mixture was stirred 
for 30 min after the addition was completed and treated with slow, dropwise 
additions of water (4.2 mL), 15% sodium hydroxide (4.2 mL), and water (12.6 mL). 
The mixture was filtered through a sintered glass disk (porosity m), and the filtrate 
was dried (sodium sulfate) and concentrated in vacuo to give a pale brown residue 
(2.19 g, 14.51 mmol, 65%). Rf 0.41 (15% diethyl ether:petrol); IR νmax/cm
-1 (neat) 
3379, 2980, 1599, 1481, 1469, 1321, 1270, 859; 1H-NMR (400 MHz, CDCl3) δ 7.20 
(1H, t, H5 J = 7.2), 6.82 – 6.71 (3H, m, H2/H4/H6), 3.78 (3H, s, OMe), 2.94 (3H, t, 
H8 J = 6.8), 2.71 (3H, t, H7 J = 6.8); 13C-NMR (100 MHz, CDCl3) δ 159.8 (C3), 141.4 
(C1), 129.5 (C5), 121.3 (C6), 114.7 (C2), 111.5 (C4), 55.2 (OMe), 43.4 (C8), 40.1 
(C7). 
 
9.26 2-(3-Methoxyphenethyl)isoindoline-1,3-dione (179) 418,419  
 
 
A suspension of phthalic anhydride (2.37g, 15.88 mmol) in anhydrous toluene (80 
mL) in an oven dried round bottom flask fitted with Dean-Stark apparatus was 
heated to reflux until complete dissolution of the anhydride and no additional water 
was removed. To this solution was the added 178 (1.74g, 13.20 mmol) and refluxing 
was continued until the water evolution was completed (4 h). The reaction mixture 
was then concentrated in vacao to give a residue, purification by column 
chromatography on SiO2 (20% acetone-petrol) afforded a white crystalline solid (1.82 
g, 6.47 mmol, 49%). Mp 89-90 °C (from acetone-petrol) (lit.418 mp 91 °C from 
diethyl ether:petrol); IR νmax/cm
-1 (neat) 2940, 1771, 1719, 1610; 1H-NMR (400 MHz, 
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CDCl3) δ 7.82 (2H, dd, H5’/H6’ J = 5.4, 3.2), 7.69 (2H, dd, H4’/H7’ J = 5.5, 3.1), 
7.22 – 7.14 (1H, m, H5), 6.92 – 6.63 (3H, m, H2/H4/H6), 3.95 – 3.87 (2H, m, H8), 
3.75 (3H, s, OMe), 3.00 – 2.90 (2H, m, H7); 13C-NMR (100 MHz, CDCl3) δ 168.3 
(C2’/C9’), 159.8 (C3), 139.6 (C1), 134.0 (C3’/C5’/C6’/C8’), 132.2 (C5), 123.3 
(C4’/C7’), 121.3 (C6), 114.4 (C2), 112.4 (C4), 55.3 (OMe), 39.3 (C8), 34.8 (C7); HR-
MS (ESI positive) found: [M+H]+, 281.1187. C17H16NO3
+ requires 281.1192. 
 
9.28 2-(2-(3-Methoxyphenethyl)isoindoline-1,3-dione)(4-
methoxyphenyl)iodonium trifluoroacetate (181) 
 
 
Product prepared according to procedure outlined for 149, using 179 in the place of 
an arylstannane reagent. Product 181 was obtained by crystallisation from 
DCM/ether/petrol followed by suction filtration to afford a white crystalline solid (0.83 
g, 1.32 mmol, 20%).  Mp 145-146 °C (from DCM-ether-petrol); IR νmax/cm
-1 (neat) 
3067, 3022, 2980, 1801, 1715, 1423, 1240, 1121; 1H-NMR (400 MHz, CDCl3) δ 7.98 
(1H, d, H6 J = 8.8), 7.93 (2H, d, H2’’/H6’’ J = 9.1), 7.83 (2H, dd, H5’/H6’ J = 5.4, 
3.1), 7.73 (2H, dd, H4’/H7’ J = 5.5, 3.0), 6.93 (1H, d, H5 J = 3.0), 6.88 (1H, s, H3), 
6.76 (2H, dd, H3’’/H5’’ J = 8.9, 3.0), 3.94 – 3.86 (2H, m, H8), 3.78 (3H, s, C6H4-
OMe), 3.76 (3H, s, OMe), 3.27 – 3.21 (2H, m, H7); 13C-NMR (100 MHz, CDCl3) δ 
168.2 (CO), 163.1 (C4’’), 153.3 (C4), 150.0 (C3), 136.8 (C2’’/C6’’), 135.1 (C6), 134.4 
(C3’/C8’), 132.0 (C5’/C6’), 123.1 (C4’/C7’), 119.5 (C1), 118.1 (C3’’/C5’’), 113.7 (C6), 
106.0 (C1), 101.8 (C1’’), 56.2 (OMe), 55.9 (OMe), 38.0 (CH2), 36.7 (CH2); HR-MS 
(NSI positive) found: [M]+, 514.0515. C24H21INO4
+ requires 514.0518; Anal. Calcd. 
for C26H21F3INO6: C, 49.78; H, 3.37. Found: C, 49.80; H, 3.34.  
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9.29 2-(2-(3-Methoxyphenethyl)isoindoline-1,3-dione)(2-
methoxyphenyl)iodonium trifluoroacetate (182) 
 
Product prepared according to procedure outlined for 149, using 179 in the place of 
an arylstannane reagent. Product 182 was obtained by crystallisation from 
DCM/ether/petrol followed by suction filtration to afford a white crystalline solid (0.61 
g, 0.98 mmol, 17%).  Mp 155-157 °C (from DCM-ether-petrol); IR νmax/cm
-1 (neat) 
3052, 2963, 1789, 1714, 1404, 1278, 1234, 1175; 1H-NMR (300 MHz, CDCl3) δ 8.06 
(2H, d, H3/H2’’ J = 8.9), 7.78 (4H, ddd, H4’/H5’/H6’/H7’ J = 28.6, 5.5, 3.1), 7.55 – 
7.30 (2H, m, H4’’/H5’’), 7.08 – 7.00 (1H, m, H4), 6.96 – 6.89 (1H, m, H6), 6.82 (1 H, 
dd, H3’’ J = 8.9, 3.0), 4.01 (3 H, s), 3.97 – 3.89 (2 H, m), 3.83 (3 H, s), 3.31 (2 H, 
dd, J 8.6, 6.8); 13C-NMR (75 MHz, CDCl3) δ 167.9 (CO), 163.2 (C6’’), 143.3 (C5), 
140.3 (C1), 134.1 (H3/H2’’), 133.3 (C5’/C6’), 133.1 (C3’/C8’), 131.9 (C4’’), 123.9 
(C3’’), 123.4 (C4’/C7’), 116.8 (C2), 116.2 (C1’’), 112.2 (C5’’), 107.5 (C4), 105.9 (C6), 
56.8 (OMe), 55.7 (OMe), 37.8 (C7/C8); HR-MS (NSI positive) found: [M]+, 514.0519. 
C24H21INO4
+ requires 514.0515; Anal. Calcd. for C26H21F3INO6: C, 49.78; H, 3.37. 
Found: C, 49.51; H, 3.27. 
 
9.30 2-(3,4-dimethoxyphenethyl)isoindoline-1,3-dione (225)418 
 
Product prepared according to procedure outlined for 179 Product was obtained by 
column chromatography on SiO2 (15% ethyl acetate-petrol) affording a white 
crystalline solid (0.94 g, 3.01 mmol, 44%). Mp 166-168 °C (from ethyl acetate-
 222 
petrol) (lit.418 mp 171 °C from diethyl ether:petrol); IR νmax/cm
-1 (neat) 2943, 1761, 
1712, 1600; 1H-NMR (300 MHz, CDCl3) δ 7.71 (4H, ddd, H4’/H5’/H6’/H7’ J = 35.6, 
5.5, 3.1), 6.75 (2H, m, H5/H6), 6.72 (1H, s, H2), 3.91 – 3.83 (2H, m, H8), 3.80 (3H, 
s, p-OMe), 3.78 (3H, s, m-OMe), 2.96 – 2.87 (2H, m, H7); 13C-NMR (75 MHz, CDCl3) 
δ 168.1 (CO), 148.8 (C3), 147.7 (C4), 133.9 (C5’/C6’), 132.0 (C3’/C8’), 130.5 (C1), 
123.1 (C4’/C7’), 120.8 (C6), 111.9 (C2), 111.3 (C5), 55.8 (OMe), 55.8 (OMe), 39.3 
(C8), 34.0 (C7); HR-MS (ESI positive) found: [M+H]+, 311.1278. C18H18NO4
+ requires 
311.1277; Anal. Calcd. for C18H17NO4: C, 69.44; H, 5.50; N, 4.50. Found: C, 69.31; 
H, 5.58; N, 4.42. 
 
9.31 2-(2-iodo-4,5-dimethoxyphenethyl)isoindoline-1,3-dione (227) 
 
Iron nitrate nonahydrate (2.02 g, 5.0 mmol) and silica gel (2.02 g, 5.0 mmol) were 
ground together in a mortar and pestle to give a fine, pale yellow powder before 
addition to a solution of iodine (1.40 g, 6 mmol) in DCM (300 mL). The suspension 
was then stirred for 5 minutes before the addition 225 (3.11 g, 10.0 mmol) then 
stirred for 16 h at room temperature and filtered to remove any solids. The filtrate 
was then stirred with aqueous sodium thiosulfate (2M, 200 mL, 400 mmol) until the 
colour dissipated then the organic layer was separated, washed with brine (100 mL) 
and extracted into DCM (3 × 100 mL). The organic layers were combined, dried 
(MgSO4) and concentrated in vacuo to give the product as a colourless crystalline 
solid (1.14 g, 2.6 mmol, 26 %). Mp 158–159 °C (from ethyl acetate-petrol) (lit.419 mp 
164-166 °C from methanol); 1H-NMR (400 MHz, CDCl3) δ 7.73 (4H, ddd, 
H4’/H5’/H6’/H7 J = 44.9, 5.4, 3.1), 7.16 (1H, s, H3), 6.65 (1H, s, H6), 3.89 (2H, dd, 
H8 J = 8.1, 6.6), 3.79 (3H, s, OMe), 3.66 (3H, s, OMe), 3.03 (2H, dd, H7 J = 8.1, 
6.6); 13C-NMR (100 MHz, CDCl3) δ 168.2 (CO), 149.3 (C4), 148.3 (C5), 134.1 (C1), 
133.2 (C3’/C8’), 132.1 (C5’/C6’), 123.3 (C4’C7’), 121.7 (C3), 112.5 (C6), 88.2 (C2), 
56.1 (OMe), 55.9 (OMe), 38.8 (C8), 37.9 (C7); HR-MS (ESI positive) found: [M+H]+, 
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437.0138. C18H17INO4
+ requires 437.0133; Anal. Calcd. for C18H16INO4: C, 49.45; H, 
3.69; N, 3.20. Found: C, 49.34; H, 3.74; N, 3.16. 
 
9.32 2-(4,5-dimethoxy-2-(tributylstannyl)phenethyl)isoindoline-1,3-
dione (228)176 
 
 
To 227 (0.74 g, 1.69 mmol) in dioxane (40 mL) at room temperature was added 
lithium chloride (0.359 g, 8.47 mmol), tetrakis(triphenylphosphine)palladium (0.20 g, 
0.170 mmol, 10.0 mol%) and bis(trimethyltin) (1.97 g, 3.39 mmol, 2.00 equiv). After 
stirring for 6 hr at 100 ºC, the reaction mixture was cooled to 23 ºC and 
concentrated in vacuo. The residue was purified by chromatography on silica gel, 
eluting with 20% ethylacetate-petrol, to afford a colourless oil (0.284 g, 0.47 mmol, 
28%). Rf 0.68 (20% ethyl acetate-petrol); IR νmax/cm
-1 (neat) 3331, 2980, 1736, 
1346, 1590, 1468, 1434, 1354, 1046; 1H-NMR (400 MHz, CDCl3) δ 7.77 (4H, ddd, 
H4’/H5’/H6’/H7’ J = 54.4, 5.4, 3.0), 6.87 (1H, s, H3), 6.84 (1H, s, H6), 3.91 – 3.86 
(2H, m, H8), 3.85 (3H, s, OMe), 3.79 (3H, s, OMe), 2.96 – 2.87 (2H, m, H7), 1.57 – 
1.47 (8H, m, SnCH2), 1.33 (8H, h, J = 7.3), 1.16 – 1.09 (8H, m), 0.86 (9H, t, CH3 J = 
7.3); 13C-NMR (100 MHz, CDCl3) δ 168.2 (CO), 149.3 (C5), 147.2 (C4), 137.7 (C1), 
134.0 (C2), 132.6 (C5’/C6’), 132.2 (C3’/C8’), 123.3 (C4’/C7’), 119.1 (C3), 112.0 (C6), 
55.9 (OMe), 55.7 (OMe), 39.9 (C8), 37.3 (C7), 29.3 (SnCH2), 27.5 (SnCH2CH2), 13.8 
(CH3), 10.6; HR-MS (ESI positive) found: [M+H]
+, 601.2266. C30H44NO4Sn
+ requires 
601.2270; Anal. Calcd. for C30H43INO4Sn: C, 60.02; H, 7.22; N, 2.33. Found: C, 
59.85; H, 7.37; N, 2.27. 
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9.33 (4-(5-N-[2-(1,2-Dimethoxy-phenyl)ethyl]-phthalimide)(2-
thienyl)iodonium trifluoroacetate (226) 
 
Product prepared according to procedure outlined for 149. Product 226 was 
obtained by crystallisation from DCM/ether/petrol followed by suction filtration to 
afford a white crystalline solid (0.51 g, 0.78 mmol, 32%).  Mp 166-168 °C (from 
DCM-ether-petrol); IR νmax/cm
-1 (neat) 3071, 3022, 1821, 1728, 1425, 1321, 1119; 
1H-NMR (400 MHz, CDCl3) δ 7.93 (2H, d, H2’’/H6’’ J = 8.9), 7.76 (4H, ddd, 
H4’/H5’/H6’/H7’ J = 37.6, 5.3, 3.0), 7.52 (1H, s, H3), 6.88 (1H, s, H6), 6.86 (2H, d, 
H3’’/H5’’ J = 3.4), 3.89 (3H, t, H8 J = 7.3), 3.87 (3H, s, OMe), 3.79 (3H, s, OMe), 
3.78 (3H, s, OMe), 3.25 – 3.17 (2H, m, H7); 13C-NMR (100 MHz, CDCl3) δ 168.1 
(CO), 162.3 (C4’’), 152.6 (C5), 149.6 (C4), 136.0 (C2’’/C6’’), 134.3 (C5’/C6’), 134.0 
(C3’/C8’), 131.9 (C1), 123.5 (C4’C7’), 119.6 (C2), 117.6 (C3), 112.9 (C3’’/C5’’), 109.6 
(C1’’), 105.4 (C6), 56.7 (OMe), 56.2 (OMe), 55.7 (OMe), 38.2 (C8), 37.1 (C7); HR-MS 
(NSI positive) found: [M]+, 544.0612. C25H23INO5
+ requires 544.015; HR-MS (NSI 
positive) found: [M]+, 544.0642. C25H24INO5
+ requires 544.0644; Anal. Calcd. for 
C27H23F3INO7: C, 49.33; H, 3.53; N, 2.13. Found: C, 49.38; H, 3.57; N, 2.18. 
 
9.34 Methyl (S)-2-amino-3-(2-bromo-4,5- dihydroxyphenyl) propanoate 
(230)408 
 
To a solution of L-3,4-dihydroxyphenylalanine (9.86 g, 50 mmol) in glacial acetic acid 
(250 mL) was added a solution bromine (2.80 mL, 52.5 mmol) in glacial acetic acid 
(50 mL) dropwise, over 1.5 h. The resulting yellow solution was then concentrated in 
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vacao to afford a yellow residue, which was then re-dissolved in methanol (200 mL) 
treated with thionyl chloride (20 mL) at 0 °C, then allowed to warm to room 
temperature before being stirred for a further 14 h. The solvent was removed in 
vacao to afford an amorphous yellow solid (19.22 g, quant.) as the 
hydrochloride/hydrobromide salt of 230 and was used without further purification. 
1H-NMR (300 MHz, CDCl3) δ 7.12 (1H, s, H3), 6.91 (1H, s, H6), 4.22 (1H, t, H8 J = 
7.2 Hz), 3.83 (3H, s, OMe), 3.22 (2H, br d, J = 7.2 Hz). 
 
9.35 Methyl (S)-3-(2-bromo-4,5-bis((tert-butoxycarbonyl)oxy) phenyl)-2-
((tert-butoxycarbonyl)amino)propanoate (231)408 
 
To a stirring solution of 230 (2.90 g, 10.0 mmol) in anhydrous methanol (50 mL) 
was added trimethylamine (1.67 mL, 12.0 mmol) followed by di‐tert‐butyldicarbonate 
(2.62 g, 12.0 mmol). The reaction was stirred at 0 °C for 2 h, followed by 15 h at 
room temperature. The solution was then diluted with ethyl acetate (60 mL) and 
washed with water (60 mL) and brine (60 mL) before being dried over MgSO4. After 
concentration in vacao confirmation of a successful amine protection was confirmed 
by 1H- and 13C-NMR. The yellow residue was then re-dissolved in anhydrous toluene, 
to which was then added trimethylamine (3.49 mL, 25 mmol) and di‐tert‐
butyldicarbonate (5.46 g, 25 mmol). The reaction mixture was then heated at 80 °C 
for 24 h. The solution was then diluted with ethyl acetate (60 mL) and washed with 
water (60 mL) and brine (60 mL) before being dried over MgSO4 and concentrated in 
vacao. Purification by column chromatography on SiO2 (0-20% ethyl acetate-petrol) 
afford the product as a colourless residue (4.55 g, 7.71 mmol, 77%). Rf 0.26 (20% 
ethyl acetate-petrol); 1H-NMR (400 MHz, CDCl3) δ 7.47 (1H, s, H3), 7.11 (1H, s, H6), 
4.60 (1H, q, H8 J = 7.7), 3.69 (3H, s, OMe), 3.16 (3H, ddd, H7 J = 56.9, 13.8, 6.8), 
1.52 (27 H, s, Boc); 13C-NMR (100 MHz, CDCl3) δ 172.2 , 155.1 (COOMe), 150.3 (Boc 
CO), 141.7 (C4/C5), 134.6 (C1), 127.3 (C3), 125.3 (C6), 120.8 (C2), 84.4 (Boc 
C(CH3)), 84.2 (Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc 
C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3))(Boc C(CH3)), 80.2 
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(Boc C(CH3)), 53.3 (C8), 52.6 (OMe), 38.2 (C7), 28.3 (NHBoc C(CH3)3), 27.7 (OBoc 
C(CH3)3); HR-MS (ESI positive) found: [M+H]
+, 590.1542. C25H37BrNO10
+ requires 
590.1543; Anal. Calcd. for C25H36BrNO10: C, 50.85; H, 6.15; N, 2.37. Found: C, 
50.72; H, 6.29; N, 2.47. 
 
9.36 Methyl (S)-3-(4,5-bis((tert-butoxycarbonyl)oxy)-2-
(trimethylstannyl)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
(233)409 
 
Product prepared according to procedure outlined for 228, utilising 231 as the 
substrate and hexamethylditin in place of hexabutylditin. Purification by column 
chromatography on SiO2 (0-60% ethyl acetate-petrol) afforded the product as a clear 
oil (1.56 g, 2.31 mmol, 31%). Rf 0.32 (30% ethyl acetate-petrol); IR νmax/cm
-1 (neat) 
3070, 3019, 1818, 1725, 1430, 1381, 1109; 1H-NMR (300 MHz, CDCl3) δ 7.14 (1H, s, 
H3), 6.90 (1H, s, H6), 4.97 – 4.41 (1H, m, H8), 3.84 (3H, s, OMe), 3.04 (2H, td, H7 J 
= 15.5, 14.9, 7.2), 1.57 (27H, s, Boc), 0.34 (9H, s, SnMe3, with tin satellites J
2 Sn-H 
= 54.8 Hz). 13C-NMR (75 MHz, CDCl3) δ 171.5 (COOMe), 155.1 (NHCOO), 151.6 
(OBoc), 151.3 (OBoc), 142.0 (C5), 138.8 (C1), 133.6 (C4), 129.4 (C3), 113.3 (C6), 
83.3 (Boc), 82.0 (Boc), 79.8 (NBoc), 55.8 (H8), 54.6 (OMe), 41.2 (C7), 28.3 
(C(CH3)3), 28.0 (C(CH3)3), 27.7 (C(CH3)3), -8.0 (SnMe3); HR-MS (ESI positive) 
found: [M+H]+, 675.2128. C28H46NO10Sn
+ requires 675.2130. 
 
9.37 (S)-4-Bromo-5-(2-(2,5-dioxopyrrolidin-1-yl)-3-methoxy-3-
oxopropyl)-1,2-phenylene dibenzoate (238)420 
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To a vigorously stirred suspension of bromo-DOPA methyl ester 230 (7.66 g, 26.41 
mmol) in anhydrous toluene (200 mL) was added triethylamine (10.9 mL, 79.1 
mmol) and succinic anhydride (3.17 g, 31.6 mmol) at room temperature. The 
reaction mixture was then stirred for 48 hours at reflux and allowed to cool to room 
temperature. Benzoyl chloride (15.2 mL, 65.9 mmol) and triethylamine (9.11 mL, 
65.9 mmol) were added to the reaction mixture at 23 °C. The reaction mixture was 
stirred for 12 h at 80 °C, allowed to cool to 23 °C, and then transferred to a 
separating funnel. The organic layer was washed with brine (3 × 50 mL). The 
combined aqueous layers were extracted with ethyl acetate (50 mL). The combined 
organic layers were dried over magnesium sulfate, filtered, and concentrated in 
vacuo. The residue was purified by flash column chromatography on SiO2 (0-50% 
ethyl acetate-petrol) to afford the title compound (5.98 g, 10.3 mmol, 39% yield) as 
a pale brown residue. Rf 0.24 (20% ethyl acetate-petrol); IR νmax/cm
-1 (neat) 3115, 
1823, 1730, 1377, 1325, 1319; 1H-NMR (400 MHz, CDCl3) δ 8.00 (4H, dd, OBz J = 
23.4, 6.8), 7.56 (1H, s, H3), 7.55 (2H, q, OBz J = 8.9, 8.1), 7.37 (4H, dt, OBz J = 
15.8, 7.7), 7.06 (1H, s, H6), 5.28 (1H, dd, H8 J = 12.0, 4.8), 3.80 (3H, s, OMe), 3.74 
– 3.46 (2H, m, H7 (ABX system)), 2.83 – 2.65 (4H, m, H2’H3’); 13C-NMR (100 MHz, 
CDCl3) δ 176.9 (CO), 168.6 (COOMe), 164.2 (COOPh), 163.9 (COOPh),  142.0 (C1), 
141.6 (C2), 134.4 (C5), 134.1 (OBz), 130.3 (OBz), 130.2 (OBz), 128.7 (OBz), 128.7 
(OBz), 128.3 (OBz), 127.9 (OBz), 126.4 (C3), 120.8 (C4), 53.1 (C8), 50.9 (OMe), 
34.0 (C7), 28.1 (C2’/C3’); HR-MS (ESI positive) found: [M+H]+, 579.0551. 
C28H23BrNO8
+ requires 579.0556. 
 
9.38 (S)-4-(2-(2,5-Dioxopyrrolidin-1-yl)-3-methoxy-3-oxopropyl)-5-
(tributylstannyl)-1,2-phenylene dibenzoate (239) 
 
Product prepared according to procedure outlined for 228, using arylbromide 238 as 
the substrate. Purification by flash column chromatography on SiO2 (0-40% ethyl 
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acetate-petrol) afforded the product as a colourless oil (0.87 g, 1.1 mmol, 45%). Rf 
0.32 (15% ethyl acetate-petrol); IR νmax/cm
-1 (neat) 3069, 3020, 1821, 1726, 1422, 
1381, 1313. 1122; 1H-NMR (400 MHz, CCDCl3) δ 8.31 – 8.18 (4H, m, OBz), 7.79 (2H, 
q, J = 7.3), 7.61 (4H, dt, OBz, J = 12.6, 7.7), 7.49 (1H, s, H6), 7.20 (1H, s, H3), 
5.56 – 5.48 (1H, m, H8), 4.04 (3H, s, OMe), 4.02 – 3.69 (2H, m, H7 (ABX system)), 
2.98 (4H, q, H2’/H3’ J = 2.8), 1.56 – 1.45 (8H, m, SnCH2), 1.32 (8H, h, J = 7.2), 
1.15 – 1.07 (8H, m), 0.85 (9H, t, CH3 J = 7.2); 
13C-NMR (100 MHz, CDCl3) δ 176.41 
(CO), 169.2 (COOMe), 166.6 (COOPh), 165.5 (COOPh), 145.3 (C2), 144.8 (C4), 
141.8 (C1), 139.9 (C5), 133.9 (OBz), 130.2 (OBz), 129.7 (OBz), 128.8 (C6), 119.3 
(C3), 61.0 (C8), 51.9 (OMe), 36.5 (C7), 29.3 (SnCH2), 28.1 (C2’/C3’), 27.5 
(SnCH2CH2), 13.8 (CH3), 10.6; HR-MS (ESI positive) found: [M+H]
+, 791.2516. 
C40H50NO8Sn
+ requires 791.2519.  
 
9.39  2,4,6-Trimethyliodobenzene (242)421 
 
 
Iron nitrate nonahydrate (4.04 g, 10.0 mmol) and silica gel (4.04 g, 10.0 mmol) were 
ground together in a mortar and pestle to give a fine, pale yellow powder before 
addition to a solution of iodine (2.79 g, 11 mmol) in DCM (500 mL). The suspension 
was then stirred for 5 minutes before the addition mesitylene (2.40 g, 20.0 mmol) 
then stirred for 16 h at room temperature and filtered to remove any solids. The 
filtrate was then stirred with aqueous sodium thiosulfate (2M, 200 mL, 400 mmol) 
until the colour dissipated then the organic layer was separated, washed with brine 
(200 mL) and extracted into DCM (3 × 150 mL). The organic layers were combined, 
dried (MgSO4) and concentrated in vacuo to give the product as a colourless 
crystalline solid (3.89 g, 15.81 mmol, 79 %). Mp 30–31 °C (from DCM) (lit.422 mp 30 
°C from ethanol); 1H-NMR (400 MHz, CDCl3) δ 6.89 (2H, s, H3/H5), 2.45 (6H, s, o-
Me), 2.25 (3H, s, p-Me); 13C-NMR (100 MHz, CDCl3) δ 141.7 (C2/C6), 137.3 (C4), 
127.9 (C3/C5), 104.2 (C1), 29.5 (o-Me), 20.6 (p-Me). 
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9.40  4-(Benzyloxy)-1-iodobenzene (138 from benzyl phenyl ether)  
 
 
Product prepared according to procedure outlined for 242. Purification by column 
chromatography on SiO2 (15% ethyl acetate-petrol afforded the product as an off 
white solid concentrated (4.56 g, 14.7 mmol, 94 %). Mp 63-65 °C (from ethyl 
acetate-petrol) (lit.423 mp 62-63 °C from DCM); IR νmax/cm
-1 (neat) 1600, 1270, 
1123, 975; 1H-NMR (400 MHz, CDCl3) δ 7.54 (2H, d, H2/H6 J = 8.7), 7.45 – 7.30 
(5H, m, H8-H12), 6.75 (2H, d, H3/H5 J = 8.8), 5.02 (2H, s, CH2); 
13C-NMR (100 MHz, 
CDCl3) δ 158.7 (C4), 138.3 (C2/C6), 136.6, 128.8, 128.2, 127.5, 117.4 (C3/C5), 83.2 
(C1), 70.6 (CH2).  
9.41  Operation of the Advion NanoTek Microfluidic System 
 
All radiosynthetic work conducted in-house, including the preparation and drying of 
[18F]fluoride was performed on the Advion NanoTek Microfluidic System, operated 
and controlled by the NanoTek 1.4 software. The system consists of a base module 
(BM), concentrator module (CM), and reactor module (RM). The BM consists of two 
reagent cartridges (P1 and P2) used to dispense metered amounts of reactants to 
the microreactors for radiolabelling reactions. These cartridges comprise of a high-
pressure syringe pump connected to an eight-way bridged valve supporting a 
looped-reservoir from which reagents are dispensed towards the microreactor. The 
RM consists of the isotope reagent (P3) and microreactor cartridges, as well as an 
eight-way distribution valve (DV) used to direct the reaction bolus to the user-desired 
location. P3 receives the solution of [18F]fluoride (PTS-1 or PTS-2) from the CM 
module where it is prepared from a volume of cyclotron produced [18F]fluoride in 
[18O]H2O. The CM module consists of a low-pressure, six-way valve reagent cartridge 
(CM1) and vessel chamber capable of rapid heating and evaporation of solvent. It is 
possible to subject the CM vessel to a combination of reduced pressure and a 
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positive flow of nitrogen gas allowing the [18F]fluoride to be dried via several 
azeotropic distillations with MeCN. 
Throughout this work, the crude reaction mixture was swept into an electronic 
injection valve (Smartline Valve Drive: Knauer, Germany) for direct injection onto the 
radio-HPLC system. The enclosed fluid paths of this tandem synthetic and analytical 
system ensured that the results obtained were representative of the crude reaction 
mixture as potential volatile products could not be lost. Operation of this valve and 
the initialisation of the HPLC analysis was also controlled by the NanoTek software. 
This software may be operated in several modes; in ‘Discovery Mode’ user-directed 
macros automate all procedures involved in the synthetic process, thereby allowing 
simple and rapid throughput of multiple reactions. These procedures can also be 
divided into their constituent parts and controlled separately within ‘Manual Mode’ 
which, therefore, allows for finer control of the system. In ‘Sequence Mode’ detailed 
macros can be written, manipulated and combined to enable extensive and complex 
processes to be performed with minimal user intervention. Throughout this study, 
user-control fluctuated between the three modes, for optimal system 
management.110 
 
9.42  Preparation of Tetraethylammonium [18F]Fluoride 
 
Cyclotron produced, no-carrier-added [18F]fluoride (5–100 mCi) in [18O]H2O (1–5 mL) 
was adsorbed onto a pre-conditioned anion exchange resin (QMA: Waters Sep-Pak1 
Light Accell Plus) before being released using a solution of K2CO3 (1.18 mg; 8 µmol) 
in MeCN/H2O (9:1 (v/v) 450 mL) (PTS-1); or Et4N·HCO3 (3.4 mg; 17 µmol) in 
MeCN/H2O (9:1 (v/v) 450 mL) (PTS-2) and into a V-vial (2 mL, Wheaton). The 
solutions were dried by two successive azeotropic evaporations using MeCN (450 mL) 
at 100 °C and under a positive flow of N2. The [
18F]Et4N·F was then dissolved in DMF 
(450 mL) and loaded into the storage loop (P3: 401 mL) on the microfluidic 
system.110  
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9.43  Radiofluorination of Diaryliodonium Salts using the Advion NanoTek 
Microfluidic System 
 
Dry [18F]fluoride (5–100 mCi, 450 mL DMF) and solutions of the diaryliodonium salt 
precursor in DMF at 10 mg/mL) were loaded into their respective storage loops (loop 
3 and loop 1 respectively). Capillaries that lead from P1 and P3 to the microreactor 
were primed with their respective reagents. Prior to recording data several priming 
reaction runs were performed to confirm the integrity of the synthetic platform and 
the in-line analytical HPLC system. A set volume of either PTS-1 or PTS-2 (10 mL) 
and a variable volume of the precursor (5–20 mL: stoichiometry assessment) were 
dispensed into the pre-heated microreactor (130-190 °C) at pre-determined flow 
rates (10–30 mL/min). This is achieved by the syringes of P1 and P3, simultaneously 
dispensing precursor and [18F]fluoride solutions (using either PTS-1 or PTS-2) from 
their respective loops, into the microreactor using a fixed volume of system solvent 
at a preset flow rate. The solutions initially mix at the entrance to the microreactor. 
User-operated computer software determines the reaction parameters – 
temperature, time and stoichiometry (P1:P3). Following completion of the reaction, 
P3 sweeps the crude mixture to the DV where it is directed towards the electronic 
injector and radio-HPLC system allowing the radiochemical yield of the process to be 
determined. At the start and end of each series of experiments the BM, RM, 
microreactor and associated transfer lines were cleaned using DMF and the CM 
system with acetonitrile.  
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (λmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture.110   
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10 Appendix 
 
10.1 Crystal data and structure refinement for (4-(benzyloxy)phenyl)(4-
methoxyphenyl)iodonium trifluoroacetate (149) 
 
Table 1.  Crystal data and structure refinement for mac120022. 
 
Identification code  mac120022 
Chemical formula (moiety) C23H20F3IO4 
Chemical formula (total) C23H20F3IO4 
Formula weight  514.26 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.6798(4) Å  = 70.088(4)° 
 b = 9.7400(4) Å  = 80.985(4)° 
 c = 13.2405(6) Å  = 81.327(4)° 
Cell volume 1033.71(8) Å
3
 
Z 2 
Calculated density  1.652 g/cm
3
 
Absorption coefficient  1.595 mm1 
F(000) 508 
Crystal colour and size colourless, 0.40  0.30  0.02 mm3 
Reflections for cell refinement 3425 ( range 3.0 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 28.6° 
Index ranges h 11 to 10, k 11 to 11, l 17 to 16 
Completeness to  = 28.6° 81.6 %  
Reflections collected 8778 
Independent reflections 4320 (Rint = 0.0417) 
Reflections with F
2
>2 3627 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5678 and 0.9688 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0226, 0.0000 
Data / restraints / parameters 4320 / 0 / 291 
Final R indices [F
2
>2] R1 = 0.0409, wR2 = 0.0654 
R indices (all data) R1 = 0.0563, wR2 = 0.0711 
Goodness-of-fit on F
2
 1.024 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.77 and 0.77 e Å3 
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10.2 Crystal data and structure refinement for (4-(benzyloxy)phenyl)(2-
thienyl)iodonium trifluoroacetate (150) 
 
Table 1.  Crystal data and structure refinement for mac12. 
 
Identification code  mac120012 
Chemical formula (moiety) C21H17F3INO3S 
Chemical formula (total) C21H17F3INO3S 
Formula weight  547.32 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 5.9984(4) Å  = 68.019(10)° 
 b = 17.5919(19) Å  = 87.701(7)° 
 c = 21.971(2) Å  = 83.912(7)° 
Cell volume 2137.8(3) Å
3
 
Z 4 
Calculated density  1.701 g/cm
3
 
Absorption coefficient  1.644 mm1 
F(000) 1080 
Crystal colour and size colourless, 0.40  0.30  0.30 mm3 
Reflections for cell refinement 5408 ( range 3.0 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 26.0° 
Index ranges h 7 to 6, k 20 to 21, l 26 to 27 
Completeness to  = 26.0° 96.7 %  
Reflections collected 17218 
Independent reflections 8153 (Rint = 0.0397) 
Reflections with F
2
>2 6983 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5593 and 0.6383 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0378, 3.8934 
Data / restraints / parameters 8153 / 0 / 591 
Final R indices [F
2
>2] R1 = 0.0464, wR2 = 0.1029 
R indices (all data) R1 = 0.0565, wR2 = 0.1095 
Goodness-of-fit on F
2
 1.126 
Extinction coefficient 0.0001(2) 
Largest and mean shift/su 0.002 and 0.000 
Largest diff. peak and hole 2.45 and 1.04 e Å3 
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10.3 Crystal data and structure refinement for (4-
(benzyloxy)phenyl)(phenyl)iodonium trifluoroacetate (151) 
 
Identification code  mac120001 
Chemical formula (moiety) C21H16F3IO3 
Chemical formula (total) C21H16F3IO3 
Formula weight  500.24 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 9.1481(11) Å  = 112.018(12)° 
 b = 9.6626(12) Å  = 96.244(10)° 
 c = 12.4431(14) Å  = 100.553(10)° 
Cell volume 983.3(2) Å
3
 
Z 2 
Calculated density  1.690 g/cm
3
 
Absorption coefficient  1.675 mm1 
F(000) 492 
Crystal colour and size colourless, 0.40  0.20  0.04 mm3 
Reflections for cell refinement 2404 ( range 3.2 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.2 to 26.0° 
Index ranges h 11 to 10, k 9 to 11, l 14 to 15 
Completeness to  = 26.0° 96.7 %  
Reflections collected 7074 
Independent reflections 3739 (Rint = 0.0597) 
Reflections with F
2
>2 3219 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5539 and 0.9360 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0560, 0.2840 
Data / restraints / parameters 3739 / 3 / 267 
Final R indices [F
2
>2] R1 = 0.0476, wR2 = 0.1097 
R indices (all data) R1 = 0.0581, wR2 = 0.1214 
Goodness-of-fit on F
2
 1.082 
Extinction coefficient 0.0003(7) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.66 and 1.31 e Å3 
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10.4 Crystal data and structure refinement for (4-(acetoxy)phenyl)(4-
methoxyphenyl)iodonium trifluoroacetate (152) 
 
Identification code  mac120013 
Chemical formula (moiety) C19H17F3INO5 
Chemical formula (total) C19H17F3INO5 
Formula weight  523.24 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 10.4335(4) Å  = 90° 
 b = 11.9198(4) Å  = 103.108(4)° 
 c = 16.8661(8) Å  = 90° 
Cell volume 2042.90(14) Å
3
 
Z 4 
Calculated density  1.701 g/cm
3
 
Absorption coefficient  1.624 mm1 
F(000) 1032 
Crystal colour and size colourless, 0.45  0.40  0.40 mm3 
Reflections for cell refinement 4854 ( range 3.3 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.3 to 28.5° 
Index ranges h 13 to 9, k 12 to 15, l 21 to 19 
Completeness to  = 25.0° 99.8 %  
Reflections collected 10253 
Independent reflections 4341 (Rint = 0.0234) 
Reflections with F
2
>2 3710 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5285 and 0.5627 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0219, 4.2244 
Data / restraints / parameters 4341 / 0 / 266 
Final R indices [F
2
>2] R1 = 0.0302, wR2 = 0.0651 
R indices (all data) R1 = 0.0389, wR2 = 0.0717 
Goodness-of-fit on F
2
 1.057 
Extinction coefficient 0.00193(15) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole              1.26 and 0.91 e Å3 
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10.5 [18F]Fluoride Drying Macro 
 
0 Wait Drying macro. Ensure needle is fully inserted into target water vial. Ensure 
QMA cartridge is loaded. Ensure all solutions are prepared and installed. Ensure all 
plumbing is correct.  
1000 L37020000800054 L3602000300004E Set Conc 1 to 80oC  
2000 /5o1V1200A6000M3000o5V1200A0M2000R Load target water  
15000 /5o6V1200A6000M2000o3V1200A0R Remove target water  
15000 L3702000100004D L3602000300004E Set Conc 1 to 100oC  
2000 /7U2M5000U1M5000u2R Turn on the Nitrogen  
10000 /5o2V1000P5000M2000go5V400D750M15000G4o2V2000A0R Add 400 uL of 
PTA  
105000 /5M90000R Wait 100s for conc vial to dry PTA solution  
100000 /5o4V1000P6000M2000o5V75D3600M2000o6V75D1200M2000o2V2000A0R 
Add 400 uL of MeCN (1) and flush back PTA line  
75000 /5M30000R Wait 20s for conc vial to dry MeCN (1)  
20000 /5o4V1000P6000M2000o6V75D3600M2000o2V2000A0R Add 400 uL of MeCN 
(2) and flush back PTA line  
45000 /5M30000R Wait 20s for conc vial to dry MeCN (2)  
20000 /7u1R Turn off the Nitrogen  
2000 /3o1V2000A0M2000o8V2000A15600M2000o6V800A0R Add 325 uL of DMF  
40000 
/3go4V1600A19200M2000V3200A0M2000G6o8V3200A3600M2000o4V3200A0R Mix 
the solvent with the fluoride. Add 75 uL of DMF to flush line F 
 
10.6 Autodiscovery Mode Operation 
 
140000 L37020000250053 L3602000300004E Set Conc 1 to 25oC 
2000 Wait End of drying macro. Pump 3 can now be prepared. 
6.11.2 Autodiscovery Mode Cleaning 
2000 Wait P1,2,3 reagent lines will be back-flushed. Place Reactor outlet into waste 
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1000 
/1o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A48000M100
0o3V100A0R P1, Clean reagent line, loop and load line 
5000 
/2o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A48000M100
0o3V100A0R P2, Clean reagent line, loop and load line 
2000 /7o1R Hub to Waste (A) 
5000 
/3o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A24000o3V1
00A0R P3, Clean reagent line, loop and load line Sweep 
1000 /6go4V600P3600M10006o2V60D3600G2R Flush APT line x2 
160000 /6go4V600P3600M10006o5V60D3600G2R Flush QMA x2 
160000 /6go4V600P3600M10006o6V60D3600G2R Flush line F x2 
230000 /3o8V3200A24000M1000o2V100A0R P3, Sweeps reactor contents to waste 
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